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Abstract 
Cancer of the colon and rectum is a major cause of ill-health. Options for 
reducing the burden of the disease include primary prevention, screening for 
early stage asymptomatic disease and improvements in the treatment of 
symptomatic disease. If the policy objective is to make a major impact on 
mortality from the disease then screening appears to be the only technically 
feasible option. 
One indication of asymptomatic colorectal cancer is small quantities of blood 
mixed with faeces. Screening tests capable of detecting bleeding are 
currently being evaluated in clinical trials. Interim measures of the costs and 
disease yield of a screening programme using a faecal occult blood test imply 
that screening may offer good value for money but only if the intended 
mortality reduction from the disease is realised. 
There are various ways of 'fine-tuning' the screening programme to improve 
the balance of costs and benefits; information for making choices regarding 
important parameters such as the age range of the population to be offered 
screening are presented. Alternative screening tests are also evaluated and 
the results presented in terms of the cost-yield trade-off. 
The policy implications of the evaluation must be qualified at this stage since 
no proof of mortality reduction will be available until the conclusion of the on- 
going trial. Nevertheless, under various assumptions about the impact of 
screening, the option appears to be an efficient way of reducing the health 
'costs' of colorectal cancer. 
INTRODUCTION 
The evaluation of health services 
In 1990 an internal market was introduced into the provision of publicly- 
funded health services in the United Kingdom. Functions were allocated to 
the charge of various management groups. Provider units took on the task of 
delivering services, either from a hospital or in the community. A separate 
function was established to consider the health needs of local people and to 
commission the services they required from the providers; the bodies carrying 
out this task are the purchasers*. The potential role of health economics is 
thus much more clear-cut: purchasers are given a fixed budget and attempt to 
achieve their objectives to the greatest extent possible. These objectives will 
include health gain (in terms of length or quality of life), as well as other 
factors. Thus, services which are commissioned must be clinically effective 
(i. e. there is evidence that patients' health will improve). 
The budget constraint also requires that efficiency be considered in terms of 
health benefits per pound spent. It is widely accepted that the cost of 
providing all of the services from which people could potentially benefit 
outstrips the resources available, thus there is a situation of scarcity. As a 
result, opportunity costs become relevant. This, in turn, has created a 
demand for information on the relative costs and benefits of alternative health 
care treatments in order to assist decision-making. Economic evaluation is a 
systematic means of evaluating two or more options in terms of their relative 
costs and benefits from a specified perspective. While easily stated, these 
ideas are not always straightforward to apply in practice. 
Health gain as a strategic goal of cancer services 
The internal market is still regulated, however: for example, targets have 
been set for purchasers in terms of reducing the health 'costs' of particular 
diseases in the "Health of the Nation" (Department of Health (1991)). The 
first set of targets concentrated on diseases with the biggest burden in terms 
of years of life lost prematurely (defined as before the age of 65); these do 
not appear to have been set with economic criteria in mind. Purchasers had 
already recognised that cancer care was one of their top priorities (Klein and 
Redmayne (1992)). Some strategies are already available, such as smoking 
cessation programmes to tackle lung cancer and screening for breast cancer. 
However, the second biggest cause of cancer deaths, cancer of the large 
bowel (i. e. the colon and rectum), is not being tackled apart from providing 
prompt surgical attention for cases diagnosed. Some advances in treatment 
are being examined but their impact will be limited at best. Advances in 
genetics research may one day allow all of those at risk of the disease to be 
identified at an early stage of their lives and treated appropriately but this is 
not yet feasible. Thus attention has turned to screening as the only option 
* Increasingly, budget-holding General Practitioners (GPs) are carrying out this role but the 
bulk of the work is still the province of the health authorities. 
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which has the potential to substantially reduce the health 'costs' of the 
disease. 
The problem is that there is little evidence that such a policy will extend lives. 
Some evidence from America is available but relates to protocols which are 
not generally considered feasible in this country on grounds of expense. In 
addition the quality of some studies suggests that the data should be taken to 
be indicative rather than conclusive. While breast cancer screening was 
introduced in this country in advance of the results of the on-going British 
trial, today's purchasers may well be more wary of commissioning services for 
which there is inadequate proof of benefit. The economic efficiency of the 
programme will also be carefully scrutinised as part of the decision; it is the 
evidence that will be needed that forms the subject matter of this evaluation. 
The issues are considered under four headings: 
what are the costs and benefits to NIAS purchasers of screening for 
colorectal cancer in an asymptomatic population aged 50-74 by an 
offer of Haemoccult 11 testing every two years? 
ii) is this the most efficient way to screen for colorectal cancer? 
iii) is this the most efficient way to reduce the health loss of colorectal 
cancer? 
iv) can such a policy be justified in comparison with other uses of health 
service resources? 
To address these questions the structure of the evaluation is as follows: 
Chapter One sets out the health and economic costs of colorectal cancer. 
The poor prognosis for advanced stage cases is noted. The causes of 
colorectal cancer are discussed and current treatment practices described. 
Neither offers immediate prospects for improving the prognosis for the 
majority of patients. In conclusion, attention switches to screening for early 
stage disease. 
Chapter Two picks up this thread by considering the conditions for an 
effective screening programme. This is shown to consist of a suitable 
disease, a suitable test and a suitable programme or protocol. The evidence 
relating to colorectal cancer in each respect is presented. Colorectal cancer 
is a good candidate for screening, although currently medical knowledge is 
deficient in a number of key areas. Suitable tests are available although 
none is particularly satisfactory. Suitable programmes can be devised on the 
basis of clinical trials. 
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Chapter Three considers some of the problem of evaluating any screening 
programme by assessing its costs and benefits. Some methodological issues 
are discussed in detail and the lessons drawn out are applied to a literature 
review of previous studies of colorectal cancer screening. 
Chapter Four introduces data from the Medical Research Council clinical 
trial. On the basis of the protocol specified a simple numerical model of the 
costs and disease yield is constructed. This allows the cost of detecting a 
case of asymptomatic disease to be calculated. The model is then used to 
identify the most important variables in determining costs and benefits; these 
are then given more detailed attention in the subsequent chapters. 
Chapter Five looks at the effects of screening using a variety of different 
methods. Data are gathered from a variety of sources in order to compare all 
of these methods on a common basis using the model constructed in Chapter 
Four. A sub-set of options which appear more efficient than the rest are 
identified and the data with which to choose between them presented. The 
chapter then considers the various possible criteria for a positive screening 
test and how this will affect the results. 
Chapter Six concentrates on the economic aspects of attempts to increase 
the participation rate in screening for colorectal cancer. A model of individual 
behaviour using perceptions of costs and benefits is set up and lessons for 
health education drawn out. Different ways of inviting people to participate in 
screening are compared. The costs and benefits of pursuing people who do 
not complete a test are then considered; on the basis of the costs and 
benefits an optimal participation rate is identified which is shown to differ from 
the commonly-perceived optimum of 100%. 
Chapter Seven extends the idea of benefits beyond the detection of early 
stage cancer alone. Screening also detects a suspected pre-cursor of 
cancer, the adenoma, although the precise benefits of detecting and excising 
these lesions is uncertain. A review of the medical literature reveals a 
number of estimates and these are compared by applying them to the 
screening trial data. The significance of variations in the results is discussed. 
Chapter Eight considers the question of which age group of the population to 
screen on economic grounds. Several of the key variables in the screening 
programme are shown to be related to age, including the proportion returning 
a test, the proportion of returned tests which prove to be positive, and the 
number of cases of disease detected (the yield). These factors have various 
implications for costs and benefits which are explored. The possibility of 
recommending different protocols for different age groups is considered. The 
costs and benefits of extending screening to very young and to very old ages 
is also evaluated. The former may well benefit from detection of adenomas 
but these are rare. On the other hand elderly people are much more likely to 
have asymptomatic cancer but are less likely to be able to undergo treatment. 
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Chapter Nine evaluates the options for diagnostic investigation of positive 
screening test results. Several options are considered including radiology, 
endoscopy (a fibreoptic telescope) and combinations of both together. Data 
are presented for symptomatic patients which allows the various aspects of a 
model to be constructed. Screening trial data are then used to consider 
which strategy is most appropriate in a screening programme. Finally the 
role of retesting of positive results before a diagnostic investigation is 
performed is considered in terms of costs and benefits. 
Chapter Ten considers the impact of screening on the costs of treating 
colorectal cancer. First of all, the methodological problems in costing 
hospital care are considered; particular attention is paid to the level of detail 
required in this type of work using a case study based on allocating nursing 
costs. Data from a large sample of cases from the MRC trial are then 
presented and the cost per case and the total costs for each option 
compared. Explanations are sought for the results. 
Chapter Eleven uses the results to date to compare colorectal cancer 
screening with other ways of treating the disease. A number of alternatives 
are identified including screening high-risk groups, radiotherapy and 
chemotherapy following surgery, treatment of advanced disease and better 
follow-up of people who have previously had an adenoma. The costs and 
benefits of each are calculated and the results are compared in terms of the 
costs per life saved. While some of the assumptions are questionable, some 
lessons can be learnt by purchasers of care. 
In the conclusion the policy implications are spelt out. The methodological 
lessons learnt are also discussed in more detail. The need for further 
research in particular areas is identified. 
Several sections of this work have already been published in peer-reviewed 
journals. The published references are as follows: 
Chapter Four appeared as: 
'The costs of screening for colorectal cancer" (with D. Whynes, J. Hardcastle 
and J. Chamberlain) Journal of Epidemiology and Community Health 1991 
45220-224. 
and 
'The hospital costs of diagnostic investigations for colorectal cancer" (with D. 
Whynes, J. Hardcastle and J. Chamberlain) Journal of Clinical Epidemiology 
199144 907-914. 
Chapter Five appeared as 
"Filtering strategies in mass population screening for colorectal cancer: an 
economic evaluation" (with D. Whynes and J. Hardcastle) Medical Decision 
Making 1992 12 2-7. 
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and 
"Cost-effective screening strategies for colorectal cancer" (with D. Whynes 
and J. Hardcastle) Journal of Public Health Medicine 1992 43-49. 
and 
"Rehydration of Haemoccult ests in mass screening for colorectal cancer: an 
economic perspective" (with D. Whynes and J. Hardcastle) Scandinavian 
Journal of Gastroenterology 199126 215-218. 
and 
"Hemoccult testing and colorectal cancer' (with D. Whynes and J. 
Hardcastle) Gastroenterology 1990 99 608. 
Chapter Six appeared as 
"Participation and screening programmes for colorectal cancer: more would 
be better? " (with D. Whynes) Journal of Health Economics 1991 10 207-225. 
Chapter Seven appeared as 
"Cost savings in mass population screening for colorectal cancer resulting 
from the early detection and excision of adenomas" (with D. Whynes and J. 
Hardcastle) Health Economics 1992 1 53-60. 
Chapter Eight appeared as 
'The effect of subject age on the cost-effectiveness of mass population 
screening for colorectal cancer" (with D. Whynes and J. Hardcastle) Journal 
of Epidemiology and Community Health 1992 46 577-581. 
Chapter Nine appeared as 
"Retesting positive results in screening for colorectal cancer: a marginal 
analysis" (with D. Whynes, J. Hardcastle, M. Thomas and J. Chamberlain) 
Applied Economics 199123 1015-1018. 
Chapter Ten appeared as 
"Screening and the costs of treating colorectal cancer" (with D. Whynes and 
J. Hardcastle) British Journal of Cancer, accepted for publication. 
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"The costing of nursing care: a study of 65 patients with colorectal cancer" (with D. Whynes) Journal of Advanced Nursing 1990 15 1305-1309. 
I confirm that the following document is my own work. While two of the above 
papers appeared in print with David Whynes as the first author these pieces 
have either been extensively reworked (in the case of the Health Economics 
paper (chapter 7)) or were based entirely on my original work (British Journal 
of Cancer, chapter 10). 
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Chapter One 
COLORECTAL CANCER 
INTRODUCTION 
The purpose of this chapter is to introduce the most important features of 
colorectal cancer. Initially, the costs of cancer and of colorectal cancer are 
described relative to the costs of other diseases. The causes of colorectal 
cancer are then explored to assess the chances of finding some means of 
eradicating the disease (although the economic desirability of pursuing such 
a policy is not considered at this stage). Factors affecting the prognosis of 
patients is described. Finally, current treatment practice is assessed and the 
prospects for improvements in prognosis (reducing the social cost of the 
disease) are discussed. 
THE COST OF CANCER 
It is common practice to commence the discussion of screening for a disease 
by estimating the so-called disease burden in terms of lives lost, working- 
days lost or resources used in treatment. The figures for cancer are daunting 
in this respect: 
" 
In 1990, the annual economic burden of cancer in America was 
$94,400 million or $120 per head of population (Brown (1990)). 
Premature mortality, valued using average lifetime earnings, 
contributed 58% of this figure, with 31% resulting from health care 
costs. Since 1985 the total has risen by 45% in real terms. 
" 
In the UK cancer contributed 6% of the total economic burden of all 
diseases in the 1970s (Black and Pole (1975)) and by the late 1980s 
cancer treatment accounted for 7% of all NHS spending, or E1,000 
million annually (1986-7 prices) (OPCS (1993)). 
These figures should not guide health policy on their own, however, since 
there is no indication of either the costs or the benefits of action to reduce 
this burden. Table One shows the number of life-years lost to various 
conditions in England and Wales in 1990, based on age at death and life- 
expectancy at that age: 
Table One 
Cause 
All causes 
All neoplasia 
Lung cancer 
Breast cancer 
Colorectal cancer 
Stomach cancer 
Pancreatic cancer 
Prostate cancer 
Life-years lost (000) 
51979 
1,803 
401 
217 
190 
88 
68 
66 
6 
Cervical cancer 35 
Ischaemic heart disease 873 
Cerebro-vascular disease 549 
(Source: own calculations based on OPCS (1987), OPCS (1993)). 
These data are also presented in Figure One. It is not evident that a major 
cause of lost life-years, such as lung cancer, is more deserving of attention, 
since apart from primary prevention there is little effective care available. 
Cancer of the colon and rectum 
Cancer of the large bowel (or colorectal cancer) has as its primary site the 
large intestine, a fleshy tube approximately 1.5m long extending from the 
margin of the anus to the junction with the small intestine. * The burden of 
colorectal cancer is also heavy: 
570,000 new cases are reported world-wide each year (Shike et al. (1990)) representing 9% of all diagnosed cancers. 
By the year 2000 it will account for 755,000,000 lost years of life world- 
wide (Eddy (1986)). 
As noted above, it accounts for 11 % of life-years lost to cancer in 
Britain and 3% of all life-years lost, shown in Figure Two. 
The disease has a poor prognosis at present with only about 35% of patients 
living to five years after diagnosis (Stower and Hardcastle (1985)). Once 
account is taken of cases never admitted to hospital or never considered for 
operation the rate may be as low as 27%, however (Slaney (11991)). 
The following sections consider the causes of the disease, hoping to 
establish some means of prevention, and the treatment, to search for 
advances which will improve cure rates. 
CAUSES 
The causes of many types of cancer are either unknown or unquantified. 
Research into the causes of colorectal cancer has concentrated on the 
influence of inherited susceptibility through genetic defects and the role of 
environmental factors such as diet. 
Genetic factors 
Support for a genetic origin to colorectal cancer has come from the study of 
two groups of patients (Canon-Albright et al. (1988)): 
i) those with inherited gastrointestinal syndromes such as familial 
adenomatous polyposis, a condition producing the growth of thousands of 
* The sites within the large bowel include: rectum, recto-sigmold junction, sigmoid colon, 
descending colon, splenic flexure, transverse colon, hepatic flexure, ascending colon and the 
caecurn. 
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small polyps thought to be the pre-cursor of cancer in the bowel, have a 
very high risk of developing colorectal cancer, and 
ii) those with a first-degree relative (i. e. parent, sibling or child) who have 
had colorectal cancer support are themselves at increased future risk. 
The higher risk in hereditary non-polyposis syndromes does not affect 
spouses implying that environmental factors are not decisive in these cases. 
A whole range of genetic defects are implicated: based on the hypothesis that 
cancer arises as the result of up to seven accumulated events, a possible 
model for mutation has implicated a total of 11 genetic defects in the 
evolution of metastatic colorectal cancer (Scoff and Quirke (1993)). These 
advances have been described as, "... the beginning of a new and exciting 
phase that holds out the prospect of understanding the pathogenesis of 
colorectal cancer at the most fundamental level. " (Anon (1991)). Ultimately it 
may be possible to identify those at high risk of developing colorectal cancer 
within the general population and then to keep them under close surveillance. 
This is not yet a practical proposition, however. 
Environmental factors 
Other evidence indicates that environmental factors play a role in many 
cases. For example, migrant populations take on the incidence rates of the 
host population within a generation (Levin and Doizois (1991)). The number 
of different elements of diet which are implicated makes research difficult. 
Simple questioning of people with and without the disease risks bias as a 
result of differences in recall, while prospective studies are long and 
expensive. The role of a 'marker' in colorectal cancer (akin to cholesterol in 
ischaemic heart disease) is not understood; this makes identifying causative 
and protective agents difficult. 
Increased fat consumption is associated with increased incidence, especially 
in combination with calcium deficiency, although the type of fat may also be 
relevant: vegetable fats may have a protective role while saturated animal 
fats increase risk (Neugut et al. (1993)). It is unclear whether excess calorie 
consumption and body weight have an independent effect (Nomura (1990)), 
but some evidence suggests an increased risk of colon cancer for those with 
sedentary life-styles, implying a protective role for physical activity (Levin and 
Dozois (1991)). 
Fibre and starch are also regarded as protective agents, but fibre is not a 
single entity; again, this makes research more complicated. There is limited 
evidence that fibre consumption is associated with less aggressive disease 
and a less advanced pre-malignant stage (Armitage (1991)). Ovprall, though, 
the link between fibre intake and colorectal cancer has been described as "at 
best, an oversimplification. " (Willett (1989)). 
A recent consensus conference concluded, "... the evidence is not strong 
enough to recommend specific dietary changes. " (King's Fund (1990)). 
However a'common-sense' approach of increasing the intake of vegetables 
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and starch while reducing fat and alcohol consumption "will not increase the 
risk of large bowel cancer and may be of benefit. " (Bingham (1990)). Dietary 
and genetic factors play a part but their role is complex, with many possible 
interactions. 
PROGNOSTIC VARIABLES 
Staging 
The spread (or stage) of cancer at diagnosis is the most significant variable 
affecting the prognosis. The pathological classification for colorectal cancer 
was originally devised by Dukes in 1932 to stage rectal cancer. Cancers 
limited to the bowel wall are at stage A, those spreading into the surrounding 
muscle but not involving any lymph nodes* are at stage B, those which have 
affected local lymph nodes are at stage C, and (a modification to the original 
proposals) those which have metastasised are stage D. A review of patients 
presenting to a British teaching hospital during the 1970s gives a typical 
distribution of stages at presentation, together with the survival rate for each 
stage (Stower and Hardcastle (1985)): 
Table Two 
Stage % diagnosed at each stage % surviving to five years 
A6 77 
B 35 58 
C 31 22 
D 27 5 
Thus, many patients present with disease at such an advanced stage that the 
prospects of cure are poor. Note, however, that the assumed effectiveness of 
the treatment of early stage disease is assumed rather than proven: surgical 
treatment of early stage prostate cancer, for example, appears to offer little 
survival gain over a policy of monitoring alone (Dearnaley (1994)). 
Dukes' stage is an imperfect predictor of prognosis, however (Deans et al. 
(1992)). While the classification system takes account of whether lymph 
nodes are involved it does not use information on the number affected, which 
may affect prognosis. 
Other factors 
The size and bowel site of the tumour appear to have little independent 
influence on survival. Clinical features of the presentation, such as whether 
or not the tumour is adhering to other organs, bowel obstruction and the age 
of the patient all have some independent effect (Chapius et al. (1985), 
Fielding et al. (1986)). In addition, the pathological histology or differentiation 
* Lymph nodes can be thought of as access points to the body's lymphatic system, a route 
which is commonly seen as the means by which malignant disease spreads (or metastasises) 
to sites distant from the primary growth, such as the liver. 
9 
of the disease is significant: this acts as a proxy for the 'aggressiveness' of 
the disease with poorly differentiated cases being the least amenable to 
treatment. 
In individual cases the surgeon performing the operation may also exert some 
influence on the outcome: differences in survival rates following a supposedly 
curative resection have been observed (McArdle and Holt (1991)). This has 
led to calls for specialists colorectal surgeons to carry out all operations of 
this type. 
TREATMENT 
Surgery is the only widely accepted treatment for the disease, although the 
use of radiotherapy and chemotherapy is being evaluated (and is discussed 
further in Chapter Eleven). Surgery involves a resection of the bowel, with 
the affected tissue removed together with a 'safety margin' of healthy tissue (about 2cm. in rectal cancer and 5cm. in colon cancer); the healthy bowel is 
sewn or stapled together in an anastamosis. The procedure is judged to be 
potentially curative if there is no evidence of residual disease. There is a risk 
of operative complications or mortality, commonly due to cardio-respiratory 
problems or wound infection. Operations for rectal cancer may also damage 
nerves in the genito-urinary system of male patients causing subsequent 
problems with urination and even impotence. 
Endoscopic excision of the cancer by means of an endoscope (a rigid or 
flexible fibreoptic telescope) is possible if the tumour is small (less than 3cm. 
diameter) and has been accurately staged. If the excision is judged to be 
complete on pathological examination of the specimen surgery may be judged unnecessary. 
A different technique is required for rectal cancers very close to the anal 
verge (usually within 4cm. of the anus). Since there is no safety margin of 
healthy tissue an anastamosis between two pieces of unaffected tissue is not 
possible, hence the anal sphincter cannot be safely preserved. The colon is 
diverted to a stoma (mouth) in the patient's abdomen. Recent advances in 
technique and relaxation of acceptable safety margins have allowed more 
rectal cancers to be treated by anterior resection, preserving the patient's 
quality of life wherever possible. A series of operations for rectal cancer 
found 40% of procedures between 1978 and 1982 involved a permanent 
colostomy compared to 21 % between 1983 and 1988 (Dixon et al. (1991)). 
Resection is also commonly performed as a means of palliating symptoms 
and avoiding obstruction of the colon where the disease is too advanced to 
achieve a cure. Operations involving a colostomy are still a common form of 
treatment in emergencies or for palliative procedures in cases of advanced 
disease: this prevents tumour growth from obstructing the colon or perforating 
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the bowel wall. Wedge resection of the liver is used in some centres to 
remove hepatic metastases but the benefits of this have not yet been proven. 
A number of reports have been made on series of patients admitted to 
hospital with a diagnosis of colorectal cancer. Differences between units, 
between the way results are reported and possible time trends make some of 
the data difficult to compare; the following sections present a summary of the 
main findings from the major British series (Anderson et al. (1992); Brown et 
al. (1991); Dixon et al. (1991); McArdle and Hole (1991); Stower and 
Hardcastle (1985); Umpleby et al. (1984)). While the summary inevitably 
generalises from a variety of studies, the potential for large variations 
between individual surgeons should be bome in mind (McArdle and Hole (1991)). 
Patient characteristics at presentation 
The average age of the series of patients is commonly between 65 and 70: 
one study reports an age range for resections of 25 to 101. The split by 
gender is fairly even. 
The primary site is the rectum (including the rectosigmoid junction) in about 
44% of cases, in the sigmoid or descending colon for 30%, in the transverse 
colon or flexures for 11 % and in the ascending colon or caecum for 15%. 
About 15% of cases are poorly differentiated. Of those with metastases the 
liver is affected in 74%, the peritoneal cavity in 33%, and the lungs in 5%; the 
brain, skeleton, adrenal gland and ovaries can also be affected but these are 
rarer. 
Type of admission 
Between 30% and 40% of admissions are emergencies. These patients tend 
to be older than average with advanced cancer of the colon; surgery is also 
more likely to be undertaken by a junior doctor. Very few rectal cancers 
require emergency admissions. 
Treatment received 
Historically, over 20% of patients were never operated upon but recent trends 
are to perform more palliative resections particularly in elderly people with 
advanced disease. Between 5% and 8% of admissions do not undergo an 
operation either because of obvious terminal disease or because they die 
before any procedure is possible; the surgery rate is age-related. A similar 
number are found to have unresectable tuMOUrs at laparotomy, while a 
further 10% have only a partial resection (again, owing to obvious advanced 
disease). About one-third of patients have operations requiring a colostomy, 
either temporarily or permanently. 
Between 50% and 60% of completed resections are regarded as curative: the 
figure is related to the age of the patient, whether the admission was an 
emergency, and the differentiation of the tumour. The mobility of the tumour 
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plays a part here: half the operations performed are on cancers which are 
fixed to other structures in the abdomen, implying spread to other organs and 
a reduced chance of a cure. 
Operative mortality 
About 20% of patients die in hospital following their first admission with the 
disease; again this is age-related. For those who have an operation the rate 
is between 10% and 15%; while most of these cases are due to pre-existing 
conditions (particularly cardiac and respiratory disease), 27% of deaths in 
one series were attributable to surgical complications. 
Other complications 
The complications of major surgery can be very serious, both for the health of 
the patient and in terms of prolonged hospital stay. The main problem in 
comparing reports of complication rates is variation in the definition of a 
complication and the thoroughness with which such data (which is not 
routinely available) are collected. 
Anastamotic dehiscence (defined as clinical evidence of a leak with resultant 
fistula formation, sepsis, or both) occurs in between 6% and 12% of cases, 
with wound dehiscence in less than 1 %. The prognosis in such cases is poor 
with 59% dying before discharge in one series. Wound infection rates vary 
from 8% to 22%. Following operations for rectal cancer 2% of patients 
require an operation on their prostate and 1% suffer from impotence (Dixon et 
al. (1991)). Other complications include chest infection (14%), pneumonia 
(5%), deep venous thrombosis (3%) and urinary tract infection (11 %). 
Recurrence 
Even following resections which are judged to be curative disease can recur, 
due to small amounts of residual disease being missed at the operation. 
"Local recurrences are an important reflection of surgical technique in cancer 
treatment and produce the worst form of death for patients, producing pain, 
incontinence, discharge, etc. " (Dixon et al. (1991)). The proportion of 
curative resections who develop recurrence varies between series but one 
review suggests bounds for the rate of 15% to 30% (Pollard et al. (1989)), 
although figures of up to 47% have been reported (Umpleby et al. (1984)). 
Most recurrences present within two years of surgery, at a median of 22 
months in one series (Devesa et al. (1988)). 
Recurrence is found in 4% of stage As, 13% of stage Bs and 18% of Cs 
(Phillips et al. (1984)); 11 % of well differentiated tumours recur, compared to 
14% and 21% of those that are moderately and poorly differentiated. Stage 
and differentiation interact, hence a poorly differentiated stage C tumour is at 
particular risk. 'Cured' rectal cancers appear to be at slightly increased risk 
of recurrence compared to cancers of the sigmoid colon (Umpleby et al. 
(1984)). 
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CONCLUSION 
Colorectal cancer is a major cause of ill-health and a significant cause of 
premature mortality. The ability to cure disease in its earlier stages implies 
that the potential gains from earlier detection are large. Treatment advances 
do not solve the problem of late-stage presentation. Prevention of the 
disease may be possible at some point in the future but is not yet a realistic 
option. This leaves screening as the only immediate prospect of reducing the 
social cost of colorectal cancer. 
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Chapter Two 
SCREENING FOR COLORECTAL CANCER 
Introduction 
Screening is defined as, "Mhe identification, among apparently healthy 
individuals, of those who are sufficiently at risk of a specific disorder to justify 
a subsequent diagnostic test or procedure, or in certain circumstances direct 
preventive action. " (Cuckle and Wald, quoted in Holland and Stewart (1990)). 
Mass screening relates to the screening of entire groups of the population as 
opposed to high-risk groups. 
The purpose of this chapter is to introduce the principles of screening for 
disease and the practical application of these principles to programmes for 
the detection of colorectal cancer. The conditions for effective screening are 
described and the evidence regarding colorectal cancer presented. 
Screening and effectiveness 
An effective screening programme will result in the detection of early stage 
disease, improving the prognosis and survival rate. Effectiveness can 
sometimes be taken for granted, however: "[T]he act of screening runs the 
risk of acquiring respectability almost by virtue of its existence. " (Holland and 
Stewart (1990)). This has led to an unwarranted assumption in favour of 
preventative medicine in advance of proper evaluation. A leading breast 
cancer screening researcher, for example, expressed her concern that 
doctors were brainwashing themselves into thinking that they were having a 
major impact upon the disease before they brainwashed the public (Roberts 
(1989)). Such assumptions have worked their way into medical training 
according to the experience of one American doctor: I recall as a medical 
resident asking whether a patient needed sigmoidoscopy and being asked in 
return, 'Does the patient have a rectum? '" (Grey (1991)). 
Others have commented upon the ethical imperative to prove effectiveness 
before implementing screening (McKeown in Gyde (1990)). It is argued that 
the doctor cannot be held to blame for the state of medical knowledge when 
the patient approaches him with symptoms of disease requiring treatment: it 
is only incumbent upon the doctor to do as well as they can, subject to 
constraints. In screening, however, doctors approach healthy members of 
the public offering a test which (implicitly) has some value. The onus should 
thus be on the medical profession to be able to quantify that value. 
Conditions for effective screening 
Public health physicians have described a number of criteria for a disease 
screening programme. These are not always clearly defined, nor are they 
based on economic principles. The following list covers the most commonly 
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mentioned factors (from Wilson and Junger plus Cuckle and Wald quoted in 
Holland and Stewart (1990)): 
i) factors relating to the disease 
the disease should represent an important health problem 
the natural history of the disease should be understood 
the disease should have a recognisable latent or early symptomatic 
stage 
ii) factors relating to the screening test 
the test should be acceptable 
the test should be accurate 
the test should be inexpensive 
the distribution of test values in healthy and in ill people should be 
known and the cut-off for a positive test defined so that the extent to 
which people with and without the disease are misclassified is 
minimised 
iii) factors relating to the screening programme 
sufficient diagnostic and therapeutic facilities should be available 
there should be an effective and widely accepted treatment protocol 
0 there should be an agreed policy on who to treat 
Despite doubts about the value of these criteria, they form a useful checklist 
for discussing aspects of colorectal cancer with regard to the possibility of 
screening. 
1. IS COLORECTAL CANCER A SUITABLE DISEASE FOR 
SCREENING? 
The burden of colorectal cancer makes it a major source of ill health and 
reduced life expectancy. The natural history is suitable for intervention: 
disease develops in a recognised pre-malignant condition (the adenoma) and 
is initially localised before spreading to other sites. While this broad 
description is widely accepted, many of the parameters in the process are the 
subject of debate. The role of the adenoma is a good example. 
Adenomas 
Polyps are small, fleshy growths protruding from the bowel wall. Pathologists 
classify polyps according to their cell structure: those suggesting neoplastic 
alteration of the epithelium (dysplasia) are known as adenomas. The 
histology of an adenoma relates to its cell structure: tubular, villous and 
tubulovillous have varying proportions of cells which are either finger-like or 
tubular when viewed through a microscope. The histology and dysplasia are 
significant because they are thought to influence the malignant potential of an 
adenoma. 
In support of the so-called adenoma-cancer sequence there is genetic 
evidence of common chromosome defects in each case (Anon (1992)). 
Familial adenomatous polyposis, a rare inherited disorder which causes 
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countless adenomas to grow in the large intestine, almost invariably results in 
cancer. Follow-up studies of patients with a previously excised adenoma 
imply that there is an increased future risk of cancer. Epidemiological 
support is also available: the distribution of adenomas and cancers is 
correlated both internationally and across ages within a population. In 
addition, there is a tendency for both types of neoplasia in young people to 
be mainly in the left-side of the bowel while older people have a higher 
prevalence of each on the right side. Clinical evidence points to a similar 
conclusion: more than half of resected cancer specimens contain residual 
adenomatous tissue, while observation of unexcised adenomas has revealed 
cancer subsequently developing at the same site (Morson (1984), Rawlinson 
et al. 1989), Stryker et al. (1987)). In one large study the removal of rectal 
adenomas was claimed to reduce the future incidence of rectal cancer below 
that expected (Gilbertsen and Nelms (1978)), but this finding is controversial (and is discussed further below). 
Thus, while there is no conclusive proof that cancers arise in adenomas, a 
large body of circumstantial evidence exists. No other theory has gained any 
widespread acceptance. However, although cancers arising directly from the 
mucosa (de novo) are rare there are some reports of small (5-15mm. 
diameter) 'button' cancers with raised edges and a depressed centre, with no 
evidence of a pre-malignant stage. Pathological evidence that more than half 
of cancer specimens contain residual adenomatous tissue implies that, at 
most, only a minority of cases arise in this way. However, some researchers 
have claimed that these could represent a more aggressive, clinically 
significant, disease while polypoid cancers, which grow into the lumen (the 
actual space within the walls of the intestine) rather than into the bowel wall, 
are less aggressive. One study has estimated that 15% of cancers miss out 
the adenoma stage of progression (Koretz (1993)) although these findings 
have been questioned (Simon (1993)). 
It is widely agreed that many adenomas remain benign and pose no health 
risk. While cancer prevalence (the proportion of the Population with a 
condition) is thought to be about 3 per 1,000 in people aged over 50, 
adenoma prevalence is as follows: 
18% in under 55s 
29% in those aged between 55 and 64 
40% for those aged 65 to 74 
41 % for those aged 75 and above (Williams et al. (1982)). 
Estimates of the exact proportion of adenomas destined to become malignant 
vary considerably from I% up to 10% (Hoff (11987)). The length of the 
sequence is also uncertain with estimates ranging from 'at least five years' 
(Simon (1985)) to 'up to 18 years' (Frank (1985)). The variation between 
individual cases is still less clear. 
This brief review Of the uncertainty surrounding the important aSPects Of the 
disease process. Similar doubts surround the progression through the stages 
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of malignancy. Colorectal cancer conforms to the broad description of a 
suitable test but several important pieces of data are missing. 
2. 'IS THERE A SUITABLE SCREENING TEST FOR COLRECTAL 
CANCER? 
The accuracy of a screening test is described by its sensitivity and specificity. 
The former is the proportion of people who have the disease who test 
positive; the latter is the proportion of people without the disease who test 
negative. The two types of information provided by a screening test may 
ultimately prove to either have been true or false, although this is not 
observable at the time. There are thus four outcomes to screening: diseased 
and positive ('true positive'); healthy and negative (true negative'); healthy 
and positive (Talse positive'); and diseased and negative (Talse negative'). 
These are considered in turn below. 
The vast majority of people completing a screening test will be negative for 
the disease. This may offer them some reassurance, although it has been 
pointed out that an individual has only a small chance of developing the 
disease so realistically this is unlikely to be very important (Frank (1985)). 
For a small number the reassurance will be false, either because the 
screening test has failed to detect the disease or because disease develops 
in the interval between screens. The negative test may cause them to ignore 
symptoms of the disease if and when these occur, although it could be 
argued that the screening process will make them more aware of the disease 
and hence cause them to react more quickly. 
A minority of people have positive test results, which are likely to cause 
anxiety. For many diagnostic investigation will confirm that the cause of the 
positive test is benign or that there is no evidence of any bowel disease at all. 
While this may reassure some, others will have persistent anxiety and 
possibly depression: this effect is also known as labelling (Marteau (1989) 
and (1990)). Only those who have disease detected and treated at an earlier 
stage than if they presented symptomatically can derive a health benefit; 
however, this group may also suffer psychological sequelae. 
Sensitivity and specificity can be expressed algebraically and the relationship 
of each to variables such as the positive rate explored. Supposing that there 
is a target population T of whom A accept and X is the rate Of participation 
i. e. A=TX. The prevalence rate in the general population is R and the rate 
among acceptors is RA. The total number of cases prevalent in the 
population is C which equals TR while the number in the accepting 
population, CA, is TXRA- 
Screening yields P positive results of whichpT aretrue Positives and PF are 
false positives; similarly of the N negative tests NT are true negatives and NF 
are false negatives. By definition A=PT+PF+NT+NFand CA=PT+NF- 
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The sensitivity rate of the test, SN is defined as PT'CA, thus PTýCA*SN. The 
specificity rate Sp is defined as NT/(A-CA) so NT' 'ý(A-CXSP' 
Expressions for NFandpFcan also be derived: 
NF'*ýCA-PT or CA-(CA*SN) 
'ýc X 
-SN) 
and 
PF=A-PT-NT-NF 
=A-(CA*SN)-SP(A-CA)-CA(l 
-SN) 
=A(1-SP)-CA(l +SP) 
Thus, while trial results can only be used to estimate sensitivity and 
specificity if a definitive test has also been used, estimates of these 
parameters can be converted into predicted trial outcomes if prevalence 
estimates are available. 
Available tests for colorectal cancer 
Three means of screening for colorectal cancer have attracted more attention 
than any other: 
direct visualisation of the large bowel (endoscopy); 
surveying the population for bowel symptoms; and 
0 testing for blood in samples of faeces. 
Other methods such as testing for raised levels of carcinogenic antigens in 
blood samples has also been proposed but has been found more useful in 
surveillance after treatment. Digital rectal examination extends up to 1 Ocm. 
from the anal verge and can detect approximately 10% of all colorectal 
cancers, as well as prostate cancer; however, it is part of a fuller health 
check-up rather than a screening test in its own right. One possible 
screening test for the future has been described as follows: "In Imaxs 
showrooms in Ginza, Tokyo, a prototype 'intelligent toilet, is on display, which 
can measure the user's weight, temperature and blood pressure (don't ask 
me how) and carry out up to eight different tests on urine and faeces; an 
electronic link to the nearest hospital will transmit all abnormal findings 
... 
By 
the year 2000, we shall all strain on lavatory bowls more intelligent than 
ourselves. " (Skrabanek (1991)). In the absence of further data this option 
has not been evaluated but the results of trials are eagerly awaited. 
Sigmoidoscopy screening 
Endoscopy is very accurate since direct viewing of the bowel combined with 
blopsying of suspicious lesions means that the examination will be sensitive 
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and specific. The extent of the examination is often limited, however, and 
only a portion of the bowel can be viewed. There is also a small health risk 
involved through post-investigation haemorrhaging, perforation of the bowel 
wall and other complications. Since it is a hospital-based investigation there 
are also concerns about its cost. 
The two main types of endoscope considered are the short rigid instrument 
and the longer flexible instrument. 
i) Rigid sigmoidoscopy screening 
Rigid sigmoidoscopy can visualise the rectum up to the junction with the 
sigmoid colon some 25 cm. from the anal verge, covering the primary site of 
40% of colorectal cancers (Stower and Hardcastle (1985), Umpleby et al. (1984)). However, the instrument is only fully inserted in 50% of cases and 
the average view is to about 17cm. In common with other types of 
endoscopy, the procedure is uncomfortable for the patient and perforates the 
rectum in 1.4 per 10,000 investigations (Selby and Friedman (1989)) and 
results in the death of the patient in about 1 in 10,000 (GOICC (1990)). 
Some uncontrolled trials have claimed that regular rigid sigmoidoscopy can 
reduce the incidence of rectal cancer (Gilbertsen and Nelms (1978); Dales et 
al. (1979)). Doubts have been expressed about the calculations made, the 
thoroughness of follow-up, and the high proportion of the control group 
undergoing screening. 
A case-control study of the effects of rigid sigmoidoscopy screening 
suggested a 59% reduction in the risk of dying of cancer sited in the area of 
the colon covered by the instrument (with a confidence interval of 31 % to 
75%) (Selby et al. (1992)). The number of new cases is low following a 
sigmoidoscopic examination; the reduction may last for up to ten years. 
fi) Flexible sigmoldoscopy screening 
Up to 70% of cases of colorectal cancer are found within 60cm. of the anal 
verge. The instrument is fully inserted and the view adequate in 80-90% of 
cases; perforation occurs in less than I in 2,000 investigations (Selby and 
Friedman (1989)). It is superior to rigid sigmoidoscopy in many respects. 
However, it requires fuller bowel preparation in advance, and is more 
expensive because of the more complex equipment required. 
N) Conclusion 
Sigmoidoscopy has proven value in detecting neoplasia. However, claims 
relating to mortality reductions are based on clinical trials which are usually 
regarded as suggestive rather than conclusive owing to the possibility of 
biases in the results. American and Canadian working parties on screening 
both felt unable to recommend screening by this means in the absence of 
more proof of effectiveness. However, other American organisations, such as 
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the American Cancer Society, feature sigmoidoscopy in their 
recommendations to physicians on screening. 
Screening using the symptom questionnaire 
Typical symptoms leading to a diagnosis of colorectal cancer include rectal 
bleeding, change in bowel habit, weight loss and abdominal pain. One option 
is to improve public awareness of the potential significance of such 
symptoms. However, overcoming the social mores surrounding bowel 
function and problems is difficult, particularly in the elderly population. 
Another problem is the frequency of the symptoms in the general population 
after middle age: about 1-in-6 in these age groups experience some rectal 
bleeding each year and 1 
-in-24 GP consultations is for bowel disease (Hannigan et al. (1990), Jones and Dudgeon (1992)). It is possible that 
significant anxiety about such symptoms could be aroused for little reason. 
Screening based on these factors by postal questionnaire has been 
attempted and found to be severely hampered by the high prevalence of such 
symptoms in the target age groups. One study had a 23% positive rate and a 
positive predictive value* for any neoplasia of only 5% (Pye et al. (1988)). 
Some symptoms have proven more useful than others: the best positive 
predictive power is from a combination of dark red rectal bleeding and 
diarrhoea (Silman et al. (1983)). In the light of the evidence, however, this 
option is rarely considered for mass screening. 
Faecal occult blood testing 
As noted above, many middle-aged and elderly people experience small 
amounts of bleeding from the rectum. Some blood is deposited on to stools 
as they pass through the bowel; the median quantity of haemoglobin (or Hb. ) 
found in healthy individuals has been measured at 0.72mg. of Hb. per 
gramme of stool (Ahlquist et al. (1985)). Cancers of the bowel also deposit 
blood onto stools, but in greater quantities; the median blood loss in patients 
diagnosed as having cancer is 6mg. Hb. per gramme of stool (Ahlquist et al. (1985)). By the time bleeding occurs invisible quantities the disease is often 
advanced. One means of detecting cancer at an early stage is to test the 
stools of asymptomatic subjects for bleeding in excess of normal 'background' 
levels. The mean blood loss in subjects with asymptomatic cancer has been 
measured at 3.3 mg Hb per gramme of stool (Ahlquist et al. (1989)), implying 
that this is technically feasible. 
However, even a perfect test for faecal occult blood (FOB) would be an 
imperfect test for colorectal cancer. 
* The positive rate Is defined as the number of people testing positive divided by the number 
completing the test. The positive predictive value is defined as the proportion of those with a 
positive test who are shown to have the disease on the basis of diagnostic Investigation. 
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i) a positive test may have a cause of little or no clinical significance e. g. 
haemorrhoids. Elements of a normal diet can also cause a positive 
test such as red meat and some types of vegetables and fruit. 
ii) not all cancers (and few adenomas) bleed in excess of the level 
commonly regarded as 'normal' in their asymptomatic stage to test 
positive, and even those that do so may bleed intermittently over time 
and/or deposit blood only in a few areas of the stool. 
This implies test sensitivity and specificity of less than 100%. 
FOB testing as a means of mass population screening was first seriously 
contemplated in the early 1970s when the Haemoccult test became available. 
It consists of a series of gualac-impregnated squares of filter paper mounted 
on a single piece of cardboard. It is completed by the patient at home by 
taking a pea-sized sample of faeces and smearing it on a square. The test 
has six squares and is completed over three days to allow for intermittent 
bleeding. The completed test is returned for laboratory development, where 
two drops of hydrogen peroxide, a reagent which reacts with small quantities 
of haemoglobin, are added. If the sample develops a blue tinge within thirty 
seconds then it is judged positive; unfortunately this fades within a few 
seconds so that 'on-the-spot' interpretation is required and a second opinion 
is ruled out. 
i) Sensitivity to cancer 
When a new screening test is developed, a simple means of assessing its 
sensitivity is to test it in symptomatic cancers: for three-day testing 70% of 
such cases were positive (Farrands and Hardcastle (1983)), although this 
figure is site-dependent (Leicester et al. (1983)). The problem with this 
method is that people who have symptoms have higher levels of rectal 
bleeding than asymptomatic cases, hence the figures are over-estimates of 
the figure for an asymptornatic population. 
It has been found that, for a given haemoglobin concentration, wet stools are 
six times more likely to test positive than a dry one (Ahlquist et al. (1985)). 
As mass population screening relies on the postal return of completed tests, 
delays may mean that weak positive reactions could give negative results 
(Macrae and St John (1982)). One technique is to rehydrate the stool sample 
with a drop of water prior to development. This makes the test very sensitive 
when applied to symptomatic cancer (Macrae and St John (1982)). 
fi) Sensitivity to adenomas 
The overall sensitivity for adenomas has been estimated at 28% (Macrae and 
St John 1982); Rex et al. (1991)). Other characteristics are also relevant: 
large, pear-shaped, villous, severely dysplastic adenomas on the left side of 
the colon are most likely to be detected (Gabrielsson et al. (1985)). 
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Evaluation of screening tests 
Clinical trials are the traditional source of data on the effectiveness of 
screening. In one form of trial, the uncontrolled study, a sample is recruited, 
offered screening and followed over time. Results in terms of stage at 
detection and 5-year survival rates can be compared with data on groups of 
patients presenting with symptoms. This evidence allows conclusions to be 
drawn about the technical feasibility of screening; however, it is insufficient 
proof of the effectiveness of screening because of the problems in uniquely 
attributing the observed effects to screening, owing to other sources of bias in 
the results. 
Lead-time bias describes the effect of detecting a disease at an earlier stage 
in its progression but not affecting the prognosis. It has been likened to 
getting on a train one station earlier to get off at the same destination. 
Consider two alternative scenarios. Under one, the disease causes 
symptoms when the patient is age 67, it is diagnosed and treated, and the 
patient dies at 70. In the other, the disease is detected on screening at age 
65, it is treated and the patient dies at age 70. A measure of outcome like the 
five-year survival rate will be improved by screening but the effect does not 
benefit the patient, and may even cause harm. 
Length bias relates to variations in the growth rate and aggression of cancers 
of a single site. Slow-growing cancers will have a longer asymptomatic stage 
than aggressive cancers. Screening will, therefore, detect a high proportion 
of slow-growing cancers, since these are present for so much longer. If these 
cancers would have remained asymptomatic until the individual dies of some 
other cause then there is no health benefit to diagnosis. Early detection is of 
little value either in cases with very aggressive, fast-growing cancers (likely to 
recur even if treated) or in cases with very slow-growing cancers. 
Bias may also be introduced by using healthy volunteer populations in trials. 
This group may take more care of their health than the general population, 
making screening appear more beneficial and making generalisation of the 
results to the general population difficult. 
Some of the problems in interpreting the evidence from uncontrolled studies 
can be illustrated by the German national programme. 92% of the population 
of that country is covered by a statutory health insurance scheme, including a 
cancer screening programme which has offered digital rectal examination for 
people aged 45 and above since 1971 and annual Haemoccult screening 
since 1977. Data protection legislation makes linkage of screening and 
cancer incidence records impossible; there is incomplete reporting of 
screening and diagnostic test use; and adenoma excision is not recorded. 
This makes the effectiveness of the programme very hard to evaluate. The 
incidence of unresectable rectal cancers has been failing since the early 
1970s and colorectal cancer mortality has been falling since 1979, but a more 
health-conscious population and improvements in diagnosis and treatment 
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could account for this. Contrary trends in neighbouring countries indicate 
that screening has some value but the decline in mortality (starting only two 
years after introduction of Haemoccult screening) implies other factors are 
also at work (Robra (1986)). 
The flaws in evidence from non-randomised studies has not deterred 
sweeping recommendations on the basis of potentially misleading results: 
"Evidence of a decline in the proportion of advanced-stage cases should be 
viewed as an acceptable analogue for mortality reduction. If screening leads 
to a higher frequency of earlier stage cases or reciprocally fewer late-stage 
cases, a good argument for the efficacy of screening can be made. " (de 
Cosse (1988)). The biases in the evidence listed above imply a more 
cautious view. "The current knowledge base, including open questions of 
efficacy can support a range of recommendations. " (Knight et al. (11989)). A 
similarly misleading claim is the following: "... within a potential group of 
patients offered regular colonoscopic screening there may be, say, 10 
patients who were otherwise going to develop bowel cancer and die of it. 
One would strongly suspect that with regular colonoscopic surveillance at 
least three of these would be diagnosed at either the adenoma or early, 
curable carcinoma stage and thus result in a 30% decrease in mortality. " 
(Meagher and Stuart (1992)). This assumes: full participation; no 
complications or mortality as a result of screening; adenoma excision 
prevents cancers occurring in the future; asymptomatic disease can be 
detected at an early stage; advancing the stage of detection increases the 
cure rate; and that people live longer as a result. 
Randomised controlled trials (RCTs) minimise the bias in results by randomly 
allocating a population to two groups, one of which will be offered screening 
and one which will not. These populations should then be identical in all 
respects other than the offer of screening and any observed differences in 
mortality rates can be attributed to screening with some confidence. 
However, such studies are also time-consuming and expensive. Evidence 
with regard to colorectal cancer screening is considered in the following 
section. 
3. CAN A SUITABLE PROGRAMME FOR COLORECTAL CANCER 
SCREENING BE DEVISED? 
Two aspects of a suitable programme are considered in this section. The first 
problem is to consider the relative risk of the disease in various sub-groups of 
the population in order to decide who will be offered screening. The second 
problem is to define a suitable screening protocol. To address this issue 
some of the options used in the on-going clinical trials of screening are 
described. 
23 
Risk factors and screening 
One of the main requirements for a screening programme is to identify a 
suitable group for screening. Ideally this will be on the basis of a set of 
factors which identify a high-risk group leaving the unscreened population at 
as low a risk as possible. 
Sub-groups of the population can be defined as being at increased risk of 
developing the disease. The following classification of risks has been 
proposed (Fleischer et al. (1989)): 
Markedly increased risk 
" 
Cancer families 
- 
inherited susceptibility to particular types of cancer 
" 
Familial adenomatous polyposis 
- 
hereditary condition producing 
thousands of adenomas in the large bowel 
" 
Extensive ulcerative colitis 
- 
much of the bowel wall shows some form of 
dysplasia, 
Moderately increased risk 
" 
First degree relative with colorectal cancer 
" 
Previous neoplasm in large bowel 
" 
Limited ulcerative colitis 
" 
Women undergoing irradiation for gynaecological cancer 
Probable increased risk 
Previous cancer of either the breast or of a gynaecological site 
Previous ureterosigmoidostomy 
Nevertheless, these groups cover only about 20% of cases of colorectal 
cancer (Jarvinen and Mecklin (1989)). To make a major impact on mortality 
from the disease, a more general risk factor must be considered. 
Screening by age gr9up 
Cancer is essentially a disease of old age: even if it were to be completely 
eradicated average life expectancy would only rise by a little over two years (Eddy (1981)). Table One shows the number of new cases in England and 
Wales in 1987 and the number of deaths from colorectal cancer in 1991 
(these are the most recent figures in both cases). Also included is a 
breakdown of the life-years lost as a result of deaths in each age group, 
calculated according to the life expectancy at the midpoint of each five-year 
age range (LYs denotes life-years lost): 
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Table One 
Age Cases Deaths LYs lost % of total 
<40 310 93 3,952 2 
40-4 354 166 5,599 3 
45-9 576 344 10,080 5 
50-4 977 584 14,362 8 
55-9 1,739 922 18,906 10 
60-4 2,695 1,600 26,795 14 
65-9 3,512 2,351 31,573 17 
70-4 3,930 2,710 28,266 15 
75-9 4,432 2,876 22,891 12 
80+ 6,340 4,481 27,154 15 
(Source: own calculations based on OPCS (1987), OPCS (1993)). 
Of all life-years lost to colorectal cancer, 18% are before the age of 55, but 
each five-year age-group carries an equal share of the total thereafter as 
rising incidence is offset by declining life-expectancy. 
Little is known about the prevalence of the disease in the United Kngdom, 
but, on the basis of American estimates (Feldman et al. (1986)), there are 
over 246,000 asymptomatic cases in the population of England and Wales, 
slightly more than half of these being in the 50 to 75 year old age group. The 
prevalence is ten times the incidence, implying a long pre-symptomatic stage 
to the disease. This is confirmed by estimates of colorectal cancer growth 
rates, which suggests that a 70-year old presenting with symptomatic disease 
may have developed the first mutation while aged about 40 (Spraft and Spratt (1985)). 
On this basis most protocols begin screening at around 50 years of age. The 
upper limit depends upon ability to undergo treatment if asymptomatic 
disease is detected; this implies stopping screening at about 75 years of age. 
Suitable screening protocol 
Much of this evaluation is concerned with defining the optimal screening 
protocol for colorectal cancer. However, in order to consider what 
alternatives are used in practice, the various clinical trials are described in 
more detail. The description of the MRC trial also sets the scene for the 
-following chapters. 
MRC trial, Nottingham (Hardcastle et al. (1980),, (1983)l (1986% (1989)) 
As the present economic evaluation concentrates on data from the Medical 
Research Council (MRC) screening trial many results are discussed in the 
following chapters. Nevertheless, some indication of the history and structure 
of the trial and a review of the main results will serve as an introduction. 
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The MRC trial is based in the Department of Surgery at the University 
Hospital in Nottingham. The grant is held jointly with the Department of 
Health Cancer Screening Evaluation Unit. A pilot study commenced in 1981 
randomising 20,525 people aged 45-74, with a Haemoccult test posted to the 
study group. The early participation rate was only 38%, but measures were 
introduced to improve this such as reminder letters to non-responders. In 
1983, an extension compared Haemoccult with another FOB test, 
Fecatwin/Feca-EIK, in a further 6,450 subjects. However, the positive rate of 
the latter test was 8.1 % which was judged to be unacceptably high given the 
limited diagnostic resources available. 
The improvement in the stage distribution of cancers detected by screening 
was adequate to justify funding for a full trial which commenced in the second 
half of 1984. The evaluation is of an offer of screening to the asymptomatic 
population between the ages of 50 and 75 by the Haemoccult 11 test. The aim 
is to reduce mortality from colorectal cancer in the group offered screening by 
30% compared with that in the control group. The offer of screening is 
repeated to those who participated in the previous round of screening only 
and this is at an intervals of two years after the previous round of screening. 
It has been calculated that 156,000 people will have to be recruited and 
followed-up for a minimum of seven years in order to show a significant gain 
on the basis of the assumptions used. The main data source is general 
practitioner records. Consent is sought from each practice to identify all 
those in the age limits specified, with participating GPs sent the list of eligible 
patients to exclude ineligible patients (e. g. those with a previous bowel 
cancer). Those remaining are then randomised and an offer of screening is 
made to the study group; only 2.3% of invitations are returned unopened by 
the GPO. 
One peculiarity of this trial is that the sample is recruited over time, thus 
spreading the workload involved but raising the possibility of time trends 
affecting the results. The length of follow-up is also difficult to calculate 
without using statistical techniques. 
The control group are not contacted in any way and do not appreciate that 
they are part of the trial. The study group are sent an offer of screening 
which consists of a standard letter signed by the individual's GP (letters 
directly from the screening unit had a lower participation rate), a Haemoccult 
test, instructions on how to complete it, and an SAE to return completed tests 
to the Department of Surgery. The letter explains that, while the individual 
has no current bowel disease, screening is advisable since early treatment 
has a better chance of success than waiting for symptoms to appear. The GP 
* The characteristics and performance of this test are discussed In More detail In Chapter 
Five. 
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therefore recommends that the individual complete and return the enclosed 
test in the envelope provided. 
Development of the test does not include the rehydration method mentioned 
above to counter any delays in the postal system. The criterion for a positive 
test is that any one of the squares on the Haemoccult test is positive when 
developed, although the exact number of positive squares is also recorded. 
An invitation is sent to those who have returned a positive test to attend a 
special out-patient clinic. This is an opportunity for the individual to discuss 
the test results and their potential implications. The clinical aim is to assess 
their suitability for further investigation; this includes taking a full medical 
history and any family history of colorectal disease. An abdominal 
investigation is then made followed by rigid sigmoidoscopy; flexible 
sigmoidoscopy is not used owing to the increased bowel preparation 
required. A blood sample is taken for routine tests. The patient is then 
offered a full diagnostic investigation. 
At the start of the trial diagnostic investigation was by means of the 60cm. 
flexible sigmoidoscope in combination with the double-contrast barium enema 
X-ray (BEXR). The excision of adenomas seen at radiology beyond 60cm. 
was by means of the limited colonoscopy facilities available at that time. The 
performance of BEXR was poor, however, despite the expertise of the 
consultant radiologist. Of seventeen cancers detected in the early stages of 
the trial following a positive screening test six were negative on radiology 
including four early stage cases. As more facilities have become available 
colonoscopy has become the favoured means of investigation with radiology 
reserved for the small numbers of patients who are unfit for sedation. 
Adenomas and polypoid cancers are excised at colonoscopy using snare 
diathermy (or polypectomy) wherever possible, with surgery reserved for 
larger tumours. Follow-up of all those recruited uses several routinely 
available data sources, including the records of the hospital's pathology 
department, the regional cancer registry and the NHS Central Registry in 
Southport. In addition, many local GPs are aware of the trial and notify the 
trial administrator of recent deaths from colorectal cancer among their 
patients. 
An interim report on the results of the first 107,344 patients recruited was 
made in 1989, although it is clear that the screening protocol has been 
subject to 'fine-tuning' and thus the results are not representative of any one 
means of testing. In total 53% of people offered a test complete one with 2.3 
cases detected per 1,000 acceptors. Cancers detected on screening are at 
an earlier stage than those presenting in the control group, are more clearly 
differentiated, more mobile and more amenable to endoscopic polypectomy. 
Participation with rescreening is high: 77% of initial acceptors accept the offer 
of rescreening, while 80% who have completed two tests complete a third. 
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The impact of dietary factors on the positive rate of the test has been 
discussed but including a restricted diet in the instructions for completing the 
test has been shown to adversely affect the participation rate. To tackle this 
problem, the MRC trial retests people returning a positive test prior to a full 
diagnostic investigation. This involves completing a second Haemoccult test, 
this time with dietary restrictions on intake of red meat and vegetables high in 
peroxidase; those testing positive are investigated. Those retesting negative 
are sent a third test three months later with positives being investigated; 
however, negative results are taken to imply that the initial positive test was 
false. The benefits of retesting are the maintenance of an acceptable 
participation rate without swamping the diagnostic facilities available; the cost 
is a small loss of sensitivity; the economic perspective is presented in 
Chapter Nine. 
As part of the trial almost 35,000 people randomised to receive an offer of 
screening were further randomised to be tested over either three or six days. 
While six-day testing had a higher yield of neoplasia the difference was not 
significant, although the false positive rate and cost were higher and the 
participation rate was lower; an economic comparison of the two tests is 
contained in Chapter Five. 
The trial has now completed recruitment and the initial offer of screening; 
most of the study group have also been offered rescreening at least once. 
No estimates of the impact on either colorectal mortality or on 'all cause' 
mortality will be made until the middle of the 1990s. In addition, mortality 
results from the trial cannot be discussed in advance of this report; this 
creates obvious problems for an economic evaluation; the solution is to 
present results in terms of interim measures like cases detected. Chapter 
Eleven makes estimates of the likely mortality reduction on the basis of the 
available published evidence. 
Danish trial (Kronborg et al. (1987),, (1989)) 
Many aspects of the protocol of the Danish RCT are similar to those of the 
MRC trial described above. A pilot study established the acceptability of 
screening in the Danish county of Funen prior to the recruitment of 61,735 
people aged 45-74 from the general population in 1985. Comprehensive 
population and health registers were used to exclude those with pre-existing 
disease and also to follow-up the population. The study group were offered a 
three-day Haemoccult test every second year, with dietary restrictions during 
initial testing. Participation following the initial offer was 67% and the positive 
rate was I%. Rescreening of previous acceptors alone resulted in 
participation of 93% with less than 1% testing positive. 
Swedish trial (Kewenter et at. (1988)) 
Apart from comparing screening with no screening, this trial also sought to 
compare screening using the rehydrated development protocol for completed 
tests with screening without rehydration. 27,700 people aged 60-4 were 
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recruited in 1982-3 and randomly allocated to a study or control group. 
Those completing a screening test were asked to observe some dietary 
restrictions; those testing positive were asked to complete a second test. 
Completed tests were developed according to the following criterion: tests 
returned by those aged 60 or 61 when the trial commenced had their returned 
tests rehydrated, while those in the older age group had their tests developed 
as normal. Investigation was by BEXR combined with flexible sigmoidoscopy. 
Rescreening took place at an interval of between 16 and 22 months. 
The main finding from this trial is that sensitivity was higher in the group 
whose tests were rehydrated; however, the figures for the group whose tests 
were not rehydrated are very low in comparison with other sources (86% for 
cancer versus 22% in the group whose tests were not rehydrated). 
Specificity fell from 99% to 96%, however. 
There are great problems in calculating the sensitivity of a screening test in 
such a trial since there is no evidence on how many cases are missed, other 
than by observing the number of cases presenting with symptoms following a 
negative screen. These may be fast-growing cases which were not present 
at screening, however. Alternatively, very slow growing cases which are 
missed may not present in the interval. 
The Memorial Sloan-Kettering Study, Now York (Winawer (1991)) 
Commencing in 1974, ý11,756 people aged 40 and above attending an out- 
patient clinic were recruited to the trial; recruitment ceased in 1979. The 
sample is thus untypical of the general population. Randomisation was by 
date of recruitment (i. e. clinic attendance); those attending between March 
and November were offered screening. This introduces a bias if those 
attending in summer are different to those attending in the winter. 
This is not a trial of Haemoccult screening alone since all those recruited 
received a full history, physical examination and an offer of rigid 
sigmoidoscopy; the only difference between the two groups is that the study 
group were also offered Haemoccult testing. There is no group which was 
not investigated in some way. Testing was recommended over three days 
following a meat-free, high fibre diet. The test initially used, the Haemoccult 1, 
was subsequently changed to the Haemoccult 11 (as used in all of the above 
trials) when this became available. 
Participation with the initial offer of FOB testing was 70-80% with between 2 
and 5% positive. It was soon appreciated that participation in rescreening 
was being affected by the means of recruitment since many People had 
originally attended the clinic on a 'one-off basis: as a result participation was 
down to 35% of the original sample by the fourth round of screening. To 
cope with this, the trial population was sub-divided into 'one-off and annual 
rescreening groups for purposes of analysis. Further problems have arisen 
in that the method of randomisation has resulted in an imbalance between the 
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annual screening and control groups, with the former being larger, including 
more women and having a higher median age. A further flaw in the trial was 
that initially no special funding was designated to follow-up the population. 
Mortality results indicate that the 1 0-year survival rate is significantly higher 
in the group not previously screened before the trial. In the screened group 
there have been 3.6 deaths from colorectal cancer per 10,000 person-years 
of follow-up as compared to 6.3 in the control group; an observed reduction in 
colorectal cancer mortality of 43% was not statistically significant. Overall 
mortality is virtually identical at 77.2 deaths per 10,000 person-years of 
follow-up in the group offered screening compared to 77.9 in the control 
group. 
Minnesota (Mandel et al. (1988)) 
Recruitment of 46,622 people aged 50 and over began in 1975 and finished 
in 1977. The trial population was drawn from a self-selected group: 30% 
were American Cancer Society volunteers while others were drawn from the 
membership lists of civic and fraternal organisations. Recruits were randomly 
allocated on the basis of age, sex and geographical area to one of three 
groups: a control group (who were not approached), a group offered 
screening every year, and a group offered screening every second year. 
Initially, test development did not use rehydration, but early sensitivity results 
were lower than expected and, in order to achieve the intended mortality 
reduction, subsequent completed tests were rehydrated. As a result each 
screening round has a different ratio of rehydrated to unhydrated tests. Also 
comparisons of unhydrated and rehydrated testing are complicated because 
the former was used mainly in the earlier screening rounds when prevalence 
of disease is higher. While the sensitivity target has been achieved there is a 
high false positive rate. In addition, a review of mortality trends indicated that 
no significant difference was likely, hence screening recommenced in 1982 
after a four year gap, with the intention of continuing until the end of 1995 
(although nobody above the age of 80 will be screened). 
A major problem for both American trials is the use of health-conscious 
groups as samples. In particular these people may seek screening if they are 
allocated to the 'no screening' arm of a trial; a survey in 1984 found 48% of 
physicians routinely follow recommended screening protocols (American 
Cancer Society (1984)). Another survey of randomly selected people aged 
between 40 and 75 found that 40% had completed a faecal occult blood test 
and 25% had done so within the last year; the figures for rigid sigmoidoscopy 
were 35% and 10% respectively (Polednak (1990)). Any advantages of 
screening will then affect the control group, making it harder to show a 
survival advantage for an offer of screening. It will also give a misleading 
impression of the participation rate. 
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Another problem is the follow-up of a population with fewer sources of 
centralised health data than in this country. In Minnesota, annual follow-up is 
by means of a postal questionnaire. 
CONCLUSION 
Colorectal cancer screening fulfils many of the criteria for a successful 
screening programme, although understanding of the disease is imperfect; a 
particular weakness is the lack of a clear risk factor for developing the 
disease. Screening for faecal occult blood as an indicator of malignancy is 
the most thoroughly evaluated means of screening. Clinical trials indicate 
that screening achieves many of the intermediate goals for an effective 
programme although these are subject to the usual biases. Mortality data 
from several American sources indicate that there is a gain to screening; 
conclusive evidence from the trials is awaited. 
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Chapter Three 
METHODOLOGICAL ISSUES IN THE EVALUATION OF 
SCREENING PROGRAMMES 
Economic evaluation compares the costs and benefits of two or more ways of 
allocating resources. This chapter discusses the application of standard 
economic evaluation techniques to screening. A literature review reveals a 
number of previous evaluations and the methodological strengths and 
weaknesses are discussed. The chapter concludes by describing the 
approach chosen for the present evaluation. 
-II 
Types of economic evaluation 
The various types of economic evaluation have been extensively discussed 
elsewhere (see e. g. Drummond et al. (1987)); where they are relevant the 
differences between the methods are discussed below. By way of 
introduction, there are commonly thought to be four types of evaluation: 
i) cost-minimisation analysis, where the outcomes (or benefits) of each 
option are identical and hence the comparison is on the basis of costs 
alone; 
ii) cost-effectiveness analysis, which compares options in terms of a ratio of 
costs to benefits where the latter are measured in terms of a 'natural' unit 
such as cases treated, lives saved or years of life ('life-years') saved; 
iii) cost-utility analysis, which generates a unit of outcome called the Quality- 
Adjusted Life-Year (QALY) encompassing changes in both quality and 
quantity of life by expressing health status as a proportion of normal 
health and weighting life-year gains accordingly 
- 
differences between 
options can thus be compared to differences in cost; 
iv) cost-benefit analysis, which seeks to value all effects in a common unit 
such as money, thus allowing a net benefit to be calculated. 
Different types of study are appropriate in different circumstances, depending 
in part on the study question addressed. 
Establishing a framework for the evaluation 
The first stage of an economic evaluation is to determine the study question, 
which is not always as straightforward as it may sound. For example, "What 
is the value of screening for colorectal cancer? " and "Is it worth screening for 
colorectal cancer? " beg the (respective) questions "of value to whom? " 
(patients? the health service? society as a whole? ) and "compared to what? " 
(other interventions in colorectal cancer? other screening initiatives? other 
health care programmes? ). Thus, the question should determine the 
viewpoint to be adopted (i. e. determining the range of costs and 
consequences to be included) and alternatives to be evaluated. 
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Screening options 
The parameters which go to make up a screening programme include who 
does what to whom, when, where, and how often. Each of these can be 
varied to produce a multitude of options based on the following: 
i) which screening test(s), which diagnostic test(s), and which 
combination(s) of the two; 
ii) how to define and identify the target population; 
iii) what retesting protocol (if any) is appropriate prior to full diagnostic 
investigation, and should it use the same screening test; 
iv) if they are endogenous, what levels to choose for the sensitivity and 
specificity of the screening and diagnostic tests; I 
V) the number and timing of rescreens (variable intervals are possible), 
plus the possibility of more frequent screening of high-risk groups; 
vi) the appropriate administrative structure (a dedicated screening unit? ), 
the method of invitation, use of means of increasing participation. 
To illustrate the number of potential options, one evaluation of cervical 
screening using a mathematical model compared 100 different protocols (Koopmanschap et al. (1990)). Clearly, no clinical trial is capable of 
evaluating more than one or two of these options. 
Identifying the costs and benefits of screening 
The next step is to identify all the relevant costs and consequences of 
screening (direct, indirect, tangible, intangible) from the viewpoint specified in 
the study question. In the absence of any clear guidelines in this area, an 
evaluation can only hope to be explicit about what has been included and 
what has been left out. The figures can thus be reworked if some users of 
the information wish to adopt a different perspective. A comprehensive list of 
the costs and benefits of screening would include: 
9 NHS costs 
screening (including administration, training, equipment and 
buildings) 
diagnostic investigation of positive screening test results 
treatment of those found to have disease 
follow-up of those treated 
treatment of recurrent and terminal disease 
primary health care 
costs of care as a result of longer survival 
other public sector costs 
use of social services 
convalescence 
costs borne by patient, family and friends 
'out-of-pocket! expenses 
emotional costs (anxiety and depression) 
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o health effects 
survival effects , 
complications and iatrogenic disease 
quality of life effects 
psychological benefits 
reassurance of a negative test (and of early treatment? ) 
societal effects 
effect on national income 
valuation of non-working time 
The next step is to measure and value these effects. 
The costs of screening 
Costing is an aspect of evaluation methodology which is frequently taken for 
granted; textbook comment (if any) is usually confined to the allocation of 
capital and overhead costs. For example, "It is often suggested that costs 
are easier to determine than benefits... [t]he process of quantifying 
- 
measuring 
- 
the inputs of a given programmatic alternative is generally 
straightforward... " (Warner and Luce (1982)). A traditional problem has been 
the lack of reliable data on which to base cost estimates; as one researcher 
found, "... [t]he attempt to compile costs for a small but identifiable group of 
patients in a large hospital proved less than straightforward. " (Brooks (1981)). 
Measuring resource use 
Some procedures, particularly diagnostic tests, are relatively homogeneous 
in terms of resource use and a'typical' procedure can be described. Other 
procedures, such as major surgery, are less predictable and there is potential 
for variation between patients. This lafter group thus requires a more 
detailed approach to costing. 
Homogeneous procedures can be modelled using data from surveys of the 
staff involved and by direct observation of a small sample of procedures to 
produce a representative cost for a'typical' procedure. To cope with 
uncertainty a probability distribution can be used to calculate the expected 
cost of the procedure (where that term is used in the statistical sense). 
If in-patient care is to be costed on an individual basis careful attention must 
be paid to the amount of research time involved. Data can be collected 
prospectively (by direct observation or using survey methods) but it is often 
difficult in this situation: it is not feasible for the researcher to be present all 
the time, while ward staff are reluctant to complete more paperwork. 
Inevitably, the main data source is from a retrospective review of the patient's 
case notes, but these are constructed as an aide memoir for medical and 
nursing staff. Not all relevant resource use is recorded, such as the time 
doctors and nurses spend with each patient. 
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Given that case notes are the main source, what exactly should be counted? 
This is a question of the level of detail required in the evaluation. As a rough 
guide, the amount of effort put into costing particular categories of resource 
use should be in proportion to the impact of that item on total cost. Thus, for 
most surgical procedures it is more important to pay attention to nursing and 
medical staff costs and general overheads rather than to diagnostic tests and 
drugs. 
While the principles involved in costing care in this way are easy to describe 
the practice is infinitely more complex. A number of other problems arise as 
the case notes are analysed. A major problem proves to be obtaining a 
single set of figures which are easily generalisable across settings; factors 
which might cause bias include: 
" medical practice variations between hospitals and between individual 
doctors e. g. due to different levels of expertise in technologies where a 
'learning curve' effect exists; 
" 
hospital cost structures, with teaching hospitals (which host many 
clinical trials) being especially expensive. A variant on this problem 
arises when patients in the sample are treated in more than one 
hospital, each with different costs. One option is to use a single set of 
unit costs to value individual patient resource use. 
Other problems relate to exactly which costs incurred to include: 
" activities carried out solely for research e. g. early admission pre- 
operatively to take part in other studies. These must be excluded 
wherever possible, but this is not always easy. 
" 
treatment for unrelated conditions should be excluded if they would 
have occurred in any event. On the other hand, iatrogenic disease 
resulting, for example, from cross-infection while in hospital should be 
included. The best that can be hoped for is that the evaluation will 
clearly specify the inclusion and exclusion criteria used. 
" while many patients are treated in NHS hospitals, a minority are either 
treated privately or are treated while overseas. This makes their notes 
difficult to obtain but also excludes their costs from the analysis if the 
perspective is that of the health care purchaser. 
" unless all of the sample have already died, there must be a defined 
cut-off point in the costing to ensure consistency in the costs. This is 
most likely to be until death or until a given period of follow-up, 
whichever is shorter. 
"a life-saving cure causes people to live longer and thus to increase the 
health service costs of treating other diseases of old age. One 
consideration is-that including these costs makes comparison with the 
results of other evaluations (which commonly exclude these costs) 
difficult. 
" screening changes the timing of health service resource use since, if 
successful, costs are incurred in the present to produce savings in the 
future. Economic theory holds that society prefers to defer costs 
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wherever possible, however, and hence a discount rate should be 
used to take account of the time profile. 
By this stage it is easy to agree with the conclusions of one group of 
reviewers: "Costs are not immutable 'facts' lying ripe in the field waiting 
merely to be garnered, or even selectively winnowed, by diligent clerical 
officers. " (Blades et al. (1987)). The costs derived are full of value 
judgements, although they are at least made explicit; none of the 
assumptions on the inclusion of particular items appears to seriously bias the 
results presented in the following chapters. 
The benefits of screening 
Identification 
As noted above, purchasers are being driven by national targets on 
reductions in mortality rates. The significance of quality of life as another 
dimension of benefit is recognised, but inevitably the demands of the policy 
target dominate decisions. Other benefits are also neglected, such as the 
reassurance value of a negative test or the value people place on better 
information about their health. Purchasing these benefits may have an 
opportunity cost in terms of achieving mortality reduction targets. 
Another issue relates to the inclusion of the indirect benefits of treatment, 
defined as the gain in economic productivity as a result of prolonged survival 
and good health. This whole area remains extremely controversial with little 
agreement among economists on the correct way to proceed (Ratcliffe 
(1993)). It could be argued that, other things being equal, a treatment which 
keeps a patient out of the workforce for a shorter period of time would be 
preferred to one requiring prolonged convalescence. This leads to ethical 
problems with giving priority to individuals with high earnings since their time 
is more 'valuable' on the basis of their wage; people who are not in paid 
employment receive a low priority on this basis. It is not clear that society is 
explicitly willing to prioritise treatments on these grounds. A second problem 
is that the principle aim of the health service is to increase health alone, with 
no judgement about what the individual should do with the good health once 
they have it; this would be implicit in any attempt to value extra life-years on 
this basis. 
Measurement and valuation 
Measures of the health benefits of screening found in the literature include: 
1) intermediate e. g. cancers detected with the implicit assumption that 
- early detection will be beneficial in health terms. 
ii) pseudo final e. g. survival rate at five years following diagnosis; 
iii) final e. g. measures of survival and quality of life gains. 
IntermediateOUtCOMGS are acceptable when comparing ways of achieving a 
similar aim such as screening for colorectal cancer. 'Pseudo'final outcomes 
are liable to some of the biases described in Chapter Two, as well as having 
other deficiencies (McNeil et al. (1978)): 
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" 
it is not always evident why five years has been chosen as the cut-off 
point; 
" 
it is implicit that survival of less than five years is of no value; 
it is implicit that the value of surviving five years is the same to 
everyone; and 
it takes no account of quality of life. 
More sophisticated trials take account of many of these problems by 
providing information on the number of life-years saved as aa result of 
screening. However, this still takes no account of quality of life in the extra 
years. 
A few clinical trials include measures of health status although the use of 
disease-specific measures creates problems for an economic evaluation, the 
aim of which is to compare the costs and benefits of screening with other 
uses of health service resources. Ideally, therefore, the health status 
measure would be as broad (and hence as generally applicable) as possible: 
this was the motive for the development of the QALY or Quality-Adjusted Life- 
Year. 
To an economist, the correct measure of the benefits of a programme are the 
alternative benefits which must be given up to achieve them: if society is not 
prepared to give something up to achieve a goal then that goal cannot be 
worth very much. One way to assess this would be to invite society to choose 
between alternative 'packages' of benefits for the same costs. There are 
many ways to use the resources, however, hence it is argued that a common 
measuring rod of value, money, could be used instead to identify the best 
alternatives. While it is easy to see how this could work for investment 
decisions in industry and in some social projects, such as motorway 
construction, its application to health care has been problematic. Problems 
arise when this is in terms of gains in quantity or quality of life. Values are 
implicit in all everyday decisions but eliciting them is harder, although it has 
been attempted in screening for gonorrhoea (Goddeeris and Broncken 
(1985)). This has resulted in continuing reliance on the unsatisfactory QALY 
measure described above. There are many problems inherent in this 
measure and still more in its application; at present, however, few realistic 
alternatives are available. 
Marginal analysis 
A decision is clear cut when one option is cheaper than the other and has a 
higher yield. Where the more expensive option also detects more disease, 
however, average costs can conceal the true nature of the trade-off. In this 
case the appropriate figure to report is the extra cost required to detect the 
extra cases. The most famous example of a marginal cost comes from an 
earlier paper on colorectal cancer screening (Neuhauser and Lewicki (1975)). 
This is a neglected aspect of evaluations of screening, in spite of this 
example 
-, as one review comments: "Despite the plethora of potentially 
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relevant margins, many studies take a very narrow perspective. " (Cairns and 
Shackley (1993)). 
Sensitivity analysis 
Mass cancer screening is very complex in terms of the protocol options and 
to this must be added the intricacies of the disease process. As pointed out 
in Chapter Two, few details of the natural history of colorectal cancer are 
known for certain. One way to cope with this uncertainty is to assess the 
robustness of the results to changes in the underlying variables. Where the 
results depend crucially on particular variables more analysis of the 
assumption is required. In Chapter Four, for example, a simple model of 
screening identifies the most important underlying variables which are then 
the subject of more detailed work in subsequent chapters. 
Decision criteria 
The appropriate decision criteria to use depends on the type of comparison to 
be made. If the comparison is between two ways of screening for the same 
disease then the costs and disease yield of each option can be used, on the 
basis of marginal analysis. However, it is inappropriate to compare the cost 
per case detected by colorectal cancer screening with that of breast cancer 
screening and cervical cancer screening, for example. The case detected is 
only an intermediate measure of benefit; each type of cancer detected is 
likely to represent a different profile of health gain to the patient. 
Comparisons with other health services are more difficult unless a common 
measure of health benefit such as the QALY or E-value (through willingness- 
to-pay estimates) are used. 
Issues of Interest to potential users of the results 
There are many practical issues which users of the results must address 
before implementing the findings of a programme. The evaluation presented 
in the following chapters concentrates on the initial round of screening and 
the two subsequent rounds, limited by the amount of data available from the 
MRC trial. The results of these later rounds are taken to be indicative of the 
costs and yields of the programme in its 'steady state'; the evaluation does 
not consider the costs of establishing the programme in terms of staff 
recruitment and training, purchase of computer equipment, etc. 
A second set of practical issues surrounds the timq profile of the costs 
incurred and the cost savings, prising from screening. While these will have 
been taken into account in the cost data via discounting future costs to a net 
present value, thisireduces a time profile to a point estimate. It may be more 
meaningful for purchasers to see what this will mean in terms of service use 
over a time horizon sufficient for the programme to reach its 'steady state'. 
This will reveal the likely 'bottlenecks' arising in the health service in terms of 
diagnostic and therapeutic capacity, etc. For monitoring purposes it will also 
be useful to have a prediction of when the health gains may be expected to 
materialise. These might take the form of the number of cases detected and 
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the change in five-year survival rate as an intermediate measure, with the 
reduction in colorectal cancer mortality for the longer term effects. 
PREVIOUS ECONOMIC EVALUATIONS OF COLORECTAL CANCER 
SCREENING 
This section reviews the literature on the evaluation of programmes of 
screening for colorectal cancer. The studies range from crude evaluations 
contained within a single paragraph of a review article up to complex 
mathematical models which attempt to predict the impact of the disease 
process not just on resource use but also on the disease process. This 
diversity makes the literature difficult to summarise adequately, but Table 
One outlines the type of evaluation used, the country of origin of the 
research, the screening test evaluated and the main data source: 
Table One 
I st author EE type Country Test(s) Data source 
Agrez (1) C Australia HM, HQ Literature 
Allison (2) E USA HM One-off study 
Applegate (3) E USA HM Pilot of RCT 
Atkin (4) E UK FS Literature 
Bolt (5) E USA IRS Literature 
CRESGE (6) E France HM, CS Literature, expert opinion 
Eddy E USA HM, FS Literature, expert opinion 
England (7) E USA HM, CS, FS Literature 
Farrands (8) B UK HM Pilot of RCT 
GOICC (9) B Italy HM Literatum, local data 
Johnson(10) E USA HM One-off study 
Joseph(11) E USA HM, HQ Literature 
Kristein (12) B USA HM Literature, expert opinion 
OTA E USA HM Literature, expert opinion 
Neugut (13) E USA CS Literature 
Notes to table 
B- Cost-benefit analysis 
E- Cost-effectiveness analysis 
C- Cost analysis 
HM 
- 
Haemoccult 
FS, IRS 
- 
Flexible and rigid sigmoidoscopy 
CS 
- 
Colonoscopy 
BXR 
- 
Barium enema X-ray 
HQ 
- 
Hemoquant (a quantitative test for haemoglobin in faeces) 
The numbers following the main author refer to references in the text below; 
the work of Eddy and of the Office of Technology Assessment (OTA) 
(Wagner et al. (1991)) is in the next section. 
39 
General comments 
The type of evaluation performed mirrors that found elsewhere in the 
literature of economic assessment of health care programmes (Adams et al. 
(1992)). 
None of the studies is based on conclusive evidence of health benefits from 
screening. Only one of the evaluations judged Haemoccult screening to be a 
failure but this had a particularly low take-up rate (10). Another study 
questioned the value of FOB screening (1), although the figures were 
challenged in an accompanying editorial (St John (1990)). Most studies are 
favourable to Haemoccult testing, including one claim that a screening 
programme would pay for itself in terms of treatment cost savings (12). 
Colonoscopy has a high yield as a screening tool but is relatively expensive 
(6,7,13). 
What are the strengths and weaknesses of these evaluations? This issue is 
considered under six headings: 
i) did the study identify, measure and value resource use in a suitable 
way? 
ii) did the study make an appropriate estimate of the health benefits, 
taking account of all the biases inherent in the results of some clinical 
trials? 
iii) did the study consider other aspects such as rescreening options, 
participation rate, choice of diagnostic investigation regime, age limits 
on target population? 
iv) did the study perform a sensitivity analysis? 
V) did the study compare options using a marginal analysis? 
vi) what decision criteria were used and is it clear why the preferred 
option was chosen? 
The studies can be divided into those that could be termed 'conventional' 
economic evaluations of one or two options for screening and those that are 
essentially mathematical models which are capable of evaluating limitless 
numbers of protocols; the latter are considered in a later section. 
Cost coverage 
Very few studies explicitly stated the viewpoint of their appraisal. All but one 
of the studies include the costs of screening and of diagnosis. Most consider 
treatment costs but only four studies also consider costs of symptomatic 
presentation (2,8,9,13). None of the studies include the costs of 
administering the programme, nor do they include non-health service costs. 
In terms of valuing resource use all of the American studies used hospital 
charges. 
Benefit estimation 
All of the evaluations consider cancer yield, at least as an interim step in the 
calculation of benefits. Four studies then apply five-year survival rate figures 
to the staging distribution (2,7,11,12). All of the cost-benefit analyses valued 
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the number of life-years saved using average earnings, with two allowing for 
participation in the workforce (8,9). 
The benefits of adenoma excision are considered in only two studies (2,6). 
Both assumed that 5% of adenomas excised would eventually have become 
cancers and that they would have presented according to the symptomatic 
staging distribution observed. 
Lead-time bias was mentioned in three studies; figures of 2,5 and 15 years 
were used (3,10,12). Length bias was only taken into account by one study 
and this only let it affect workload, not benefits (9). 
None of the studies estimates any benefits to screening beyond length of life 
(except where quality may impinge upon ability to undertake paid 
employment). One study mentions that benefits include extra productive time 
at work and 'other intangibles' (13). 
Other aspects of screening 
All of the studies assume that cancers presenting symptomatically are a 
homogeneous group, whether they occur in the 'no screening' option, among 
people refusing screening or in the interval following a negative test. 
Rescreening is considered in three studies, but in one this is only as a cost 
comparison with the initial screen (3). None of the studies considers the age 
limits most appropriate for screening, and very few are explicit about the 
economically optimal age range they would suggest. 
Sensitivity analysis 
Seven studies did not perform a sensitivity analysis (2,3,5,6,8,10,13), while 
the remainder vary factors such as test costs, prevalence, lead-time bias, test 
performance. Many key assumptions go unchallenged such as the 
remarkably high prevalence rate of 8 per 1,000 assumed in the Italian model. 
Marginal analysis 
Only four studies consider the marginal effects of different policies (1,4,6,7), 
with the French study alone adopting a true incremental approach (6). 
Decision and conclusion 
The cost-benefit analyses make a judgement on the basis of the net benefits 
of options (8,9,12). Three of the six of the cost-effectiveness analyses 
estimate the cost per life-year saved (2,7,11) while a further three report the 
cost per cancer detected or prevented (3,5,10). Another reports the cost per 
life saved (13). The French study presents the marginal analysis as its 
results (6). 
Models of disease and screening 
The mathematical models developed are as much about the disease process 
and how this is affected by intervention as they are about screening. In terms 
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of structure Eddy's model is the most sophisticated and has proved the 
inspiration for several simpler attempts. Originally the model was intended as 
an aid to the design of randomised controlled trials by identifying the option 
most likely to be economically efficient, given current knowledge. It has 
subsequently acquired a'life of its own'with the results underpinning the 
recommendations for screening of various American medical societies and 
insurance companies. 
It consists of a nine-state, time-varying Markov chain. The states considered 
include: alive and healthy; asymptomatic adenoma; asymptomatic cancer; 
cancer diagnosed (by Dukes' stage); died of colorectal cancer; died of other 
cause. This assumes that health states are discrete and there are specific 
probabilities of the likelihood of a given individual progressing from one state 
to another between two time periods. These probabilities are determined by 
a series of disease- and test-specific variables. For example: 
i) The probability that an asymptomatic adenoma or a cancer will be 
present at a given point in time is estimated by age/sex-specific 
prevalence rates, other risk factors present, the length of the 
detectable pre-clinical phase of the disease and the individual's 
screening history. 
ii) The probability that a screening test will detect an asymptomatic 
tumour is determined by the stage of the disease, its site within the 
bowel, the extent of the bowel covered by the test, and the test's 
random false-negative rate. 
iii) The progression through adenoma to cancer and thence through the 
various Dukes' stages are determined by estimates of growth rates. 
iv) The probability of dying of colorectal cancer in the coming time period 
is determined by stage-specific mortality rates for colorectal cancer. 
V) The probability that the individual will die of other causes in the coming 
year is determined by general age/sex-specific mortality rates. 
From a given population, the numbers in each health state at any point in 
time can be calculated; typically, the results are presented as an analysis of 
the optimal lifetime screening strategy for someone who is 50 years of age. 
Several versions of Eddy's model have appeared and, while the structure is 
largely unaltered, the values of some of the key variables have changed to 
reflect developments in medical knowledge and opinion. For example, in 
1980 it was assumed that 75% of cancers arise in adenomas, but this 
increased to 90% in the 1984 version and to 93% by 1987. 
Other models have used a simplified form of this approach: for example the 
American Office of Technology Assessment (OTA) have evaluated the 
inclusion of colorectal cancer screening in the Medicare (publicly funded) 
programme for the elderly on a similar basis (Wagner et al. (1991)). 
How do the models compare on the same criteria as those used above? 
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Cost covGrage 
Eddy's model includes the costs of screening tests, diagnostic 
investigations (including adenoma excision), treatment (with separate 
figures for early stage and for advanced disease), and terminal care. 
The OTA model uses a similar approach including a full consideration 
of the five-year follow-up costs following diagnosis plus the 
implications of adenoma follow-up on the basis of one complete 
investigation poSt-convalescence followed by colonoscopy every three 
to five years until 85 years of age. Eddys model does not include 
adenoma follow-up. 
Costs are based on hospital charge data in both cases. 
A discount rate of 5% is common to both models. 
The comparison in the OTA case is with "no screening" yet 
opportunistic screening is already so widely practiced in America that 
this may be inappropriate. 
The annual net cost of the OTA programme is between $1.5 and $2.6 billion 
assuming full participation at all stages of the programme. The costs of 
adenoma follow-up are very important; screening itself constitutes only 4% of 
the total cost of annual FOB screening. 
Benefit estimation 
Both models calculate the years of life saved by screening net of losses due 
to diagnostic and operative mortality. Neither model considers quality of life 
during those years, although the OTA "assumed that such considerations 
would enter into individual clinical decisions about the value of colorectal 
cancer screening in a particular person. " The source of Eddy's data is RCT 
evidence wherever this is available, supplemented by expert opinion; for 
example the latest version of his model is based on a questionnaire survey 
of 72 'experts' in the field of colorectal cancer. 
To construct the disease model detailed estimates of the progress through 
the adenoma-cancer sequence and then through the various Dukes' stages 
are required. Stage-specific survival rates are then applied to the staging 
distribution. 
In Eddy's model benefits are discounted at 5% per annum although the 
undiscounted results are also presented. It is unclear whether the OTA 
results are discounted or not. 
Eddy has cross-checked the yield and benefits predicted by his model 
against the results of the on-going randomised trial in Minnesota and found 
them to be accurate to within 1% of the observed total. 
Other aspects of screening 
Eddy's model: 
does not include a variable for participation and hence has no non- 
responder group. 
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assumes all symptomatic presenters, including those in the interval 
following a negative test, to be homogeneous with respect to cost and 
outcome. 
considers rescreening with varying intervals. 
evaluates a wide variety of screening protocols. 
In the OTA model: 
" cases occurring in the interval following a negative screen and among 
those declining testing are ignored, implicitly assuming cost and 
survival are unaffected by screening. 
" 
the only protocol evaluated is screening by annual, unhydrated 
Haemoccult commencing at age 65 and finishing at 85. 
" 
the implications of screening such an elderly group in terms of 
participation and operative mortality are not discussed. 
Sensitivity analysis 
In his 1984 paper, Eddy used expert opinion as his main data source: his 
results varied by 25-50% according to individual opinions. The most 
important assumptions are those relating to: 
i) the proportion of cancers arising in adenomas; 
ii) the time from an adenoma first becoming detectable by radiology or 
endoscopy until it becomes malignant; 
iii) the time a pre-cancerous lesion is detectable on FOB testing. 
The total cost is very dependent on the specificity of the screening test since 
diagnostic test charges are very high in America. 
The key assumptions in the OTA model are those relating to the proportion of 
symptomatic presenters with early stage cancer; the prevalence, incidence 
and recurrence rate of adenomas; and the proportion of rectal adenomas 
which regress. 
Marginal analysis 
Eddy compares all options in terms of a trade-off of the net present value of 
total costs against life-years saved: this is presented explicitly as a value 
judgement which must be made. The OTA model does not include a marginal 
analysis. 
Decision and conclusion 
Both models predict that screening will not result in a net cost saving, 
implying a decision must be made on the trade-off of costs and benefits. The 
results arrived at can be compared in terms of the one common option 
evaluated, annual FOB screening. As noted above, the OTA assumptions 
are slanted against screening and this is reflected in the results which imply 
that the cost per life-year saved is $35,000 as compared to Eddys figure of 
$2,420 (both compared to a situation of no screening). 
Eddy chooses annual FOB screening with 3 to 5 yearly flexible 
sigmoidoseopy as the most technically efficient way of screening for 
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colorectal cancer; allocative efficiency is given less attention although some 
rudimentary comparisons with other programmes are made. While the 
information on each option is clearly presented, it is unclear how the final 
choice was made in the absence of further information on societal 
will ingness-to-pay to save one more year of life. Additionally the 
recommended option in the most recent version of Eddy's paper has higher 
costs and lower benefits than several other options. He has sought to justify 
this on grounds of discomfort of diagnostic investigations, lower participation 
in some regimes, etc., being excluded from the figures. This is certainly the 
case but this information was not presented (or even mentioned) in the 
original conclusions. Subsequently, he has back-tracked still further by 
saying, "Colorectal cancer screening is an excellent example of a medical 
practice for which no single policy will be best for all patients, and the maxim 
'talk to your doctor' applies. " (1991). This seems at odds with the purpose of 
the analysis which was to identify the economic'best practice' in this area. 
A particular feature of the OTA analysis is the role of colonoscopic 
surveillance following excision of adenomas. Under the assumptions used 
any screening programme involving flexible sigmoidoscopy will eventually 
result in 55% of the population being involved in an adenoma follow-up 
programme. 
Neither model considers how screening might be stopped if the results of the 
on-going clinical trials eventually show that their benefit calculations are too 
optimistic and screening has no benefit. 
Summaty 
Mathematical models are of more value than 'one-off evaluations since they 
can be applied to many different protocols. If the data used are good enough 
then clinical trials of each protocol become unnecessary, saving on the cost 
and time involved in evaluating a new test. They are commoner in America 
because of the problems of restricting the spread of new health care 
interventions in advance of proof of their effectiveness in that country. 
Nevertheless such models need RCTs in the first place to assist with their 
construction: for example, the predictions should be carefully validated 
against RCT evidence. Since they require data which are often not available, 
one possibility would be to design clinical trials to fill in gaps in the model; 
this will require a shift in current thinking, however. Until then, the 
, 
assumptions made must be presented alongside the model results so that 
wary readers can judge the value of the analysis for themselves. 
METHODOLOGY OF THE PRESENT WORK 
The sections above have posed many methodological dilemmas which must 
be resolved. As noted at several points, there are often no right or wrong 
answers and the best that can be hoped for is a clear statement of the 
judgements made. These are listed below. 
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Type of evaluation 
As set out in the Introduction, this evaluation addresses four related 
questions, assuming the viewpoint of the health service purchasing 
organisation. The first question asks simply for the costs and benefits of one 
of the options and hence is not an evaluation per se. The second question 
can be answered using cost-effectiveness analysis, comparing different ways 
of screening in terms of costs and cases detected. The third question can 
also be addressed by cost-effectiveness analysis if the outcome measure 
chosen is lives saved or some similarnatural' unit. If both length and quality 
of life are thought to change then measuring benefits on a single dimension is 
inappropriate and cost-utility or cost-benefit analysis must be used. These 
comments are also appropriate to the fourth study question, since 
comparisons are now being made with a broad range of alternative uses of 
the resources; these may affect the health of those concerned in quite 
dissimilar ways. 
Viewpoint of the evaluation 
Identifying the appropriate viewpoint is not straightforward, however. At the 
start of the evaluation (October 1987) it was common practice to adopt a 
societal perspective (although the practice often fell some way short of this). 
With the onset of the 1990 NHS reforms, however, the role of evaluation 
altered to one of informing the decisions of those placing contracts i. e. health 
authorities and GP fundholders. This implies a greater emphasis on health 
service costs than was. the case previously, where El of cost incurred 
counted equally whether it be incurred in the operating theatre or in terms of 
visiting by relatives. -At the same time national policy documents such as 
'Health of the Nation' (Department of Health (199 1 )) have established targets 
for purchasing in terms of health gains (or, to be precise, mortality 
reductions). This implies that the evaluation should focus upon health 
service costs and mortality reductions as the only benefit. 
Costs 
With the advent of the internal market, most acute hospitals can quote prices 
for most of the procedures they carry out. The divergence between prices 
and costs is well understood in North America. Some prices may be 
increased to reflect uncertainty over workload or to cross-subsidise between 
services. Guidelines state that prices should be equal to average costs, 
producing no netprofit'(NHS Management Executive (1993)). However, this 
assumes that average costs are known in advance. Others have questioned 
the motives of hospitals: "Essentially, the first rule of charges is to make the 
institution solvent 
... 
Researchers attempting to assess economic efficiency 
must clearly defend their reasons for believing these gaps are small if they 
use charges as a proxy for cost; otherwise they should collect data on 
resource consumption and directly attempt to measure economic costs. " (Finkler (1982)). The evidence implies that these gaps are very large in the 
NHS at present. For example, the prices of day case colonoscopy in five 
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acute hospitals in Glasgow lie between E550 and E650, but the cost of the 
resources used is little more than E100 (from Chapter Four). Given that 
American charges for colonoscopy are about $500 and a return ticket to 
America costs about E200 the Glasgow purchaser could afford to fly all 
patients requiring day-case procedures to New York for the same pricel 
There is a dilemma. On the one hand producing information for purchasers 
implies using the prices they face in the analysis. On the other hand the 
prices bear little relation to the resource costs and, once more detailed 
information becomes available, it is hard to believe that they will remain at 
this level. A possible resolution lies in the fact that the price tariffs relate to 
individual referrals by GP fundholders, whereas the majority of cases are 
dealt with under block contracts whereby the hospital agrees to deal with all 
the referrals made by non-fundholders for a given total reimbursement. Thus 
neither party knows exactly what is being charged. If these contracts are 
ever disaggregated it seems likely that costs will be set on the basis of work 
studies such as those carried out in the course of economic evaluations 
rather than by the allocation of blocks of costs as favoured by accountants. 
For this reason the present evaluation uses costs rather than charges. 
It would not be appropriate to simply use the costs incurred in the course of 
the MRC trial, however. The main problem is to estimate the costs of the 
screening protocol as they would be if it were implemented nationally. The 
cost of the clinical trial provides some information but this is biased by the 
inclusion of research items and the exclusion of the costs of some facilities 
provided for free by the teaching hospital. Other items may be provided at a 
reduced cost such as items of screening equipment. 
When costing hospital'procedures the following rules for inclusion and 
exclusion of particular items are used: 
" 
treatment of other conditions is included unless there are clear reasons 
for not doing so, assuming that most care related to the disease or its 
complications. Treatment of conditions noted in the patient's medical 
history at initial admission but unrelated to the onset of cancer were 
excluded 
" 
treatments for colorectal cancer which are clearly experimental, such as 
resection of liver metastases, have been excluded since they would only 
be attempted in a few'centres of excellence'; 
" patients treated privately or overseas are included wherever adequate 
information was available. In this context, 'adequate' was defined as 
including number of admissions, duration of stay and a description of 
treatment. 
" various time cut-off points are used depending on the availability of data. 
Given the stage of the IVIRC trial, there is little information on what 
happens after the third round of screening, and even in that case the 
numbers are small; screening beyond this is not considered. Treatment 
costs incurred up to three years after a diagnosis of cancer were 
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recorded; while arbitrary, this is the resolution to the trade-off of sample 
size (to be maximised) against allowing follow-up costs such as those 
related to recurrent disease to be incurred. 
at present, the medium- to long-term effects of colorectal cancer 
screening are uncertain; median follow-up of the sample is only a couple 
of years. Over such a time horizon discounting at standard rates makes 
little difference to the results, although the potential implications are 
considered where appropriate. 
Benefits 
No data are available at present on the effects of screening on mortality from 
the disease; indeed, the MRC discourages discussion of this issue, in case 
the on-going trial is jeopardised in any way. This has an important bearing 
on the way in which each of the study questions can be addressed. The first 
question can only be answered in terms of interim measures of benefit such 
as cases of disease detected, although health gains can be included quite 
simply, once they are available. The second question can still be addressed 
in terms of cost per case detected, although cases must be defined either in 
terms of asymptomatic cancers or adenomas, but not both; this creates 
problems when different tests have different sensitivities to types of disease. 
The third issue can be addressed on the basis of literature values if it is 
accepted that lives saved is the main benefit dimension. The final issue is 
more difficult: QALYs are difficult to construct without survival figures, while 
cost-benefit analysis requires knowledge of the full benefits of screening for 
valuation purposes. 
Indirect benefits have been excluded. Given the age of the target population 
it is unlikely that they would play a crucial part in the analysis. Additionally, 
review articles indicate that they are included in only about 10% of 
evaluations, so excluding them makes the results of this study more easily 
comparable with the majority of other analyses. 
CONCLUSION 
None of the studies found in the literature is entirely satisfactory, either 
because important aspects are not considered or because the analysis 
(particularly via mathematical models) relies so heavily on assumptions for 
the values of key variables. In the absence of a consensus among 
economists on evaluation methodology, the assumptions used in constructing 
the results from the following chapters have been set out. While the 
limitations imposed on the current study do not allow all of the study 
questions to be fully addressed, enough data is available to carry out much of 
the work; once survival data is available it will be relatively simple to 
complete the evaluation. 
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Chapter Four 
BASIC MODEL OF SCREENING FOR COLORECTAL 
CANCER 
Introduction 
This chapter describes a simple model of screening for colorectal cancer in a 
defined population according to the MRC trial protocol for the study group. 
The costs of screening and of diagnostic investigation to the health service 
are calculated for the first three rounds of screening and compared to the 
yield of asymptomatic cases detected. An analysis of the robustness of the 
results with respect to changes in the variables then provides material for the 
subsequent chapters. 
Modelling the screening process 
Converting the experience of a research trial to a more general setting 
requires a number of assumptions. These have two purposes: firstly, to 
remove costs related solely to research (e. g. recruitment of GPs and 
randomisation of patients), and secondly to allow for differences between the 
MRC trial protocol and the likely form of a national programme if one were to 
be implemented. The IVIRC protocol of offering a three-day Haemoccult test 
to every person aged 50-74 every two years is evaluated in this chapter. To 
calculate the costs and cancer yield of screening the data are applied to a 
target population of 100,000 eligible people. 
Administration 
The IVIRC trial is administered by two whole-time-equivalent clerical officers. 
These officers have a variety of additional duties which would not be relevant 
outside the context of the trial; initially it is assumed that one clerical officer 
and two clerical assistants with the appropriate computer software would be 
sufficient. In addition, a supervisor of senior administrative grade would be 
appointed with responsibility for co-ordinating local efforts. 
The programme would use Family Health Services Authority (FHSA) records 
to identify the target population. This data source is known to contain 
inaccuracies of up to 20% (Stilman (1984)), implying that a proportion of 
distributed tests would not reach their intended destinations, let alone be 
completed or returned. However, this can be expected to improve over time 
as more use is made of FHSA lists for other purposes and better linkage of 
information systems isachieved; thus, it is assumed initially that FHSA 
records are accurate. 
it is assumed that the screening administration will be run from an office at 
the FHSA; an opportunity cost for rental value of 1,800 square feet of office 
space is included, valued at El 0 per square foot (Ridley at al. (1991)). 
Access to the existing mainframe computer is assumed to be available at 
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minimal extra cost. There will also be set-up costs covering, for example, the 
purchase of furniture, computer equipment, and lines to the FHSNs 
mainframe computer. Administrative staff would need to be in post for some 
months prior to the initial invitations being sent out. Fixed costs such as 
power, heat and light are ignored on the assumption that they would be 
incurred irrespective of the existence of the screening programme. 
Screening 
The current cost of a 3-day Haemoccult test is E1.13, including reagent 
(based on the purchase price of one pack of 50 tests). Each test costs EO. 41 
to send (including postage, stationery and instruction leaflet). 
Participation in screening is voluntary and the rate of 57.8% is adopted from 
the randomised evaluation of 3- and 6-day testing in the MRC trial (Thomas 
et al. (1990)). Publicity surrounding the introduction of a national programme 
may increase this but no effect is assumed. Completed tests are returned to 
the pathology laboratory of the local hospital; observation suggests that a 
sustained test development rate of 60 tests per hour is feasible and the time 
of a laboratory technician is costed accordingly. 
Investigation 
A positive rate of 1.29% of completed tests, as in the MRC trial, implies 746 
positives tests out of 57,800 returned in the population of 100,000. Following 
the MRC trial protocol these people are invited to a screening clinic (run by a 
consultant surgeon with a nurse present), which assesses 6 patients per 
session; this unambitious throughput allows time for discussion of the results 
with the patient. Routine blood test are conducted and rigid sigmoidoscopy 
performed. Further investigation is by colonoscopy for preference: 88% of 
the patients are investigated by colonoscopy and 12% by flexible 
sigmoidoscopy plus double-contrast barium enema X-ray (BEXR). As no 
reliable costs are available for these procedures they have been valued 
separately: the details are provided in the appendix to this chapter. The cost 
of a colonoscopy is E105.10 while the cost of BEXR plus flexible 
sigmoidoscopy is E126.68. 
Results 
Cost and yield In the initial round of screening 
The total cost of the initial round of screening for a population of 100,000 
people appears in Table One (all cost figures are expressed in 1989/90 
prices): 
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Table One 
Sub-totals % of total 
Programme overheads El 03,818 28 
Administration E37,818 
Supervisor E30,000 
Office space E36,000 
Screening E158,884 43 
Tests El 13,000 
Postage E41,000 
Development E4,884 
Investigations E109,775 29 
Out-patient clinic E29,479 
Colonoscopies E681946 
BEXR / flexible sigmoidoscopy El 1,335 
Total E372,477 100 
These results are presented graphically in the top half of Figure One. 
In the MRC trial, three-day testing detects 1.97 asymptomatic cancers per 
1,000 persons completing a screening test, i. e. 114 cases in the population 
modelled at an average cost of E3,271. 
These are not the only effects, however, as noted in Chapters Two and Three 
above. In total, 7,456 people return a positive test. If they all agree to further 
testing, then seven will suffer a major complication as a result of investigation 
(on the basis of evidence presented in the Appendix to Chapter Four). Many 
of those with a positive test will have an adenoma detected will be entered 
into an endoscopic surveillance programme; depending on the protocol used, 
further complications (and deaths) will occur. There is also a danger of 
anxiety provoked by the positive test which is not fully dispelled by the 
investigation which shows a benign cause or finds no abnormality. It is 
possible that the 50,344 people who test negatively derive some reassurance 
value from the finding. 
In addition, 61 people who had a negative Haemoccult est will present with 
symptomatic cancer within the next two years (interval cases), assuming 
three-day testing to be 65% sensitive (Thomas et al. (1992)). There will also 
be 78 cases in the group who refuse screening in the two year interval 
between screens, based on the incidence in that group of the MRC trial. This 
gives a total of 253 cases over the two years after the implementation of 
screening. Without screening there would have been 144 cases in the age 
cohort, based on the incidence rate reported in the IVIRC control group (Hardcastle et al. (1989)). Theory would predict such an excess as the 
prevalence of cases of disease is cleared, with future incidence reduced as a 
result. However, the number of symptomatic ases following screening is 
almost as great as the number without screening (139 versus 144). 
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Cost and yield in subsequent rounds of screening 
For the second round of screening two years later, administrative staff input 
can be halved since many of the 'set-up' tasks will be complete; the effect of 
this is shown in Figure One. MRC trial data shows changes in the 
participation rate, positive rate and detection rate: these are set out in Table 
Two. The programme can be assumed to be reaching a'steady-state' by the 
third round, hence these figures are taken to be typical of subsequent rounds. 
Table Two 
Round 1 
Number offered screening 1001000 
Participation rate (%) 57.8 
Positive rate (%) 1.29 
Detection rate (per 1000 screened) 1.97 
Total cost (E) 381,105 
% on administration 27 
% on tests 41 
% on investigation 31 
Cost per cancer detected (E) 3,347 
Round 2 Round 3 
57,800 44,390 
76.8 84.2 
1.20 0.47 
1.56 1.65 
2621261 184,324 
32 46 
35 39 
32 15 
3,787 2,989 
In the second round of screening 533 people test positive and require 
investigation but this figure falls sharply on the third round to 176 (i. e. only 
seven per month). The total cost in the second round of screening is 31 % 
lower than in the original screening round but the average cost is 13% higher; 
fixed costs are still substantial but less people are being screened since 
screening is only offered to previous acceptors. (Other rescreening policies 
are considered in Chapter Six). This is reflected in the costs of the third and 
subsequent rounds of screening where administration costs constitute almost 
half the total. 
This assumes that the MRC screening interval of two years is appropriate; 
several sets of American guidelines endorse annual FOB screening, (e. g. 
American Cancer Society). Little evidence is available which would allow a 
comparison to be made within the above framework. However, it has been 
reported that most interval cancers occur in the first twelve months after 
screening (Allison and Feldman (1990)). This implies little benefit from 
reducing the screening interval to one year. Case-control studies of 
Haemoccult screening have confirmed that the claimed protective effect of 
FOB screening does not decline greatly from the first to the second year after 
the test is completed; there is little protective effect by the third year, however 
(Selby et al. (1993)). A screening interval of three years or more would result 
in many interval cases in the third year, substantially reducing the ability of 
the programme to detect cases at an early stage: a sensitivity rate with a four- 
year interval of 25% has been recorded (Allison and Feldman (1990)). 
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Who should be rescreened? 
An alternative to only offering rescreening to previous acceptors is to 
concentrate efforts on persuading those who have previously declined 
screening to participate. In the IVIRC trial, two methods have been used. 
Firstly, non-acceptors have a card placed in the records of their general 
practitioner to prompt discussion at future consultations. Secondly, a postal 
invitation was sent to a sample of non-responders to the initial offer inviting 
them to request a test. Trials of these methods are still at an early stage, 
hence the numbers are rather small. Overall, 13% of previous refusers have 
accepted a subsequent invitation. The relative potential benefits of 
rescreening previous acceptors versus previous refusers is considered in 
more detail in Chapter Six. 
Sensitivity analysis 
. Many assumptions have been used to derive the model; how robust are the 
results to relaxation of those assumptions? One way to look at the 
robustness of the model is to consider the effects of an equi-proportional 
change in each of the variables; this gives some indication of the relative 
importance of each variable: 
Table Three 
Variable increased by 10% 
Detection rate 
Participation rate 
Positive rate 
Haemoccult cost 
Target population 
Colonoscopy cost 
Postage cost 
Administration costs 
Office costs 
All other variables 
% change In average cost 
-9.1 
-6.3 
+3.0, 
+3.0 
-2.5 
+1.9 
+1.1 
+1.0 
+1.0 
<1.0 
The detection rate emerges as the most important variable in determining the 
average cost per case detected, in line with the findings of other studies 
(Eddy (1991); Wagner et al. (1991)). 
An increase in the participation rate reduces the average cost because more 
cancers are detected; however, more people now test positive so the total 
cost rises by 3%. 
An increase in the positive rate with no offsetting increase in the detection 
rate is akin to a reduction in the specificity of the test; the effect is similar to 
abandoning the retesting protocol described in Chapter Two. 
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Increasing the target population spreads fixed costs more thinly but total 
costs rise by 7%; this assumes that the extra work involved can be handled 
within the existing administrative structure at little extra cost. 
The cost of colonoscopy is also significant; while the cost calculations in the 
appendix are quite detailed they too encompass many assumptions. 
The remaining variables have only a limited impact on the model, implying 
that these variables do not merit further detailed attention. 
How can the cost per case detected by Haemoccult be reduced? Fixed 
administration costs represent between 14 and 28% of the total and the 
programme cannot influence the costs of the tests or of postage; differences 
in development costs are trivial. However, there is a potential for savings in 
asking those people who do not wish to complete a screening test to return it 
for re-use: if half of the non-responders did so the total cost would be 
reduced by E24,000 for three-day and by E53,000 for six-day testing. In the 
latter case this represents a 10% saving on total costs. 
Another way to analyse robustness is to consider a number of different 
scenarios which may arise. This method also gives some indication of which 
of the variables is most likely to change from its baseline value. A selection 
of scenarios is presented below. 
The implementation of a national programme results in bulk 
purchasing of tests and a 10% discount on the purchase price per test 
is negotiated: the average cost falls by 3%. 
The local costs of investigations are 10% higher than those in 
Nottingham owing to practice variations: average cost increases by 
2.2%. 
Local circumstances mean that the catchment population is 10% larger 
than that described above; total costs rise by 7.3% but average costs 
fall by 2.5% as fixed costs are spread more thinly. 
" 
As a result of the publicity surrounding the implementation of a 
national screening programme participation achieves the breast 
cancer screening target of 70%; total costs rise by 6.5% while the 
average cost per case detected falls by 12.1 %. 
" 
FHSA registers are found to be very inaccurate, reducing participation 
by 20% and requiring 50% more administration and clerical time to 
correct. The average costs rises by 24% as fewer people complete a 
test and the yield falls, but the net effect on total costs is close to zero 
since the savings on investigating fewer people almost exactly offset 
the extra administration costs. 
" 
Access to a fully-equipped endoscopy suite is not available, forcing 
surgeons to use the combination of BEXR and flexible sigmoidoscopy; 
average and total costs rise by 3.8% (assuming the cancer detection 
rate is unaffected). 
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Long-term follow-up reveals the sensitivity (and the detection rate) of 
the Haemoccult test to be 10% lower than is currently thought, 
increasing the average cost by 9.1 %. A 20% fall in sensitivity 
increases the average cost by 25%. 1 
As the programme relies on the postal system to distribute and return 
tests, a 10% rise in postage costs would appear crucial but the 
average cost only rises by 1.1 %. 
These relative effects are shown in Figure Two. Further factors can also be 
considered once survival data are available to convert cost per case figures 
into cost per health gain. A notable example would be the effects of inter- 
surgeon variability in survival rates; such variations have been previously 
demonstrated to exist, independent of case-mix and other measurable factors 
(McArdle and Hole (1991)). 
Other limitations of the model 
Diagnostic investigation costs departed from the health service perspective 
stated by including costs to patients: these represent 20% of the cost of 
colonoscopy and 22% of the cost of the combined radiology/sigmoidoscopy 
investigation. As the above figures show, excluding these figures would not 
have a significant effect on the results (Le. less than 5% off the average 
cost). If the aim is ultimately to compare the costs and benefits of colorectal 
cancer screening with those of other uses of the resources, however, it may 
raise problems of comparability since so few other studies include these 
costs, despite the importance of the societal viewpoint in economic evaluation 
textbooks. 
While the sensitivity analysis has helped with the variables that were 
included in the model it has not considered those factors which are excluded 
and therefore are implicitly assumed to have no effect. Two of the most 
significant exclusions are the net effect of screening on the costs of treatment 
and the health effect of adenoma excision. These are considered in more 
detail in later chapters. ' A further category of benefit excluded is the value of 
information to the individual: no satisfactory means of eliciting this value have 
yet been developed. It is, therefore, assumed that the benefits to the patient 
at least outweigh the costs of performing the test, awaiting the results, 
attending the clinic, and so on. On this basis, excluding both costs and 
benefits means that, from the patients' perspective, the results are the upper 
limits on the net societal cost per case detected. 
Conclusion 
The cost per case for a 'typical' target population Was derived from a set of 
assumptions based on the MRC trial. It may be Possible to rule out screening 
for some diseases on this basis alone if the cost per case is so high that it 
could not be justified by any plausible magnitude of health gain. FOB 
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screening for colorectal cancer does not fall into this category, thus it is 
worthy of more detailed consideration. Ideally, data on health gain would be 
used but in advance of the analysis of the MRC trial results this is not 
possible at this stage. 
Sensitivity analysis reveals that the key variables underlying the results are 
the performance of the screening test, the participation rate and the size of 
the target population; each influences the likely costs and yield. Other 
factors excluded to date also require consideration including treatment costs 
and the benefit of adenoma excision. These are considered in more detail in 
the following chapters. 
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APPENDIX 
HOSPITAL COSTS OF DIAGNOSTIC PROCEDURES FOR COLORECTAL 
CANCER 
Introduction 
Diagnostic investigation of the colon and rectum can be undertaken either by 
radiology or by endoscopy. The barium enema X-ray was virtually the only 
technique of visualising the colon up until the 1970s. This involves coating 
the lining of the colon with barium as a contrast medium; the development of 
the double contrast method has enhanced accuracy, especially for small 
lesions. Endoscopy has been available for many years in the form of the 
short (25cm. ) rigid sigmoidoscope, but developments in the 1970s led to the 
introduction of longer, flexible instruments using fibreoptic technology to allow 
direct visualisation of the colon. The colonoscope is capable of reaching the 
caecum if fully inserted, while the 60cm. flexible sigmoidoscope reaches 
beyond the sigmoid colon and towards the splenic flexure. 
Resources used include: staff time, drugs, films and chemicals, pathology 
specimens, equipment depreciation, hospital overheads, the opportunity cost 
of the building, in-patient stay (for observation or to treat complications), and 
costs to patients of aftending. Assumptions based on observations of all 
three techniques and discussed with the staff involved, are set out below. 
Colonoscopy is performed by a consultant conducting seven investigations 
each day in a dedicated endoscopy unit with supporting nursing and clerical 
staff. The total staff costs of the unit are divided across capacity workload, 
calculated as the maximum number of colonoscopies that could be performed 
in one year. At seven patients per day the throughput of a single suite of the 
unit would be 1,820 cases; assuming there are two suites then half the 
nursing and support staff costs can be allocated to each. All patients receive 
a laxative and most are sedated. If a polyp is seen on examination, it is 
removed by snare diathermy via the colonoscope wherever possible and is 
sent to the pathology laboratory for histological analysis. The biopsy rate is 
dependant on the number of abnormalities; in the calculation the case-mix 
arising from the IVIRC trial is used. 
Barium enema X-rays are'performed by a consultant radiologist, with a 
radiographer and an auxiliary nurse present. Each'day, twelve patients can 
be investigated; this requires a total of two hours of clerical time to 
administer. Patients receive a laxative but are not sedated. Each patient 
requires a barium contrast medium and ten films; chemical costs are 
calculated according to a 'rule-of-thumb' used in radiology departments. 
Flexible sigmoldoscopy is performed in clinic by a consultant with an 
auxiliary nurse present. Twenty patients can be seen in one day, requiring 
two hours of clerical time to organise. Patients are given a laxative but no 
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sedation. The biopsy rate is assumed to be 72.9% of that of colonoscopy, 
based on MRC trial data for the distribution of cancer in the bowel. 
Thus the staff, drug, film and chemical, pathology and equipment costs are as 
follows: 
Staff costs (f) 
The Personnel Department at University Hospital, Nottingham (UHN) 
supplied the following figures: 
Table Four 
Consultant 
Endoscopy staff (total) 
Auxiliary nurse 
Radiographer 
Clerical officer 
Gross annual cost (E) 
381379 
47,885 
61676 
12,543 
6,303 
Cost per day (E) 
147.60 
191.50 
25.70 
48.20 
24.20 
Gross annual cost represents the full NHS costs of employment (salary, 
national insurance and pension contributions). Note that the endoscopy staff 
cover two suites. 
Drugs and disposables 
Costs are based upon figures in the British National Formulary, March 1989. 
Table Five 
Quantity used Cost (E) 
Sodium picosulphate 2 sachets 0.60 All CS and BXR patients 
Sodium phosphate enema 1 sachet 0.43 All patients 
Diazepam 20mg. 0.00 95% of colonoscopies 
Hyoscine butylbromide 20mg. 0.19 25% of colonoscopies 
Naloxone hydroxide 0.4mg. 3.57 5% of colonoscopies 
A preliminary assessment of the costs of d1sposable items, such as pads and 
syringes, indicated that these were negligible and they are excluded. 
Films and chemicals 
The barium X-ray medium costs E4 and one film costs EO-88 with 10 used per 
patient (Radiology Department, UHN). The total cost per procedure is E14.34 
(= E4 + (10 x EO. 88) + E1.54 for chemicals valued at 17.5% of film costs). 
Biopsy rate and cost - 
The following is based on discussions with staff of the Histopathology 
Department, UHN). The cost of a biopsy is F-5.76, comprising E4.77 for 
labour, EO. 56 for equipment depreciation and EO. 43 for materials. The biopsy 
rate in the screening study is 1.51 per colonoscopy and 1.1 per flexible 
sigmoidoscopy based on the following assumptions: 
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12.3% of investigations find a carcinoma, requiring 4 biopsies; 
37.3% find adenomas, requiring 2 biopsies; 
27.2% find other abnormalities, requiring 1 biopsy; 
22.8% are normal, requiring no biopsy. 
Equipment depreciation and maintenance 
All equipment is valued at replacement cost, excluding Value-Added Tax. A 
simple division of the cost by working life is made and the annual cost, 
including maintenance, is then divided by the annual workload. 
Coldnoscopy 
Colonoscope and forceps cost E9,998 and last for one year if used full-time 
under the workload assumption; annual maintenance costs E1,000 (figures 
from Keymed Supplies). The electro-surgical unit, suction apparatus, video 
display unit, trolley and monitor cost El 9,144 in total but last for ten years. 
Barium enema X-ray 
The X-ray machine itself costs E240,000 and lasts for ten years with annual 
maintenance costs of E4,630 (figures from Radiology Department, UHN). A 
processor costs E10,000 with a ten-year life. Cassettes cost E3,000 for 15 
and last for five years. 
Flexible sigmoidoscopy 
Sigmoidoscope and forceps cost E3,740 and are assumed to last for one year 
if used intensively; annual maintenance costs E250. 
Costs to patients of attending 
There are costs to patients in attending for investigation including the cost of 
travel and the value of the person's time. A survey of patients attending a 
follow-up clinic for colorectal cancer at UHN measured the time and travel 
costs involved. Time was valued using the Department of Transports figures 
for the value of travel time savings updated to E2.23 per hour. 
Table Six 
Mode Cost (E) % using mode 
Public transport fare 1.90 35 
Car mileage 0.55 60 
Walking time 1.55 5 
Vehicle time 1.19 95 
The expected cost of attending the hospital is E2.90. In addition, the person 
will be in the hospital for about two hours, valued at E4.46. About 10% of 
people are accompanied by a friend or relative: this increases the expected 
cost by EO. 29. The average total cost of attending the hospital is E7.65. 
None of those interviewed reported any lost income from paid employment as 
a result of attending. 
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This figure is taken as a proxy for the costs of attending for a flexible 
sigmoidoscopy or BEXR, with an adjustment to allow for the person being in 
hospital slightly longer. For a colonoscopy, however, sedation is necessary 
and hence patients are advised not to drive themselves home. Assuming that 
these people therefore use public transport, the cost of the journey is E3.72. 
While the procedure itself is relatively quick, the patient will be required to 
stay in hospital for about five hours, including time to recover from sedation. 
If a similar proportion are accompanied the total cost is El 5.27. This also 
assumes no lost income as a result of the procedure. (Note that in the 
Australian breast cancer screening study 52% were accompanied (Hurley 
and Livingstone (1991)); this would raise costs to El 6.49). 
In-patient costs and general service overheads 
In-patient admission can occur if the patient requires overnight observation 
before or after investigation. The experience of the MRC trial is that 6% of 
colonoscopy patients are kept in for overnight observation while about 0.6% 
are admitted for two nights. An expected in-patient cost based on these 
figures is included. Admission following the other investigations is rarer, in 
the absence of similar series admission rates of 0.5% following BEXR and of 
0.1 % following flexible sigmoidoscopy are assumed. 
A diagnostic investigation can also be the cause of morbidity and mortality. 
Treatment of complications such as haemorrhaging and perforation of the 
colon require in-patient care and even surgery. If care for minor 
complications is included in the above admission rates then the proportion of 
patients experiencing major complications from each type of procedure is 
taken to be as follows: 0.09% of colonoscopies (Hall et al. (1991)), 0.04% of 
BEXR (Ott et al. (1985)) and 0.05% of flexible sigmoidoscopies (Selby and 
Friedman (1989)). A major complication requires surgery and the total in- 
patient stay is valued at E2,000; this figure is tested in the sensitivity analysis. 
Total general service expenditure from UHN cost returns is divided by a 
factor reflecting the time each type of patient (inpatient, outpatient, day 
cases) spends in the hospital, to give a cost per hour. In 1989-90 total 
spending on general overheads at UHN was E14,266,694. Assumptions are 
required on the number of hours patients of each type spend in hospital, as 
follows: 
Table Seven 
Type 
in-patient days 
out-patient attendences 
Day Cases 
A&E attendences 
Number Duration (hours) Total 
372,188 24 8,932,512 
309,730 2 619,460 
7,888 
.8 63,104 166,913 3 
-500,739 
In total there were 10,115,815 patient-hours using the assumed durations. 
These require adjustment to reflect the fact that the day of admission plus the 
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day of discharge of an in-patient admission are only part days. Assuming 
that they make up one full day between them then allowing for the number of 
episodes (69,179) gives a revised total of 7,272,216 patient-hours. The 
average overhead cost per hour is E1.70 and the overhead costs of each type 
of contact are E40.80 per in-patient day, E3.40 per out-patient attendance, 
El 3.60 per day case attendance, and E5.12 per ME attendance. 
Colonoscopy patients are assumed to occupy five hours of hospital time (at 
E1.70 per hour), while the other procedures require three hours since there is 
no need to recover from sedation. From cost returns, the in-patient cost for 
general surgery comprises E40.80 for service overheads (i. e. 24 hours at 
E1.70 per hour) and E76.1 0 for patient care excluding theatre, diagnostic and 
support service costs. 
Oppoilunity cost of the building 
An allowance must also be made for the opportunity cost of the building. 
Ridley et al. 's estimate an opportunity cost in terms of vacant rental value of 
El 0 per square-foot per year (in 1989/1990) and an area of 2,702 square-feet 
for an intensive therapy unit. This gives an annual total of E27,020 or 
El 03.92 per working day. Assuming that endoscopy and radiology suites are 
of a similar size, the same costs can be allocated across total workload. 
Results 
The average costs per investigation borne by the hospital for the three 
diagnostic techniques are: 
Table Eight 
Category Colonoscopy BEXR Flexible sig 
Medical staff 21.09 12.30 7.38 
Nursing and support staff 13.18 12.62 7.75 
Drugs and disposables 1.26 1.03 0.43 
Films and chemicals 0 14.34 0 
Biopsy 8.70 0 6.34 
Equipment 7.09 9.69 0.77 
General services 8.50 5.10 5.10 
Building 14.85 8.66 5.20 
Inpatient stay 8.04 0.70 0.14 
Complications 1.80 0.80 1.00 
Patient costs 20.63 13.74 13.74 
NHS variable 57.35 40.30 21.90 
NHS direct 87.79 63.74 32.96 
NHS total 97.63 65.13 34.08 
NHS plus patient total 105.10 78.87 47.81 
Definitions: 
NHS variable cost = medical & nursing staff, drugs & disposables, biopsy 
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NHS direct cost = NHS variable cost + equipment, overheads and building 
NHS total cost = NHS direct costs + admissions and treatment of 
complications 
NHS plus patient total = NHS total + patient cost 
Rather than considering BEXR and flexible sigmoidoscopy individually it 
would be more realistic to consider them as a combined strategy. The 
components of the costs of each option are compared in Figure Three. The 
choice of diagnostic strategy, comparing the test cost against accuracy, is 
considered in more detail in Chapter Nine. 
Sensitivity analysis 
Clearly, the above calculations rest upon a number of assumptions and thus 
an analysis of robustness is required. Each of the variables was increased 
by 10% and the effect on the cost of each diagnostic procedure noted (the 
NHS plus patient definition was used). The most important variables are 
listed in Table Nine below, showing changes relative to the baseline values in 
Table Eight above: 
Table Nine 
Variable changed by 10%: Colonoscopy BEXR Flexi sig 
Throughput 
-4.9 -4.2 -2.8 Working days per year 
-3.6 -4.0 -3.0 
X-ray film cost 0 +1.8 0 
Consultant salary +2.0 +1.6 +1.6 
Time patient is in hospital +2.0 +1.6 +2.6 
Opportunity cost of space +1.4 +1.1 +1.1 
Endoscopy staff costs +1.3 0 0 
Value of patient time +1.2 +0.9 +1.5 
Overhead costs +1.1 +0.7 +1.1 
Clerical officer salary 0 +0.8 +1.4 
Pathology cost per specimen +0.8 0 +1.3 
Equipment replacement cost +0.6 +1.0 +0.2 
None of the other variables has an impact greater than 1% for any of the test 
costs. In general labour costs are more important in endoscopic procedures 
and capital costs are more important in radiological procedures, despite the 
extreme assumption that endoscopes are replaced every year. The analysis 
reveals that the results are quite robust although account should be taken of 
local workload factors when they are being generalised for use elsewhere. 
Increasing throughput and reducing the numbers of support staff would 
reduce costs, although this could affect the quality of care and ultimately 
increase total costs if more repeat procedures were required. 
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Chapter Five 
ALTERNATIVE SCREENING TESTS FOR 
COLORECTAL CANCER 
Introduction 
Chapter Four set out a basic model of faecal occult blood testing for 
colorectal cancer according to the MRC trial protocol. However, the three- 
day Haemoccult test developed without rehydration of the stool sample is not 
universally accepted as the best of its type, nor is faecal occult blood testing 
the only way to screen for the disease. 
Alternative screening protocols 
No clinical trial could compare all the screening protocols that have been 
advocated so any comparative evaluation must be based on the data from a 
number of research centres. In order to compare the options the results 
should be used in such a way as to minimise sources of bias e. g. apply the 
figures to a single population with stated prevalence, a common screening 
'environment' (e. g. administrative structure), and (where appropriate) a 
common participation rate. This suggests that the literature results for a 
variety of test can be compared through the model described in Chapter Four 
but using the appropriate values for test cost, positive rate, detection rate and 
participation rate. Other assumptions are as for the initial round of screening. 
The tests to be compared are: 
I. Variants on the Haemoccult test protocol including development of test 
with rehydration of sample as in the Swedish and Minnesota trials and 
screening over six days rather than three. 
2. More sophisticated faecal occult blood tests such as Hemeselect, 
Hemoquant or Fecatwin/Feca EIA. 
3. Tests designed to enhance participation such as Coloscreen, 
Ez-Detect and the symptom (or risk) questionnaire. 
4. Sigmoidoscopic screening, especially flexible sigmoidoscopy. 
Given literature values on sensitivity and specificity the model inputs can be 
calculated using the algebraic manipulation described in Chapter Two. 
Method for comparing the options 
The average cost per case detected for three-day testing was reported in 
Chapter Four but the potential for this to mislead is well-established 
(Neuhauser and Lewicki (1975)). When comparing two screening protocols it 
is assumed that A is preferred to B if A has lower costs and a higher yield. In 
cases where one option is more expensive but also has a higher yield there is 
no simple decision criterion; the choice rests on a judgement of whether the 
extra yield justifies the extra expense. To this end the relevant figure is the 
extra cost per extra case detected i. e. the difference in total costs divided by 
the difference in cases detected. 
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Haernoccult protocols (without rehydration) 
The greater sensitivity of six-day FOB testing to known cancers was 
commented upon in Chapter Two. As part of the MRC trial the two test 
periods have been compared and the relative performance is set out in Table 
One: 
Table One 
3-day 6-day 
Cost of test (E) 1.13 2.26 
Cost of sending test (E) 0.41 0.60 
Rate of developing test (number per hour) 60 30 
Participation rate (%) 57.8 53.8 
Positive rate (% of those completing) 1.29 1.69 
Cancer detection rate (per 1000 acceptors) 1.97 2.56 
Six-day testing has a lower participation rate resulting from the extended 
testing period and higher screening costs (two three-day tests, greater 
postage and slower test development). Extended testing detects more cases 
of disease which bleed sporadically but at the expense of a greater number of 
people giving false positive reactions, whether through 'natural' blood loss or 
dietary factors. One result of this is a higher total cost of diagnostic 
investigation. The detection rate difference in the clinical trial was not 
significant given the sample size, but assuming that a larger study would 
confirm the results then six-day testing on the same basis would have a 
sensitivity of 84% compared to 65% for three-day testing (Thomas et al. 
(1992)). 
Applying the data to the model from Chapter Four gives the following results: 
Table Two 
3-day 6-day 
Number testing positive 746 902 
Total cost (E) 372,477 531,708 
% on admin 28 20 
% on tests 43 55 
% on investigation 29 25 
Cases detected 114 136 
Average cost (E) 3,271 3,920 
Extra cost per extra case (E) 7,238 
In comparison with the three-day testing, the incremental yield and cost of 
six-day testing is 22 cancers and El 59,321, giving a cost per extra cancer 
detected of E7,238. 
Note that the difference between the specificity rate of the two tests is 0.3% 
(98.6% and 98.9% for 6- and 3-day testing respectively) which could be lost 
as a rounding error but the cost of this difference is 134 extra false positives 
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(156 extra positives minus 22 extra true positives). The health service costs 
are over E14,000 or 9% of the difference in costs of the two options. Care 
should therefore be taken to be precise when estimating the specificity of a 
screening test. 
The above data are based on a comparison of 3- and 6-day testing in 
randomised groups; an alternative, which has also been used in the MRC 
trial, is to use a single population but to number the order in which the 
squares on the test were completed. A sample of 9,000 asymptomatic people 
were offered a six-day test with the squares numbered and the respondents 
asked to provide samples in the order specified. Of the 140 people who 
completed a test which was found to be positive, 70% had at least one 
positive test out of the first six squares numbered. Positive results were 
retested and persistent positives investigated, according to the usual 
protocol. Of the 41 who would have been negative over three days of testing, 
27 were still negative. Two of the 14 investigated had cancer while five 
others had large adenomas, compared to nine and seven cases respectively 
in the 105 people who had one or more positives out of the first six squares. 
The cost of this extra yield consists of the extra tests sent to the whole group, 
retesting those positive on the second six squares plus the subsequent 
diagnostic investigations. The extra cost of six-day testing is EI. 32 (test plus 
postage plus EO. 08 for the extra time to develop the tests returned). To this 
must be added 41 retests at E3.03 each (six-day test, postage, development) 
and 14 colonoscopies. The total cost is E12,959 (of which 85% is on the 
extra initial tests). The cost per extra cancer detected is thus E6,480, within 
12% of the figure calculated as the incremental cost of six-day testing as 
compared to three-day testing above. 
Rehydrated Haemoccult protocol 
This protocol is modelled from the Swedish trial which reports a sensitivity of 
85% and specificity of 94.5% (Kewenter et al. (1988)). Note, however, that 
this trial is aimed at people aged between 60 and 65; the positive rate is 
known to be age-related and hence may be different in another population. 
The model inputs are as follows: 
Table Three 
Rehydrated case 
Cost of test (E) 1.13 
Cost of sending test (E) 0.41 
Rate of developing test (number per hour) 45 
participation rate 57.8 
Positive rate (%) 5.8 
Cancer detection rate (per 1000 acceptors) 2.54 
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Rehydration of the sample prior to development has no effect on 
participation, on the cost of the test or on the cost of postage. The sensitivity 
of the test is increased but at the cost of a greatly increased number of false 
positives. 
Table Four 
Number testing positive 
Total cost (E) 
% on admin 
% on tests 
% on investigation 
Cases detected 
Average cost (E) 
Extra cost per extra case (E) 
Rehydrated case 
3,352 
757,891 
14 
21 
65 
150 
5,043 
10,706 
The rehydration method detects more cancers than unhydrated testing but at 
greatly increased cost 
- 
total and average screening costs are almost 
doubled and cost per cancer detected is 54% higher. The extra test 
development costs of rehydration is a minor factor, the principal source of the 
difference is the reduced specificity resulting in more diagnostic 
investigations of healthy people. Rehydration increases the yield of cancers 
by 36 relative to unhydrated three-day testing at an additional cost of 
E385,414 i. e. at an incremental cost of El 0,706 on average (approximately 
three times the average cost without hydration). In comparison with six-day 
testing the incremental cost is E16,156 per extra case. 
Other FOB protocols 
Hemeselecf is an immunochemical test specific to human haemoglobin i. e. 
dietary factors cannot cause false positive results. While there are no 
published data on the performance of the test in an asymptomatic population 
of comparable age to that considered here, one study has reported results for 
a study of people attending a surgical out-patient clinic with lower 
gastrointestinal symptoms (Thomas et al. BJC 1992). The results indicate a 
sensitivity of 94% and a specificity of 84.1 %. Note, however, that the data 
source may underestimate the specificity as the sample used is more likely to 
have rectal bleeding than the general population: in the same group the 
three-day Haemoccult test (unhydrated) had a specificity of 96%, compared 
to the 98.9% found in the general population. Assuming that Hemeselect 
would experience the same proportionate increase in specificity the following 
model inputs are used: 
Table Five 
Cost of test (E) 
Cost of sending test (E) 
Participation rate (%) 
Hemoselect 
2 
0.41 
57.8 
66 
Positive rate (%) 13.6 
Cancer detection rate (per 1000 acceptors) 2.69 
The cost of developing the test is approximately E4, including technician time, 
chemicals and overheads. Once again an improvement in the sensitivity of 
the test is 'purchased' at a greatly increased false positive rate. 
Table Six 
Hemeselect 
Number testing positive 7,861 
Total cost (E) 1,733,334 
% on admin 6 
% on tests 27 
% on investigation 67 
Cases detected 155 
Average cost (E) 11,148 
Compared to three-day (unhydrated) Haemoccult screening the extra cost per 
extra case detected is E33,192; the figure compared to six-day testing is 
E63,243 and compared to three-day (rehydrated) Haemoccult is E205,089. 
Hemoquant provides a quantitative measure of the blood in the faecal 
sample and thus allows an explicit choice as to the criterion for a positive test 
result, allowing a trade off of sensitivity against specificity. The feasible 
trade-offs are: 
83% sensitivity, 92.7% specificity if levels greater than 1.5mg of 
haemoglobin per gramme of stool constitutes a positive test; 
74% and 94.7% if 2. Omg. is the cut-off, and 
62.9% and 97.3% if 3. Omg. is the criterion (St John et al. (1992)). 
None of these options is preferred to three-day Haemoccult (rehydrated) and 
the test is far more expensive to develop. Thus, assuming that Hemoquant 
has no advantage in terms of improved participation, it would not be chosen 
as the most efficient screening test. 
Fecatwin*eca-EIA is a combination test intended to follow a highly sensitive 
test (sacrificing specificity) with a more specific test and only investigating 
those positive on both. This test was used in the early stages of the MRC 
trial and has also been tested in a separate group (Pye et al. (1989)). The 
results indicate that it has a sensitivity of 67% and a specificity of 91 %; it is 
therefore outperformed by the more sensitive Haemoccult options since it has 
no cost or participation advantage. 
Tests designed to maximise participation 
Coloscreen and Ek-Defect are self-Completion tests designed to maximise 
participation. The results are interpreted and reported by the patient with the 
help of a reference card showing what a positive and negative test should 
look like. Tests commonly involve dropping prepared cards or sheets of 
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paper into the toilet bowl after passing a motion with testing over three days; 
haemoglobin produces a change in colour. 
Both tests have been evaluated using samples of surgical out-patients with 
symptoms of lower gastrointestinal disease. The results of the two studies 
are remarkably similar: Coloscreen was completed by 86% and was found to 
have a sensitivity of 33% and a specificity of 94.1 % (Pye et al. (1990)); the 
comparative figures for Ez-Detect were 88%, 36.4% and 89.3% respectively 
(Tate et al. (1989)). These convert into positive rates of 6.08% and 11.08% 
and detection rates of 1 and 1.09 per 1,000 acceptors for Coloscreen and Ez- 
Detect respectively. Assuming each test to cost El plus EO. 41 postage, the 
model provides the following results: 
TableSeven 
Coloscreen Ez-Detect 
Number testing positive 5,229 9,750 
Total cost (E) 1,014,635 1,680,333 
% on admin 10 4 
% on tests 14 5 
% on investigation 76 91 
Cases detected 86 96 
Average cost (E) 11,798 17,518 
Thus, both tests are easily dominated by the more sensitive Haemoccult 
protocols. A later study (Tate et aL (1990)) confirmed that in a further sample 
of out-patients with large bowel symptoms Ez-Detect was significantly less 
sensitive than Haemoccult with no gain in participation. These tests are not 
considered further. 
The symptom questionnaire is a postal survey of bowel symptoms, allowing 
an assessment of risk without faecal sampling. The experience in 
Nottingham is that the response rate is poor (34%) with 24% of responders 
reporting one or more symptoms (Farrands et al. (1984)). Further 
investigation revealed that none of these people had cancer, however, two 
asymptomatic cancers were later detected by Haemoccult in the same group. 
Even the most optimistic data indicate that a questionnaire has too high a 
false positive rate to be preferred to the more sensitive Haemoccult tests. 
Endoscopy screening 
Some researchers have supported colonoscopy as a screening test 
(Reasbeck (1987)). The cost of colonoscopy is El o5.1 0; pooled trial data 
give a sensitivity of 94% (England et al. (1989)). Assuming the same 
participation rate as for FOB testing and a specificity of 100%, the model 
predicts the total cost will be E6,178,598 (57,800 colonoscopies plus admin 
costs) and 165 cases will be detected at an average cost of E37,446. In 
comparison with the next most sensitive option, Hemeselect, the extra cost 
per extra case is E439,526 each. 
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Given the availability of endoscopic facilities support for a flexible 
sigmoidoscopy screening programme would appear to be more realistic (Atkin et al. (1993); Jass (1989)). A postal invitation to 100,000 people would 
cost EO. 33. Claims of 70% participation seem ambitious (Atkin et al. (1993)): 
of three supporting references, two are of doubtful comparability (based on a 
Norwegian population and a single general practice in Hertfordshire). The 
third reference is incorrectly quoted: the true figure is 44%. In the MRC trial 
46% of the population accept three-day testing with no prompting implying 
that they are well motivated in health matters. As this is in line with the 
reference mentioned above, participation of 45% is assumed. 
The prevalence for the target population is 3.03 per 100,000 of which 61.6% 
are in the range of the flexible sigmoidoscope (Atkin et al. (1993)); within this 
range a sensitivity to cancer of 98% and a specificity of 100% is assumed. 
Given that the cost per examination is E47.81 (from Chapter Four), the total 
cost is E: 2,288,268 (of which 94% is the cost of the investigations). The yield 
is 134 cases, at an average cost of El 7,076 each. In addition the protocol 
proposed would colonoscope everybody with a'high-risk' adenoma (diameter 
of 1 cm. or more, villous element) representing 5% of the those screened; this 
adds E236,475 to the total and a few cancers may be found beyond 60cm. 
As a whole, the option is inferior to 6-day Haemoccult testing and rehydrated 
Haemoccult testing. If the claims of 70% participation were justified the cost 
would rise to E3,483,518 (plus E367,850 for colonoscopy) and the yield to 
208 cases, at an average of El 6,753 each; this would be preferred to 
colonoscopy as the'Rolls Royce'screening option. 
Such a screening programme would have the detection and excision of 
adenomas as one of its main aims, yet no benefit is assumed here. The 
reduction in future cancer incidence likely to result from excision is discussed 
in Chapter Seven. 
Comparison of options 
The options evaluated can now be compared in terms of their incremental 
cost (i. e. the extra cost divided by the extra number of cases detected): 
Table Eight 
Test 
3-day (unhydrated) 
6-day 
3-day (rehydrated) 
Hemeselect 
Colonoscopy 
Total cost (E) 
372,477 
531,708 
757,891 
1,783,334 
6,178,598 
Cases incremental cost (E) 114 
136 7,238 
150 16,156 
155 205,089 
165 439,526 
The incremental costs are plotted in Figure One and the sr-atter of plots of 
cost and yield in Figure Two. Ideally a screening test should be as close to 
the origin of the graph as possible. This indicates the trade-off to be 
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addressed as a policy issue. To resolve it, information on the health benefits 
of early detection will be necessary, allowing the cases to be converted into 
health gain. 
Discussion 
The same deficiencies apply to these results as to those quoted in Chapter 
Four, since the same model is used. However, several biases work against 
the more sensitive tests. As they detect more adenomas any benefit from 
preventing future cancers bears more on them. Similarly if there is a cost in 
terms of extra treatment costs to missing a case there should be an extra 
penalty to a missed case. A particular factor working against endoscopic, 
screening is the one-off screening considered above: in fact, FOB testing will 
have to be regular, whereas the interval between endoscopic investigations 
can be considerably longer. 
Given their positive rates it is unlikely screening by Hemeselect or 
colonoscopy would be considered with the resources currently available to 
the health service. Even rehydrated Haemoccult testing requires substantial 
health gains to justify its extra cost. 
THE DEFINITION OF A POSITIVE SCREENING TEST 
So far it has been assumed that any one positive square on a test means that 
the whole test is judged to be positive; it is possible that different diagnostic 
protocols should be adopted for each number of positive squares on a test. 
The issue can be explored using unpublished MRC trial data based on 
screening the general population. 
Table Nine 
Slx-day Three-day 
Squares positive Number Cancers Number Cancers 
1 45 2 114 8 
2 69 7 117 12 
3 30 
.3 48 5 
4 19 4 28 4 
5 29 3 23 4 
6 19 2 31 9 
7 17 4 
8 14 4 
9 30 
10 84 
11 21 
12 83 
Total positive 263 37 361 42 
Since occasional bleeding among 'healthy' people is adequate to trigger a 
false positive, there are grounds for regarding one positive square as a 
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chance finding. On three-day testing this would have averted 114 
colonoscopies (saving of almost E12,000) but the sensitivity of screening, 
already criticised for being too low, would fall by 20% of its original value. 
The implication is that so many cancers bleed only intermittently that all 
positive results (following retesting) should be subject to the same 
investigations. 
The sixth stool gualac re-revisited 
The questions of the most efficient criterion for a positive Haemoccult test 
and of the appropriate number of squares to be used on such a test was first 
addressed by Neuhauser and Lewicki almost twenty years ago. Based on the 
results of an early clinical trial (Greegor (1969)) they considered the extra 
cost and yield of increasing the number of squares on a Haemoccult test. 
The rapidly diminishing gain in yield, approaching zero by the sixth square, 
when compared to the constant average cost per square, resulted in 
extremely high marginal costs. 
This example of the contrast between average and marginal costs has 
become a celebrated piece of health economics but there are a number of 
reasons for doubting its relevance to colorectal cancer screening policy. 
First, the calculations were performed using results from a very small sample 
of symptomatic patients (n=278), amongst whom only two cancers were 
detected; as both of these cases had eleven out of twelve positive squares on 
their test this implied that there was very little benefit to having more than one 
or two squares on the test. As has been shown above, this is not the case in 
larger samples of asymptomatic people. Second, they assumed that each 
additional square would identify an identical proportion (11/12 or 91.7%) of 
the cancers remaining undetected by the previous number of squares. Third, 
the effect on the participation rate of increasing the number of squares was 
not considered. Fourthly, the specificity of each square was miscalculated, to 
the extent that the false positive rate for a single square, calculated as 37% in 
the original article, has been re-estimated at 0.47% by subsequent 
researchers (Brown and Burrows (1990)). Finally, the study used charges to 
value diagnostic investigations rather than resource costs. 
While Neuhauser has defended his original work against the criticism 
directed at it (in particular that the re-estimated figures do not predict 
Greegoes results), he has also accepted that it is open to improvement 
(Neuhauser (1990)). Given the established manufacturing processes, the 
number of squares placed on a Haemoccult test is unlikely to change in the 
foreseeable future, although it is feasible that those offered screening could 
be requested to only complete (say) two of the six squares. What are the 
costs and benefits of implementing such a policy? 
As noted above, the only experience available on the use of the Haemoccult 
test in an asymptomatic population is either over three or six days i. e. six or 
twelve squares. For each of the key variables in a screening programme 
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(participation, positive and cancer detection rates) there will be a function 
relating them to days of testing. Participation, for instance, is 53.4% for a six- 
day test but rises to 57.8% for a three-day test. The straight line joining these 
points has the equation: 
Participation rate (%) = 62.2 
- 
1.467. D 
where D denotes the number of days of testing (at two squares per day). 
This implies that the maximum participation rate that can be expected in the 
MRC trial population is 60.7% with one day of testing. Similar equations for 
the other variables are as follows: 
Positive rate (%) = 0.89 + 0.133. D 
Cancer detection rate (per 1,000 acceptors) = 1.38 + 0.197. D 
An asymptotic functional form may be more intuitively appealing but the 
straight line appears to be an adequate approximation other than at the 
extremes: for example, the equations predict that 1.38 asymptomatic cancers 
per 1,000 people will be detected with no screening at aIll However, for 
values of D of one or more they seem to offer a reasonable approximation up 
to six-days of testing; at this point non-linearities may set in as limit values 
are approached. Studies in symptomatic patients suggest little gain to testing 
beyond eight days (St. John and Macrae (1982)). 
The model derived in Chapter Four can be used once the equations have 
been solved for each day of testing. Some examples are provided below: 
Table Ten 
Days of testing Participation (%) Positive (% ) Detection rate 
1 60.7 1.02 1.58 
3 58.7 1.29 1.97 
5 54.9 1.56 2.37 
8 50.5 1.95 2.96 
Given the linear nature of the relationships, the incremental cost per extra 
case detected of adding an extra day to testing is virtually identical 
throughout the range. The extra cost per extra case as a result of extending 
the test period is approximately E7,000. 
CONCLUSION 
The simple model can be used to compare the costs and disease yields of 
screening by various means, although the exclusion of any benefits from the 
excision of adenomas biases the results against some options. A sub-set of 
options clearly dominates the remainder in terms of the cost and cancer yield; 
these protocols use three- and six-day Haemoccult testing (with and without 
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rehydration), an immunological test and colonoscopy. On the grounds of 
economic efficiency, none of the other options for screening should be 
considered given their current performance. The choice between the options 
within the sub-set depends on the exact health gains and the willingness of 
purchasers to pay for these. 
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Chapter Six 
PARTICIPATION IN SCREENING 
"Occult blood screening is unique in that it requires a combination of 
considerable preparation and action by the patient outside the medical 
office. " (Knight et al. (1989)). 
Introduction 
Participation in faecal occult blood screening trials is voluntary, hence the 
proportion of people completing and returning a test is less than 100%. 
implying that the full health gain of screening (if any) is not realised. If 
participation is independent of prevalence then 50% uptake means half the 
cancers in the population are neither detected nor treated at an early stage. 
This could jeopardise the success of the whole programme, given the limited 
sensitivity of the Haemoccult test: 58% participation and 65% sensitivity as in 
the MRC trial of three-day testing means that at most 38% of cases benefit 
from early detection. 
Participation in the American screening trials is 80% but these use volunteer 
groups; in an unmotivated population a figure of 15% seems more 
appropriate (Winawer et al. (1985)). Participation in Scandinavian countries 
has been closer to 70%. 
Colorectal cancer is not a well-known disease: a Cancer Research Campaign 
poster described bowel cancer as two taboos in one subject. Initially, 
participation was low in the MRC trial but increasing sophistication in 
techniques of invitation and persuading non-responders to reconsider has 
raised the figure from 38% to over 60% in the later stages of the trial. 
The economic significance of participation 
This improvement has only been achieved through considerable effort 
devoted to persuading more people to take up the offer of screening: "It is 
essential that we approach the topic of FOB screening aggressively and with 
rigor to develop a means to increase participation" (Blalock et al. (1987)). 
Little attention has been paid to the economic costs and benefits involved: 
maximising participation must take some account of the costs involved. For 
efficiency, the expected benefits of increasing participation would be 
compared to the extra costs involved. 
A rational individual's decision to participate in a voluntary screening 
programme depends upon a subjective cost-benefit calculus of expected 
value. However, the results of a number of studies (Jansen (1984); Klaaborg 
et al. (1986); Nichols et al. (1986); Pye et al. (1988); Silman and Mitchell (1984)) suggest that participation is also a function of the method of invitation 
to participate (e. g. whether the invitation is made by the hospital or the 
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general practitioner), whether the subjects receive their tests automatically or 
whether they have to obtain them for themselves, and so on. Participation 
can be increased by giving more appropriate information regarding the test 
and the disease, the specific targeting of individuals at risk (e. g. those with a 
family history of cancer) and reminders to complete the test. Each measure 
involves extra cost, but there is no general rule as to which is the most 
efficient. 
The decision to participate in the screening programme 
Subject participation in the major European colorectal cancer screening trials 
lies within the range 55-70%, implying that a significant minority of individuals 
in each case are not taking up the offer of screening. On the other hand, the 
vast majority of individuals who participate in a mass screening programme 
derive no health benefit. Research into cervical screening programmes 
(Elkind et al. (1989)) has identified technical reasons for non-participation 
including: 
i) inaccessibility (e. g. unrecorded change of address or death); 
ii) ineligibility (already screened or does not fulfil screening criteria); 
iii) unsuitability (medical problem prevents completion of test); 
iv) communication failure (e. g. offer of screening not received, target 
illiterate). 
These seem equally appropriate to faecal occult blood testing: the potential 
size of the 'wrong address' problem in existing age-sex registers has been 
noted already. The most significant set of variables relate to attitudes to and 
perceptions of screening, however. 
The Health Belief Model (Rosenstock (11975)) offers a convenient way of 
thinking about the behaviour of the rational individual (taking all factors into 
account) when faced with this problem. The model attempts to predict 
individual behaviour on the basis of the individual's general health motivation, 
self-perceived risk of disease, perceived consequences of the disease, and 
any'cues to action' in the individual's environment (Gillam (1991)). 
Variations between the behaviour of individuals can therefore be explained in 
terms of different perceptions, motivations and spurs. This suggests that the 
rational individual is more likely to participate if they perceive (i) that they are 
personally susceptible to the disease, (ii) that the consequences of the 
disease would be severe for them, (iii) that screening and subsequent 
treatment would result in an improved prognosis if the disease were present, 
and (iv) that the costs involved are small. It has been found that self- 
perceived risk is a far better predictor of screening participation than 
objectively calculated risk (Vernon et al. (1990)). 
This framework can be used as a model of the expected net value of 
participation in screening. Participants obtain new information of one of two 
types 
- 
test results may be positive or negative for cancer. This information 
may prove either true or false. The individual will assign both values (or 
utilities) and subjective. probabilities to each of the outcomes, yielding the 
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following expression for the expected value of information (1) received from 
the test result: , 
EVVI " VaPa + VbPb + VcPc + VdPd (Pa + Pb + Pc + Pd :" 1) 
where subscript'a' refers to a true positive result, V to a false positive result, 
V to a true negative result and'd'to a false negative result. This information 
is not free, and the costs facing the individual are the expected disutility and 
inconvenience incurred in undertaking the test (v, ), and the opportunity cost 
of time foregone (vf). It follows that an individual will participate in screening 
if. 
EV[ll > E[V. + vfl 
(Note that in private health care systems there can also be a fee or charge for 
the test). An earlier formulation of this model used the expected net values of 
participation and of non-participation in cervical screening although the 
differences otherwise appear small (Haycox: and Haran (11988)). 
For a given individual, the subjective probabilities depend upon the 
individual's knowledge of cancer prevalence, prognosis and of test 
performance, as well as their perceptions of personal risk. True results take 
a positive sign while false results take a negative sign; one exception would 
be those who do not believe early detection increases the chances of cure, 
and they place a zero or negative value on v.. A lack of confidence in the 
predictive power of the screening test would imply high values Of Pb and Pd, 
thus inaccuracies in screening techniques are not widely publicised.. 
Individuals 'convinced' they have cancer value p,, as one, and those equally 
convinced they do not value pc as one. 
The framework can be used to interpret typical justifications given in surveys 
of non-participants (Dent et al. (1983); Farrands et al. (1984)): 
i) "Cancer worries me, I would rather not know and I'm afraid of what the 
test might show" implies high values for p. and for v. but the latter is 
negative. 
ii) "I have no symptoms" / "I feel all right" / "I have not had this problem 
before so am not likely to have it nov/' implies p. is one, p. is zero and 
vc is negligible. 
iii) 'The whole idea put me ofr'/ I couldn't face it" 'The test seemed 
messy, unpleasant, distasteful" indicates a high value for v.. 
Research findings are consistent with the predictions of the model: 
Participation is higher amongst those who perceive the effects of 
colorectal cancer as serious and who view screening as improving the 
prognosis i. e. v. and v, valued high and Positive, Pb and Pd presumed 
low (Jansen (1984)). 
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" 
Past experience with FOB testing is a positive influence upon 
participation (Blalock et al. (1987)): ex post v. is lower than ex ante 
expectations. In the MRC trial, re-testing of initial positives produces 
very high participation, suggesting consistency on the part of initial 
acceptors; those refusing the retest may be scared by the implied 
increased chance they have the disease. 
" 
Screening that increases costs (vf) to the subject reduces participation 
e. g. six-day testing, dietary restriction. 
" 
The presence of gastrointestinal symptoms increases participation 
(Thompson et al. (1986)) presumably because of greater self- 
perceived risk of the disease (p. high) and a high positive value to 
confirmation (v, and v. high). 
" 
Embarrassment and distaste are significant causes of 
non-participation (v, high) (Macrae et al. (1986)). 
" 
Those who regard themselves as being especially susceptible to 
cancer (p. high) are either particularly likely to participate (v. high and 
positive) or particularly likely to refuse (va high and negative) (Macrae 
et al. (1984)). 
" 
Tests which do not require taking stool samples (reducing Q increase 
participation (Pye et al. (1990), Tate et al. (1989)); but these sacrifice 
sensitivity and specificity, ultimately undermining pa and p.. 
" 
Mant et al. (1990) found 96% of false positives would not be deterred 
from participating in screening programmes in the future; this implies 
that ex post vbis small and negative. 
Supporting evidence from studies of take-up of breast cancer screening 
includes the increased participation when a mobile mammography unit is 
used, reducing access costs (Haiart et al. (1990)). It was shown that a 10% 
increase in the'crow-fly distance from the unit to the individual's home 
reduced the uptake by 2.4%. Other studies have shown that women with 
positive health concerns and a knowledge of screening methods are more 
likely to take part (high positive values on v. and v. and realistically low 
values on Pb and Pd) (Vernon et al. (1990)). Many British women appear to 
believe in the effectiveness of mammography screening but do not perceive 
themselves as being at personal risk of having the disease (Fallowfield et al. 
(1990)). Other research indicates that it is better to educate people about 
screening rather than individual risk since this can be an important constraint 
on take-up (Vernon et al. (1990)). Non-participants are a heterogeneous 
group with either very good or very bad self-perceived health (Hunt et al. 
(1988)), implying feelings either of invincibility or of fatalism. 
The model assumes rationality on the part of the individual, but is this always 
the case? There is some evidence that non-participants are coping with their 
fear of ill-health by not thinking about it and specifically by not considering 
their personal risk of getting ill or of dying (Fallowfleld et al. (1990)). Making 
the calculation may itself be costly to the individual in terms of the anxiety it 
induces: from this perspective it may be an entirely rational decision. 
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Health education based upon the health belief framework has been used as 
an enclosure to the Haemoccult test at the initial screening invitation in the 
MRC trial (Pye et al. (1988)). The leaflet was designed to persuade the 
target population: (i) bowel cancer was more common in their age-group than 
they probably believed (p. is high); (ii) "unlike most cancers it's the one most 
treatable if caught early", i. e. v, was strongly positive; and (iii) a negative 
result is reassuring (vc Is high). No mention was made of the possibility of a 
false test result (implying Pb and Pd were zero). However, there was no 
significant difference between the group randomised to receive health 
education and the group who were not, implying that the invitation letter alone 
forecruits all those susceptible to postal recruitment and there may be little 
scope for further improvement". Another study reported similar results (Nichols et al. (1982)). The implication appears to be that health education is 
either ignored or amounts simply to preaching to the converted. 
Methods of inviting people to complete screening 
The findings from the last section suggest that the method of screening 
invitation might influence the individual's decision through the costs to the 
individual. Health education offered with the invitation could be more 
personal (e. g. from the individual's GP). This section draws on several 
British studies of participation in an asymptomatic population of similar age 
and with no special a priori motivation for undertaking screening. Note that 
while the remainder of the evaluation uses the viewpoint of the NHS 
purchaser, it is appropriate in this example to also consider the viewpoint of 
the individual and the costs involved in participating. 
Five different methods of invitation were compared varying the source of the 
invitation between the individual's GP, a health visitor or a postal invitation 
from a screening unit. The alternatives are as follows: 
1)A test is posted to each member of the target Population from the 
screening unit (Thomas et al. (1990)); 
2) Individuals are invited by letter to consult their GIR at a specified time 
to discuss screening (Nichols et al. (1986)); 
3) Individuals are invited by letter to make an appointment to discuss 
screening with their GP (Box et al. (1984), Nichols et al. (1986)); 
4) Individuals are invited by letter to discuss screening with a health 
visitor at a specified time (Nichols et al. 0 986)); 
5) Individuals are invited by letter to collect a screening test from 
reception at their local GP surgery (Nichols et al. (1986)). 
In modelling the invitation regimes it is assumed that: 
0a register of the population to be screened is already available; 
0 completed tests can be 
developed at any health care facility; 
40 non-participants do not return unused tests for re-use; and 
do general administration costs, 
development costs and overheads are 
constant for all options and can thus be excluded. 
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A accepting a test and K completing and returning a test. All data are from 
the studies cited with the exception of: 
(i) the number of invitations for methods 2 to 5 (assumed to equal T), and (ii) the number of acceptors for methods 2,4 and 5 (assumed that 10% of 
those taking a test away with them do not complete and return it in line 
with the results of method 3). 
The costs of each method of invitation can be expressed algebraically: 
1. T(c + 3s +2P2 + t)/K 
2. {T(c + 3s + 2p, ) + A(I +1 Og + 2s + P2 + t)YK 
3. {T(c+3s+2p, )+A(I+c+10g+2s+P2+t)YK 
4. {T(c + 3s + 2p, ) + A(I + 15h + 2s + P2 + t)YK 
5. {T(c + 3s + pl) + A(I + 2c + 2s + P2 + t))/K 
where the letters denote the following, with associated costs (E): 
b telephone call, per minute 0.014 
c clerical assistant time, per minute 0.05 
g general practitioner time, per minute 0.34 (Hughes (1991)) 
h health visitor time, per minute 0.07 
P, postage, letter only 0.15 
P2 postage, test 0.20 
S stationery, per item 0.01 
t 3-day Haemoccult test 1.13 
T denotes the cost to the individual of attending the GP and is calculated as 
follows. There are two elements to this cost: travel and time. A national 
survey of the accessibility of surgeries (Ritchie at al. (1981)) found that: 
i) 49% of the population live less than one mile from their local surgery, 
most of this group walk to the consultation; 
ii) 26% live 1-2 miles from their GP, half travel by car with the remainder 
equally split between walking and bus; 
iii) 25% live more than 2 miles from the surgery, two-thirds travel by car 
with the reminder using the bus; and 
iv) average waiting time is 15 minutes. 
The average time taken to consult a GP is about one hour altogether. Time 
is valued at E1.75 per hour according to Department of Transport (1987) in 
1985 prices, updated at 5% p. a. to E2.23 in 1990 prices. About half the 
population only incur'shoe leather costs but the remainder incur travel costs 
assumed to be El (at EO. 3/mile). The average cost to the patient of a GP visit 
is thus M. This is consistent with the finding that 9o% of the population 
regard visiting the GP as'easy (Ritchie at al. (1981)). 
The cost of each alternative, based on the given assumptions, is presented 
Table One. All calculations are normalised for a target Population (T) of 
1,000 persons: 
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Table One 
Method % accepting 
1 100 
2 59 
3 30 
4 50 
5 19 
Notes 
TC 
- 
Total cost 
AC 
- 
Average cost per acceptor 
% completing TC (E) AC (E) 
46 1,610 3.50 
53 4,953 9.34 
27 2,720 10.07 
45 3,080 6.84 
17 846 4.98 
The results are also presented in Figure One, demonstrating the trade-off 
between cost and uptake; ideally an option would be located in the bottom left 
hand corner of the graph. The MRC trial method of postal invitation offers the 
lowest cost per person completing a test. The health visitor option has the 
lowest total cost but this places the greatest onus upon the individual (vf is 
highest). While GPs can achieve higher participation (an extra 70 cases in 
option 2) the extra cost involved is E3,343, an incremental cost of E48 per 
extra participant. 
Enhancing participation In postal-based mass screening programmes 
The European trials of colorectal cancer screening all use the postal 
invitation method (number I above), although each trial also uses a variety of 
means of persuading people who have not completed a test to do so. 
The MRC trial follows the initial invitation with a reminder letter to 
non-responders, pointing out the potential benefits of early detection and 
the ease of completion of the test. People who still do not respond have a 
Tag' placed in their notes at their GP surgery, which will prompt the GP to 
discuss screening with them when they next attend. 
In the Swedish trial, a reminder letter is sent, with persistent refusers 
receiving a second reminder letter with another test. 
In the pilot study of the Danish trial a reminder letter was sent, with 
persistent refusers contacted by telephone or a second letter (Adamsen 
and Kronborg (1984)). 
The main Danish study uses a more complex protocol based on two 
reminder letters and a telephone call. At each mailing (including the initial 
mailing), a questionnaire is included, to be returned by those not wishing 
to complete a test. Those completing a questionnaire were telephoned to 
correct misperceptions and to attempt further persuasion (Klaaborg et al. (1986)). 
These methods can be costed using a similar method to that in the previous 
section. The appropriate cost equations, 
based on siMilar lettering, are: 
i) For the initial invitation: (c + 3s + 2P2 +0 
ii) For each reminder letter (c + 3s + pl) 
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iii) For the GP prompt card: mark notes (2c + s), assume GP discusses 
with 50% (2g). Each'converf sent test (c + 3s +2P2 + 0- 
iv) For telephone contact: 2c per target; (5c + 5b) each contact, each 
acceptor sent test (c + 3s +2P2 + 0- 
The results of costing the four alternatives are presented in the table, 
indicating for each trial, the average cost and participation rate and the 
subsequent incremental cost per incremental responder and the additional 
participation rate at each stage (Danish (1) and Danish (2) are the Danish 
pilot and main studies respectively): 
Table Two 
MRC Sweden Danish (1) Danish (2) 
E% E % E % E % 
Invitation letter 3.53 45.7 3.15 51.1 2.64 61.0 2.77 58.5 
Reminder letter 1 1.13 10.0 1.10 9.8 1.83 4.7 1.05 5.0 
Reminder letter 2 1.20 1.9 
Reminder 2 with test 13.69 4.6 
Phone refusers 19.29 1.3 6.12 3.3 
GP prompt card 5.97 2.5 
Using the MRC protocol, 45.7% of those contacted respond to the initial 
invitation at an average cost of E3.53 per responder. A reminder letter is sent 
to the 54.3% who do not reply: another 10% of the whole sample reply at an 
average cost per extra responder of El. 13. A total of 44.3% of the sample 
have not yet replied and a prompt card is placed in their GP notes: this adds 
2.5%age points to the total response at a cost of E5.97 per extra responder. 
A high response to the initial invitation results in a low average cost but low 
initial participation is often followed by a good response to the first reminder. 
Thereafter, persuasion becomes progressively more expensive, because of 
the smaller number of further successful 'conversions'; this mirrors earlier 
findings in screening for asymptomatic bacteriuria (Rich et al. (1976)). 
optimal participation rates 
Mass population screening programmes often aim for 70% participation (e. g. 
Forrest (1986)) as an 'optimal' participation rate. This section sets out to 
determine the economic optimum on the basis of the balance of the extra 
costs and benefits involved in increasing response. 
In a given population of N people, n complete a screening test and the 
prevalence of disease is p. All screen detected cases are early stage and all 
symptomatic cancers are advanced stage. The benefit of treating early stage 
disease is B, and of late stage disease is B2 with treatment costs of C, and C2 
respectively. The net benefit of the screening programme is np(B, 
- 
B2)- 
The cost of screening is nCt (where Ct represents the cost of the test plus 
postage and development) plus the net costs of treatment: 
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nCt + np(Cl - C2) 
Screening is efficient if marginal benefits exceed marginal costs: 
np(BI - B2) > nCt + np(Cl - C2) 
However, the probability of participation might be enhanced by additional 
expenditure i. e. participation can be a direct function of cost, n= f(Ct) or Ct 
g(n). Optimal participation from the economic point of view, where marginal 
benefits equal marginal costs, can be derived from the equation: 
np(BI - B2) = n[g(n)] + np(Cl - C2) 
i. e. g(n) = p[(BI 
- 
B2) 
- 
(cl 
- 
CA 
To make the model operational requires some proxy measure of the net value 
of screening in the absence of trial results. Based upon UK cancer 
registration figures (OPCS (1988)), the average age of new cases of 
colorectal cancer is 70 years for females and 67 years for males; life 
expectancy at these ages is 84 and 79 years respectively (OPCS (1987)). if 
early stage treatment has a 100% cure rate, patients have an average life 
expectancy of 13 years after treatment. By contrast, the average life 
expectancy of those treated for late-stage cancer is approximately 3 years, 
i. e. there is a net gain from early treatment of 10 life-years. Based on the 
most recent evidence from the MRC trial, p=0.0035. The cost of cancer 
treatment is estimated to be E2,000 (Tuck et al. (1989)). All benefits and 
costs are discounted at 6% per annum. It is assumed that treatment for 
screen-detected cancer takes place immediately after screening and that for 
late-stage cancer occurs three years later. 
The function n= f(Ct) can be estimated for each of the four trials from the 
data presented in Table Two, assuming that the relationship is continuous. A 
logarithmic form 
n=a+b. ln(Ct) 
was chosen assuming that (i) a minimum level of participation will occur 
without any encouragement, and (ii) there will be diminishing returns to 
persuasion. The equation coefficients and test statistics (in brackets) are 
presented in Table Three: 
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Table Three 
a b R2 (%) F 
MRC 0.3695 0.0944 67 2.026 
(3.123) (1.423) 
Sweden 0.4698 0.0667 71 2.462 
(5.587) (1.569) 
Danish pilot 0.6032 0.0226 67 2.063 
(18.278) (1.436) 
Danish main 0.5328 0.0674 '88 15.165 
(18.369) (3.894) 
Although these equations fail classical statistical significance criteria, they 
are satisfactory under the criteria for very small sample sizes estimated by 
Leamer (1978). 
Reworking the optimal participation equation gives: 
n=b. lnfp[(B, 
- 
B2) 
- 
(Cl 
- 
COD 
and this permits the calculation of the implicit value of a life-year gained for 
any given level of participation. These are approximately E448 (MRC), E464 (Denmark main), E734. (Sweden) and E871 (Denmark pilot) for the present 
levels of persuasion used. If the value of a life-year exceeds these amounts 
then it is worth incurring additional persuasion costs. A participation of 100% 
would be optimal only if the value of a life-year exceeded E34,780, E123,700 
and E45,000 for IVIRC, Swedish, and Danish main trials respectively; the 
Denmark pilot study would require a valuation in excess of El billion for 
optimal participation to be 100%. Note that the technical reasons for non- 
participation noted earlier restrict the realistic maximum participation to less 
than 100%. 
These values are proportional to cancer prevalence (p) i. e. life-year values 
will halve if prevalence doubles. Changing the assumption of life-years 
gained as a result of early detection, from 10 to 9 years raises the implicit 
life-year valuation by approximately 8% for all four protocols. Halving the 
number of life-years gained to five increases the values by 71-74%. The 
results are not sensitive to treatment costs: doubling the costs to E4,000 only 
raises the implicit value of a life-year by between 2 and 7%. 
Discussion 
The results assume that participation is independent of prevalence, thus the 
gain in yield for a given number of extra participants is constant. However, in 
the Danish trial the proportion of colorectal cancer deaths is significantly 
higher amongst refusers than among acceptors (Kronberg et al. (1987)). The 
83 
MRC trial accepts "... some degree of selection bias is apparent in the high 
frequency and poor prognosis of cancers diagnosed among non-responders" 
(ardcastleHardcastle et al. (1989)). Prevalence of colorectal cancer and 
participation in FOB screening are both age-related, with screening uptake 
being lowest where the incidence (and prevalence? ) is highest, i. e. in the 
older age groups of the target population; this is considered in more detail in 
Chapter Eight. A similar effect has been noted for breast cancer screening: 
in the Edinburgh trial the proportion of breast cancer deaths was far higher 
among refusers than acceptors (34% versus 12%), while participation also 
fell with age (64% of ages 45-49,57% of ages 60-64) (Roberts et al. (1990)). 
This cannot be taken to mean that it would be those refusers most at risk who 
were amenable to persuasion of the types described above. This question 
can only be conclusively answered by long-term follow-up of the on-going 
randomised trials. In the case of breast cancer screening, the New York HIP 
trial found breast cancer yield and mortality rates were lower among 
'reluctant' acceptors than among those who needed no persuasion (Fink and 
Shapiro (1990)). Table Four shows the number of breast cancers per 1,000 
life-years in each group and the rate of breast cancer deaths per 10,000 life- 
years: 
Table Four 
Case rate Death rate 
'Keen'acceptors 2.35 5.6 
'Reluctant' acceptors 1.95 3.8 
Refusers 1.89 4.9 
Controls 1.95 5.0 
(Note 
- 
the original article does not record whether these differences are 
statistically significant). 
This would suggest that the women who were initially reluctant to accept but 
succumbed to persuasion were less at risk than the other groups; in terms of 
the research findings outlined in an earlier section they may have been those 
with a very high regard of their own health (and with some reason). The poor 
prognosis in the refuser group (less cases, more deaths) implies that this 
group may consist of women with a pessimistic view of their own health 
(again, with reason). However, a higher mortality rate from other causes was 
noted in the refuser group and (to a lesser extent) in the 'reluctant' acceptor 
group, suggesting that co-morbidity may reduce the incentive to take part in 
screening. 
The list of technical reasons for failing to participate earlier can be corrected 
without any recourse to changing individual behaviour, although this is not to 
say that this means of increasing participation is free. Inaccurate address 
registers can be very significant as 3 million individuals in Britain change 
addresses annually. A study of FHSA-based breast screening in Inner 
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London found 16% of invitations were returned by the Post Office (McEwan et 
al. (1989)). In inner cities FHSA registers have incorrect address for up to 
50% of cervical and breast screening targets (Bowling and Jacobsen (1989)). 
GP records, used as the source of recruitment for the MRC trial, are generally 
more accurate with 2-3% test returns via the postal system. Birth dates are 
also inaccurate in 5% of entries (Ross (1989)); this is of some relevance 
when the target population is defined on the basis of age. 
Protocols for other forms of screening have used other means of persuasion 
involving alternative data sources and direct contact with screening targets. 
One study of cervical screening used the electoral register to cross-check the 
population coverage of cervical screening (Cook and Wald (1985)). Of 500 
names drawn from the register, 309 were excluded on age or gender 
grounds, with the remaining 191 being cross-checked against cytology 
records; 86 were found to have undertaken a recent test. The remaining 105 
were contacted by post (42 requiring further reminders), enclosing a clinic 
appointment. The 22 individuals who did not respond to this offer were 
visited at home by a district nurse 
- 
11 people attended following the posted 
appointment and a further 2 following a home visit. Applying the cost data 
used earlier in this chapter and assuming (i) 6 electoral register names and 2 
cytology names can be checked per minute, and (ii) home visits take 30 
minutes each, the average cost for the final 13 responders equals 
approximately E8 (for an additional participation increase of 6.8%). When 
compared to the other methods of pursuing non-responders this result seems 
reasonable. 
Conclusion 
A model based on expected utility theory is consistent with the observed 
behaviour of populations offered screening and can help in the design of 
health education to accompany the initial contact. In terms of motivating 
people to complete a test a postal-based system of Haemoccult screening 
outperforms creening organised through general practitioners. This 
difference is likely to be accentuated if the trial results used related to well- 
motivated GPs. In terms of prompting people to complete a screening test, 
some persuasion appears to be efficient. Going to the extremes used by 
some trials, however, means that the marginal costs are high relative to any 
extra benefits. The economic optimum for participation is less than 100% as 
the costs of persuasion rise once a 'hard core' of people, apparently 
determined not to complete a test. is reached. 
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Chapter Seven 
THE BENEFITS OF ADENOMA EXCISION 
Introduction 
Although it is commonly accepted that the initial malignant stage of many, if 
not most, colorectal carcinomas is within an adenoma the benefit of adenoma 
excision is difficult to quantify. While the evaluation to date has excluded any 
effects of adenoma excision, the sensitivity analysis of the simple model of 
FOB testing in Chapter Four showed that the cancer detection rate was the 
most significant variable. This implies that quantifying the effect of breaking 
the adenoma-cancer sequence is potentially crucial for the evaluation: cases 
prevented may prove as important as cases detected. No systematic, 
analysis of the data on adenoma detection in the MRC trial is yet available, 
hence the first section of this chapter gathers together the relevant figures for 
the first time. The next section compares various ways of estimating the 
impact of adenoma excision on future cancer incidence. The final section 
considers the costs and benefits of adenoma excision. 
Adenornas In FOB screening trials 
At the time this work was carried out (mid-1 991) 139 people in the control 
group of the MRC trial had had adenomas excised, as had 552 members of 
the group offered screening. The ratio between the sexes is identical in each 
group with 61 % of the patients being male. The mean age in the study group 
was 65 with their control counterparts being one year older. More study 
group cases had multiple adenomas (29% versus 19% of cases in study and 
control groups respectively). 
The commonest way to classify adenomas is according to the diameter of the 
largest recorded specimen for each person: 
Table One 
Group Small Medium Large 
Control 44 53 42 
Study 109 287 156 
'Large' 
-2 cm. or more in diameter, 'medium' -1 cm. to 2 cm. diameter; 'small, 
- 
less than I cm. diameter. 
These data are presented in Figure One. The mean age of each of the six 
sub-groups was identical at 65 years old. 
Five times as many adenomas were found in the study group as in the control 
group; the excess was particularly notable for medium and large adenomas. 
Screening detects 9.6 adenomas per 1,000 people completing a test at the 
initial screen and 3.8 per 1,000 at the second screen. Theory predicts a 
86 
CL 
:3 CL 
eZ 
me C» 
>N 1-= -0 
ci cn 
CL 
0 
13 
c 
cc 
(D 
N 
1) O; A-
cts 
E 
0 
&w 
Z 
LL 
(D 
LM 
E 
-g 
E 
cn 
C) C) 00 
Lf) Q LO 
CO ýQn 8 
large yield from the early rounds of screening as the prevalent adenomas are 
cleared from the study group, with differences in rates of detection equalising 
over time to reflect incidence alone. Note, however, that post mortem series 
do not find a similar excess of medium and large cases (Williams (1982)). In 
the Danish trial the figures for adenomas detected at the initial screen are 
substantially lower although figures for the second screen are similar (Bech 
et al. (1991)). 
Table Two shows the rate of adenoma detection (per 1,000 persons) in the 
control group (C) and for the study group (S) following recruitment to the trial. 
Table Two 
All Large Medium Small 
Year c S c S c S c s 
1 0.3 2.1 0.1 1.1 0.1 1.6 0.1 0.4 
2 0.3 1.2 0.1 0.4 0.1 0.6 0.1 0.1 
3 0.4 1.4 0.1 0.2 0.1 0.8 0.2 0.4 
4 0.5 1.0 0.1 0.1 0.2 0.5 0.2 0.3 
5 0.5 0.8 0.1 0.1 0.2 0.6 0.2 0.1 
6 0.4 0.8 0.1 0.2 0.2 0.3 0.1 0.3 
7 0.4 0.5 0.1 0.2 0.2 0.3 0.1 0.3 
The incidence in the control group rises slightly over time as the population 
ages, although part of the effect may be attributed to improved methods of 
diagnosing and excising polyps as the trial progresses. The yield in the study 
group falls steadily as prevalent cases are removed and by the seventh year 
of the programme the rate is almost equal to that of the control group: after 
three rounds of screening the yield is only slightly above the incidence rate. 
The fall in the rates of detection of medium and large adenomas is much 
more marked than the figures for small adenomas. 
In terms of the site of the largest adenoma, screening seems to detect a large 
number of cases in the'left side of the colon: 
Table Three 
Small 
Right side 
Transverse 2 
Left side 16 
Rectum 25 
Control 
Medium Large 
02 
11 
26 18 
26 21 
Study 
Small Medium Large 
2 1 3 
9 4 7 
50 202 110 
48 80 36 
Right side 
- 
caecum and ascending colon; transverse includes both flexures-, 
left side 
- 
descending and sigmoid colon; rectum includes the recto-sigmoid junction. 
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There is very little difference between the groups beyond the descending 
colon but there is a very heavy predominance of adenomas in the sigmoid 
colon. This is not borne out either by a British post mortern series (Williams 
et al. (1982)) or by the Danish screening trial where the distribution is more 
uniform. 
In summary, the MRC screening trial has been very successful at detecting 
and excising adenomas. However, the data show some inconsistencies with 
other reports in terms of the number of adenomas detected at the initial round 
of screening, their site within the colon and their size. 
Screening and the reduction of future cancer incidence 
A number of methods have been used to estimate the benefits of adenoma 
detection and excision. As has been noted in Chapter Three the results of 
several economic evaluations of colorectal cancer screening depend crucially 
on these estimates (Eddy (1990), Wagner et al. (1991)). In this section six 
means of calculating the significance of the adenoma-cancer sequence are 
explored in more detail. Each method is described below and then applied to 
a standardised sample of adenomas. 
Method One: Eddy and expert opinion 
In Eddy's model 93% of cancers begin as adenomas and hence are 
potentially preventable by adenoma excision (Eddy (1990)). 5% of the 
adenomas which reach a diameter of 5mm are destined to become cancers 
after an average duration of seven years. This is based on reviews of 'expert 
opinion', although the lack of scientific data must raise questions as to what 
this'opinion'is based upon. 
Method Two: HoWs growth rates 
A Norwegian study achieved ethical approval to leave 35 newly diagnosed 
adenomas of less than 5mm diameter unexcised for two years (Hoff et al. (1986)). At the follow-up investigation 17 had grown, 13 were the same size 
and 5 had shrunk. Growth was most common in the sigmoid colon. On 
average the adenomas that grew were 2.8mm. in diameter and originally and 
4.1 mm subsequently, while those that shrunk went from 3.6 to 2.4mm. on 
average. From these figures it was estimated that a small adenoma takes 10 
years to double in size. Assuming that the sequence takes between 10 and 
15 years from the small adenoma to cancer the annual risk of cancer is I% in 
small adenomas, 20% in medium-sized adenomas and 50% in large 
adenomas (Hoff (1987)). 
kfethod Three: Eide's prevalence calculations 
On the basis of a post mortem series Eide, a Norwegian pathologist, 
estimated age-specific prevalence rates and hence the total number of 
prevalent adenomas in the Norwegian population (Elde (1986)). These 
figures assumed similar distributions of characteristics (size, histology, 
dysplasia) in the general population and in the post mortern series. Based on 
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cancer incidence data he then calculated the annual probability that an 
adenoma with one of the above characteristics would become malignant and 
be detected. Overall, the annual conversion probability was 0.25%, but for 
adenomas larger than 1 cm. in diameter the probability was 3% per annum, for 
a villous element to the histology the annual probability was 17%, and for 
severely dysplastic adenomas the annual risk was 37%. 
Method Four., Stryket's observational study 
American researchers reviewed the records of 226 patients with medium or 
large colonic adenomas where diagnosis was not followed by excision either 
because of the patient's general medical condition or their preferences 
(Stryker et al. (1987)). Regular BEXR surveillance was carried out and the 
adenoma excised only when 'significant' growth was observed. In total, 47% 
of cases eventually underwent resection, with 21 cancers found at an 
average follow-up of 9 years (range 2-19 years). Cumulative malignancy 
probabilities over time were also calculated: the chance of cancer developing 
at the adenoma site was 2.5% after 5 years, rising to 8% after 10 years and 
24% after 20 years. 
As the authors admit the study has a number of weaknesses: for example, it 
is impossible to be sure that malignancy was not present in the first place. 
However, if a curve is fitted to the data, the equation gives the cumulative 
probability of carcinoma arising in an adenoma (P) on the basis of the 
number of years since diagnosis (Y). The equation passes through the origin (assuming malignancy was not present at initial diagnosis) and takes the 
following quadratic form: 
0.003505 Y+0.000426 Y2 
Differentiating gives the probability that malignancy develops during any 
given year following detection. 
Model Five: Stryker adjusted for smafl adenomas 
As the above data apply only to medium or large adenomas there is no 
possibility of small adenomas growing to pose a threat of malignancy. To 
allow for this the growth rates described by Hoff above can be used: these 
would imply that small adenomas become medium-sized after ten years; after 
this the equation above applies. 
Method Six: Shyker adjusted for hiStology and dysplasia 
Method Four does not take any account Of the malignant potential of 
adenomas in terms of histology (tubular, tubulovillous, villous) or degree of 
dysplasia (mild, moderate, severe). Method Three, in line with conventional 
wisdom, implies that villous and severely dysplastic adenomas have the 
greatest malignant potential. How can the Stryker equation be adjusted to 
reflect this? 
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There is no longitudinal study upon which to base these weights, yet leaving 
the equation unadjusted implies no extra weight for these factors. One 
possible data source is the report of a cross-sectional endoscopic study of 
over 1,000 excised adenomas including the proportion showing malignancy 
according to each characteristic (Muto et al. (1975)). Taking the Stryker 
equation as representing the malignant potential of the most common type of 
adenoma (medium-sized, tubular) weights can be derived from the ratio of the 
malignancy rate for any pair of characteristics compared to the rate for the 
medium tubular. For example, malignancy was found in 4.5 times as many 
large, tubulovillous adenomas as in the base case (medium tubular): thus, the 
Stryker equation for large tubulovillous equations has coefficients 4.5 times 
those of those of the base case. The weights used are presented in Table 
Four: 
Table Four 
Size Dysplasia 
Small Medium Large Mild Moderate Severe 
Histology 
Tubular 0.1 1.0 3.4 0.2 0.9 2.7 
Tubulovillous 0.4 0.7 4.5 1.4 3.1 3.3 
Villous 0.9. 1.0 5.3 3.5 4.0 4.9 
Dysplasia 
Mild 0.03 0.3 4.1 
Moderate 0.2 1.4 4.9 
Severe 2.6 2.4 4.7 
Unfortunately, the cross-section study only reported malignancy rates for 
pairs of characteristics. A given adenoma, therefore, falls into three different 
categories; for instance, a small, severely dysplastic, villous adenoma has a 
weight of either 4.9 (villous, severe dysplasia), 2.6 (villous, small) or 0.9 
(small, severe dysplasia). It is not clear which characteristics dominate or 
how they interact, hence the analysis uses the middle estimate for each case. 
Data sample 
In order to compare these methods the characteristics of the adenomas 
detected in each group of the MRC trial were compared. The aim was to 
specify the characteristics of the adenomas which were in excess in the study 
group i. e. those which were detected by screening but which would not have 
presented symptomatically. The results are presented in Table Five 
Table Five 
Size Histology Dy3plasia Control Study 
S T Mild 4 24 
S T Moderate 6 25 
S T Severe 3 3 
S TV Mild 1 2 
S TV Moderate 1 3 
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S TV Severe 0 0 
S V Mild 0 0 
s V Moderate 0 1 
S V Severe 0 0 
M T Mild 8 32 
M T Moderate 5 77 
M T Severe 2 15 
M TV Mild 2 11 
M TV Moderate 6 48 
M TV Severe 4 14 
M V Mild 0 0 
M V Moderate 0 2 
M V Severe 0 2 
L T Mild 1 10 
L T Moderate 3 15 
L T Severe 4 4 
L TV Mild 3 6 
L TV Moderate 4 38 
L TV Severe 5 17 
L V Mild 1 4 
L V Moderate 2 6 
L V Severe 1 5 
Note the table only records cases with complete data for all three 
characteristics, excluding 34% of study group cases and 53% of control 
group cases. 
For example, Table Five shows an'excess' of 34 large moderately dysplastic 
tubulovillous adenomas in the study group over the control group. Rather 
than working with the exact number of excess cases for each category, the 
proportion of the excess falling into each category was used to define the 
characteristics of a group of 1 00'typical' excess cases. The composition of 
this group was as follows: 
24 medium tubular moderate dysplasia 
14 medium tubulovillous moderate dysplasia 
12 large tubulovillous moderate dysplasia 
8 medium tubular mild dysplasia 
7 small tubular mild dysplasia 
6 small tubular moderate dysplasia 
5 medium tubular severe dysplasia 
4 large tubular moderate dysplasla 
4 large tubular severe dysplasia 
3 medium tubulovillous mild dysplasia 
3 medium tubulovillous severe dysplasia 
03 large tubular mild dysplasia 
1 small tubulovillous moderate dysplasia 
1 medium villous moderate dysplasia 
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1 medium villous severe dysplasia 
1 large tubulovillous mild dysplasia 
1 large villous mild dysplasia 
1 large villous moderate dysplasia 
1 large villous severe dysplasia 
As the average age of the sample was 65 years, their remaining life- 
expectancy was 15 years (OPCS (1987)). 
Each of the six methods of estimating the adenoma-cancer sequence was 
applied to this population in turn, taking account of the appropriate 
restrictions e. g. small adenomas were excluded from the original Stryker 
model (method 4). 
Results 
Table Six shows the predictions of the six methods of the number of cancers 
that would have developed in the 100 adenomas if they had not been excised 
in Year 0 (Stryker (2) refers to the modification to take account of small 
adenomas and Stryker (3) refers to the weighted Stryker equation): 
Table Six 
Years Eddy 
1 0 
2 0 
3 0 
4 0 
5 0 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
0 
0 
5 
5 
5 
5 
5 
5 
5 
5 
Hoff 
25 
42 
53 
61 
67 
71 
74 
77 
79 
81 
82 
84 
84 
85 
86 
Eide 
12 
21 
28 
34 
39 
43 
46 
48 
51 
53 
55 
56 
58 
59 
60 
Stryker 
0 
2 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
13 
Stryker (2) 
0 
2 
2 
3 
4 
5 
6 
7 
8 
9 
10 
12 
13 
Stryker (3) 
1 
2 
3 
4 
5 
7 
9 
10 
12 
15 
17 
19 
22 
25 
28 
The results are also shown in Figure Two. The range of results is extremely 
wide: unless there are grounds for believing that one method is far superior to 
the others (implying more weight should be attached to one set of results), 
the magnitude of the benefit will be very uncertain. 
Discussion 
Ultimately, these predictions can be compared with observed declines in the 
incidence rate following screening: for example, Eddy claims that he 
constantly revises his assumptions in the light of new trial data. However, 
this requires many years of follow-up and in the interim models will be judged 
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on the perceived validity of the assumptions used. A randomised trial of 
adenoma removal has been proposed (Pollock and Quirke (1991)), leaving a 
group of diagnosed adenomas unexcised, but the ethical problems are 
severe. 
How can the differences in results be explained? One possibility is that 
colorectal cancer is a more aggressive disease in Norway than in America, 
hence a higher proportion of Norwegian adenomas eventually become 
malignant. A second explanation is that there is a difference in definitions 
between the research studies; the Norwegians calculated the proportion in 
which cancer was clinically present, while Stryker was calculating the 
proportion in which symptoms occurred. If this were the case then the 
Norwegian surplus cases would be'lifetime latent'cancers. 
Another explanation is that Eide assumes all cancers begin as adenomas: to 
the extent that some arise de novo in the bowel, his figures are over- 
estimates. If 40% of cancers arise de novo, then Eide's method would predict 
51 cancers rather than 60 as in Table Six. 
While each explanation holds some truth it is hard to escape the conclusion 
that all of the researchers are making (more or less) intelligent guesses. 
Adenoma excision almost certainly has a health benefit but we simply do not 
know how large this is: as few as 5% of adenomas may have become 
malignant or as many as 85%. But is this all that can be said? Leaving this 
factor out of the evaluation altogether means that the benefits are 
underestimated and the programme may not be implemented as a result. In 
particular, screening the younger age groups may be hard to justify if the only 
source of health benefit from screening is via cancer detection. Which 
estimate is more realistic? The Norwegian figures seem to bear less 
resemblance to the available facts since they imply a large reduction in 
cancer incidence in the year following screening, an effect that has not been 
observed in any of the clinical trials. , Eddy's method is also discarded since, 
despite its simplicity, it'is the average of many subjective opinions; while this 
is not inherently bad, the guesses are not based on any evidence. The 
Stryker equation is unsatisfactory but is at least based on an observational 
study. 
Which of the Stryker variants is most appropriate? The adjustment for small 
adenomas makes virtually no difference to the results: this is not surprising 
since there are only 14 cases in the sample and they can have no effect 
whatsoever until five years before the end of the patients' lives. The 
weighted Stryker equation has an intuitive appeal, but is not based on 
observed experience. This leaves the simple Stryker model alone, although 
as noted above, the figures are subject to several sources of bias. For 
example, they are an overestimate to the extent that any of the cancers 
eventually detected were present at the first diagnosis of an adenoma. They 
are also calculated on the basis of the time taken for them to double in size 
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rather than to cause symptoms and thus affect health: the high proportion of 
excised cancers at Dukes' stage A in their study illustrates this. The figures 
are upper limits on the true benefits, therefore. 
Possible extensions to the analysis include applying the Stryker equation to 
each patient according to their individual life-expectancy: a preliminary 
estimate implies that this does not make much difference to the results. 
Another possibility is to take account of the number of adenomas found in 
each patient: those with multiple adenomas are thought to be at higher risk of 
developing cancer. While there are good grounds for thinking that this is a 
relevant factor, the problem is once again of a lack of data to use. Resorting 
to cross-sectional studies would imply weights of between 1.3 (OBrien et al. (1990)) and 2.1 (Muto et al. (1975)). There is the danger, of course, that 
these would produce yet more estimates which could not be verified. 
All of the discussion to date has assumed that preventing cases of cancer in 
the future will carry with it health gain. Some have suggested, however, that 
adenomas are merely the benign manifestation of the factors which cause 
colorectal cancer. This school of thought would argue that an adenoma 
detected on screening has remained asymptomatic for so long that there is 
no reason to believe it would ever have affected the patient's health. Even an 
enthusiastic advocate of endoscopic screening for adenomas has written, 
"One must certainly consider the possibility that prophylactic polypectomy 
might lead only to a reduction in the incidence of the more benign-behaving 
tumours. " (Jass (1989)). 
While the health benefits of adenoma, excision are uncertain there are also 
cost implications in terms of the cost of conducting an endoscopic, 
polypectomy and the benefits in terms of treatment cost savings. Can 
adenoma excision be justified on these grounds alone, leaving any health 
benefit as a'bonus'? 
Economic evaluation of adenoma excision 
The distribution of treatment cost savings over time is calculated by 
multiplying Stryker's prediction of cancer incidence by unit treatment costs, 
appropriately discounted into present values. An earlier study (Tuck et al. 
(1989)) calculated the mean length of inpatient stay for the treatment of 
colorectal cancer patients to be 17 days. Using an average cost per inpatient 
day of El 40, the treatment cost per cancer amounts to E2,380. Future costs 
are discounted at 6% per annum, in line with Treasury recommendations for 
public sector projects. 
The costs of excision are the additional resources of the procedure itself, the 
need for any follow-up investigations and the associated risks to the patient's 
health status. In the MRC trial, adenomas are excised endoscopically during 
the course of a diagnostic colonoscopy with a small marginal cost: excision 
requires few additional resources. The proportion of cases where a follow-up 
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investigation is undertaken either to complete the excision or to review the 
completeness of the procedure is high, however: in the MRC trial 30% of 
patients require BEXR and 6% need a second colonoscopy to complete the 
investigation. 
With respect to health risks, a study of complications in 3,153 colonoscopic 
excisions (Macrae et al. (1983)) found further treatment was required in a 
total of eight cases (0.25%); six patients required minor operations to control 
haemorrhages and two to remedy perforations. No deaths from excision per 
se (as opposed to investigation) were reported. 
Thus for 100 patients diagnosed as having adenomas at colonoscopy the 
cost of polypectomy is: 
30 patients requiring BEXR to complete @ E78.87 each 
6 patients requiring a second colonoscopy @ El 05.10 each 
0.44 patients requiring an operation for complications @ E2,380 each 
The total cost to the NHS is thus E4,044. 
The discounted cost saving is E17,851, implying a net saving on each 
adenoma of El 38. Assuming that the Stryker equation is an approximation to 
the number of cancers prevented, excision can be justified on cost-saving 
grounds alone with any health benefit being an additional gain. People who 
have an adenoma excised may subsequently develop cancer, which would 
serve to reduce any savings. 
CONCLUSION 
A review of the literature has found several different ways of calculating the 
effect of adenoma excision on future cancer incidence. Applying these to a 
standard population derived from previously unpublished IVIRC trial results 
shows that each gives a different answer. The range involved means that 
there is no consensus. Some methods can be ruled out because they do not 
correspond to observed behaviour, although it is harder to choose between 
those in the plausible range. It is concluded that about 13% of excised 
adenomas would have become cancers within the lifetime of the sample, but 
only further observation of the IVIRC trial population will confirm this. 
Polypectomy is justified in terms of the cost savings it produces alone, 
irrespective of any health benefit from cancer prevention. 
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Chapter Eight 
AGE AS A RISK FACTOR FOR TARGETING 
SCREENING 
Introduction 
Most types of screening are targeted at a particular group: the MRC trial 
protocol uses age as its discriminator on the basis of the incidence figures 
presented in Chapter Two. The age range was not arrived at on the basis of 
a rigorous comparison of the costs and benefits of alternatives, however. 
This chapter assesses the effects of screening either only a sub-set of the 50- 
74-year-old group or of extending screening to younger and/or to older 
groups. 
Epidemiological versus economic considerations 
The most common age limits for colorectal cancer screening trials are from 
45 or 50 up to 75. These are based on considerations of incidence to 
determine the lower age limit and the ability to undergo treatment to 
determine the upper age limit. (See for example American Cancer Society 
recommendations, European research trial protocols). 
Economic evaluation has been used before to compare different target 
groups for screening. Opportunistic cholesterol testing, for example, costs 
E200 per quality-adjusted life-year (QALY) for men aged 40 to 69 (with diet 
therapy) but for men aged 25 to 39, the cost is El 4,150 per QALY (Standing 
Medical Advisory Committee (1990)). Similar analyses of breast cancer 
screening for women aged less than 50 have provided an economic input into 
that controversy (Eddy et al. (1988)). For colorectal cancer screening 
strategies the only study to date indicates that commencing screening at 40 
rather than 50 has little benefit but doubles the cost of a lifetime screening 
programme (Eddy (1990)). 
Data for the evaluation 
The MRC trial results were divided according to the patients' age and 
grouped into five-year age bands. (Rescreening results use the age of the 
patient at the rescreen). Projected screening costs, diagnostic costs and the 
yield of cancers and adenomas were made for each age group using the 
model derived in Chapter Four. This allows a comparison of results to be 
made on the basis of a common size of target population offered screening. 
Table One 
- 
Initial offer of screening 
Detection rate (per 11000) 
participation (%) Positive Cancer Adenoma 
TOTAL 52.8 1.51 2.217 3.364 
45-49 34.9 1.58 0 2.764 
50-54 54.2 0.81 1.673 0.907 
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55-59 56.1 1.17 0.627 2.932 
60-64 55.3 1.33 1.768 2.321 
6C Mn 5-613 53.4 1.74 2.741 5.187 
70-74 48.2 2.7 6.309 6.419 
Table Two 
- 
Second round of screening 
Detection rate (per 1,000) 
Participation (%) Positive (%) Cancer Adenoma 
TOTAL 76.3 1.23 1.735 2.167 
45-49 78.4 3.09 1.931 1.531 
50-54 73.7 0.76 0 2.029 
55-59 75.4 0.87 0.713 0.94 
60-64 77.9 1.27 1.563 2.842 
65-69 78.2 1.17 2.423 2.625 
70-74 75.5 1.4 2.8 2.75 
75-79 73.1 2.35 4.334 1.812 
Table Three 
- 
Third round of screening 
Detection rate (per 1,000) 
Participation Positive Cancer Adenoma 
TOTAL 
-87 - 0.79 0.621 1.755 
50-54 83.5 0.38 0 0 
55-59 88.2 0.63 0 1.548 
60-64 89.6 0.47 0.334 1.797 
65-69 87.8 0.81 0.7 3.074 
70-74 86 0.98 0.978 1.26 
75-79 81.6 1.77 2.214 1.204 
To calculate the significance of adenoma excision the Stryker model 
described in Chapter Seven was used, based on the life-expectancy for the 
midpoint of each age group (OPCS (1987)). The cumulative probability that 
an adenoma of I cm. diameter or more would eventually have progressed to 
cancer is as follows (LE denotes life expectancy): 
Table Four 
Age at detection 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
Life Expectancy 
30 
25 
21 
17 
14 
11 
8 
Cumulative chance 
47 
36 
26 
19 
13 
9 
6 
The combined total of cancers detected and prevented was then used as the 
output of the programme to calculate a cost-effectiveness ratio for each 
group. Cases detected in the future were not discounted to a present value, 
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in line with Department of Health recommendations* (Parsonage and 
Neuburger (1992)). 
Results 
The results for each round of screening broken down by age group are as 
follows (ACI denotes the cost per case detected alone and AC2 the cost per 
case either detected or prevented): 
Table Five 
- 
Initial screen 
Cases * Cases 
Detected Prevented ACI (E) AC2 (E) 
TOTAL 117 23 3,271 2,677 
45-49 0 45 
- 
7,542 
50-54 91 18 3,607 3,018 
55-59 35 43 10,212 4,609 
60-64 98 24 3,792 3,035 
65-69 146 25 2,727 2,330 
70-74 304 19 1,491 1,405 
Table Six 
- 
Second round of screening 
Cases Cases 
Detected Prevented ACI (E) AC2 (E) 
TOTAL 132 21 2,190 1,924 
45-49 151 56 3,978 2,898 
50-54 0 54 
- 
6,085 
55-59 54 18 6,359 4,736 
60-64 122 42 3,213 2,388 
65-69 189 27 2,007 1,759 
70-74 211 19 1,896 1,742 
75-79 317 8 1,572 1,533 
Table Seven 
- 
Third rou nd of screening 
Cases Cases 
Detected Prevented ACI (E) AC2 (E) 
TOTAL 139 19 2,190 1,924 
50-54 0 0 
- - 
55-59 0 35 
- 
9,245 
60-64 30 31 10,308 5,097 
65-69 61 35 5,712 31636 
70-74 84 10 41402 31945 
This point Is contentious. The article referenced points to Illogicalitles In applying the 
Treasury discount rate for public sector projects to health benefits: the arguments in favour of 
a 0% discont rate are weaker and have not been widely accepted by health economists. 
Indeed, using a 0% discount rate limits the comparability of results with other well-designed 
evaluations which use rates of 5 or 6%. The use of the 0% figure is on the assumption that 
the Department of Health will seek to enforce Its views In the future, both In evaluations 
carded out by its own economists and also via the award of research funding. 
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75-79 181 6 2,538 2,457 
Note that the rescreening figures for ACI do not correspond exactly with 
those in Chapter Four owing to the different sample size bases used in each 
calculation. 
Discussion 
Despite the large sample size of the MRC trial, the numbers in each 
sub-group can be quite small and hence the figures are subject to the wide 
confidence intervals. For instance, 45-49 year olds were only recruited in the 
early stages of the trial, with initial screening offered to 1,447 but only to 661 
at first rescreen and only 13 at second rescreen. In most other groups the 
sample size is around 8,000 but by the second rescreen the cancer yield is 
extremely low (0.6 per 1,000 acceptors) and the problem re-emerges. Thus, 
the figures should be taken to be indicative rather than a precise calculation. 
Substantial differences between age groups exist with regard to the rate of 
participation, likelihood of a positive test and yield of neoplasia. Participation 
tends to be highest in the middle of the population age range i. e. around 60 
years of age. The positive rate rises with age, as does the yield of cancer 
(whether detected or prevented). The exception is the cancer yield in the 
55-9 age group on the initial screen, but this may be a chance finding. In 
other respects the trends in the results are in agreement with those reported 
by the Danish trial (Kronborg et al. (11987) and (11989)). 
The cost per case either detected or prevented ranges from a low of E1,405 
to a high of E9,245; in one sub-group no neoplasia at all have been detected 
to date. This suggests that a screening protocol which ignores age will have 
higher costs and lower benefits than one that adopts different policies for 
different sub-groups. 
By virtue of including differential probabilities for the chances that an excised 
adenoma would have become malignant during the lifetime of the age group, 
the analysis has moved one step beyond that of Chapter Four. However, 
cost per case is not a basis for prioritising screening intensity because it 
takes no account of the remaining life expectancy (and hence of the ability to 
benefit) of each group. A full evaluation of must await the results of the 
on-going trial, but what are the chances of each sub-group achieving the 
necessary survival gain for screening to be justified? 
Examination of existing cost-effectiveness league tables implies that 
treatments with a net cost per life-year saved of up to E2,000 are usually 
judged efficient. Thus, if it costs E6,000 to detect (or prevent) a cancer then it 
follows that it is necessary for the average benefit per case to exceed 3 life- 
years. On this basis, screening of all groups can be justified if early detection 
results in a gain of 4 life-years on average. For comparison, Eddy has 
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estimated that people with colorectal cancer die, on average, 6-7 years 
ahead of full life-expectancy. 
Several studies have been carried out to test whether age is an independent 
prognostic factor for colorectal cancer. Those under 60 years of age have 
the best prognosis after controlling for all other differences between age 
groups (Svendsen et al. (1989)). 
In terms of identifying the most efficient age group to screen, the effects of 
cancer prevention by adenoma excision are extremely important. On the 
basis of cancers detected alone it is hard to justify screening those younger 
than 55 on economic grounds; in particular, no cancers have been detected 
in those aged under 50 in either the MRC or the Danish trials. Given the life 
expectancy of this group, however, there is a high probability that excised 
adenomas of I cm. or more in diameter would have become malignant within 
the person's life-time. The results above imply that the under 50s should be 
considered for screening before anybody aged 50-64. The importance of the 
prevention effect lessens with the age at which the adenoma is excised, and 
is countered by the increasing yield of asymptomatic cancers detected with 
age. As a result, screening the two extremes of the age distribution gives the 
lowest average costs. Unfortunately, these groups are also the least likely to 
participate. 
Possible extensions 
The MRC trial protocol could be varied in three different ways to take account 
of the results above: (i) using a different test for different age groups; (ii) 
screening age groups at different intervals; and (iii) screening a different age 
range. These points are considered in turn. 
A different test for different age groups? 
The sensitivity of three-day Haemoccult esting for asymptomatic ancer is 
67% (Thomas et al. (1992)). This is an average across all patients: 
sensitivity may be age-related which would open the possibility of using a 
different test for different groups. Unfortunately, no data are available to 
explore this further, but there may be justification for using a very sensitive 
test where ability to benefit is greatest i. e. in the youngest age groups. 
Flexible sigmoidoscopy has been proposed in this role, although some of the 
assumptions of advocates have already been challenged in Chapter Five 
(Atkin et al. (1993)). The option is considered in more detail in Chapter 
Eleven. 
Different intervals for dffferent age groups? 
The second option is to rescreen different age groups at different 
frequencies. In terms of cost and yield, it is easy to justify offering a second 
screen to those aged 60 and over and even offering a third screen to the 
oldest age group; it is harder to justify offering repeated screening to those in 
the middle of the age range. (Numbers are insufficient to comment on the 
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youngest age group). A potentially efficient protocol would offer screening 
once or twice to those aged 45-50 with more frequent screening beginning at 
60 or 65. The rising average costs for all ages in the third screening round 
indicates that it may be necessary to extend the interval between screening 
rounds at some point after the second round. 
Are age limits of 50 and 74 appropriate? 
The third possibility is to extend the target age to include those aged less 
than 50 and those aged over 75. In the former group, medium or large 
adenomas stand a very high chance of eventually becoming malignant (62% 
according to the Stryker equation). However, data from post mortem studies 
contain too few cases in this age group to allow further analysis. Account 
must also be taken of the likely participation rate in this group. 
Over 75s have too short a life expectancy to benefit much from adenoma 
excision but cancer incidence increases dramatically in these age groups; on 
the other hand, the chance of a patient of this age surviving a colonic 
resection diminishes. In one surgical series 29% of over 70s died in hospital (Umpleby et al. (1984)); a second study found a mortality rate of 6% for the 
70-79 year olds but 20% for those aged 80 or over (Lewis and Khoury (1988), 
Ozoux et al. (1990)). Patients detected as a result of screening would be 
generally healthier and would not be emergency admissions, however, 
implying that a lower figure is more appropriate. Screening this older age 
group may also encounter problems of poor participation; this effect has been 
shown to be smaller than expected in breast cancer screening, however 
(Hobbs et al. (1990)). If this can be taken to be indicative of a constant level 
of health consciousness in the older age groups then the results may apply to 
colorectal cancer screening as well. 
If choices must be made between age groups, surveys of public opinion 
favour treating younger people ahead of older people (Wright (1986); Charny 
et al. (1989)). This would suggest wider approval of a policy which sought to 
extend screening to younger rather than to older age groups. 
CONCLUSION ' 
Including the effects of adenoma excision implies that screening younger age 
groups offers a low cost per case prevented or detected. Screening the older 
age groups has a similarly low cost per case owing to the high prevalence of 
cases in this group. The figures are consistent with a policy of one-off 
screening of the population in their 50s using a very sensitive test with more 
frequent screening in later life. Further evidence on the adenoma yield in 
people aged 45-55 would be helpful in determining the precise age at which 
this early screen would be most efficient. 
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Chapter Nine 
THE INVESTIGATION OF THE POSITIVE SCREENING 
TEST 
Introduction 
An accurate diagnostic test is an important element of any screening 
programme: inaccuracies result in either cases being missed or unnecessary 
treatment. The problem in colorectal cancer screening is that there are 
several diagnostic options, but no definitive comparison by clinical trial to 
compare them. The most widely used tests are colonoscopy, flexible 
sigmoidoscopy and the double-contrast barium enema X-ray (BEXR). 
Endoscopic techniques are capable of biopsying suspicious areas of the 
bowel and hence are more specific than radiology. However, colonoscopy is 
more likely to result in complications such as haemorrhaging or perforation of 
the bowel wall, while sigmoidoscopy covers only a limited area of the bowel. 
Patients undergoing colonoscopy often require sedation, so some patients 
will be unsuitable for this type of investigation except when the operator is an 
expert endoscopist. Radiological investigations are safer but require a 
subsequent endoscopy to biopsy any findings. 
A review of the clinical literature shows little consensus: some clinicians 
advocate colonoscopy (Aldridge and Sim (1986); Lindsay et al. (1988); 
Maxfield (1984); Thorson et al. (1986)), while others favour radiology (Feczko 
and Halpert (1986); Oft et al. (1985)) or even combinations of methods 
(Abrams (1982); Irvine et al. (1988); Kalra and Hamlyn (1988); Reiertsen et 
al. (1988)). The costs of the test is one factor but clinical recommendations 
are not based on the results of a full economic evaluation. 
A model for evaluating diagnostic strategies 
Algebraically the expected cost of detecting a cancer can be expressed as 
C/NS 
, 
where C is the total cost of using the diagnostic procedure, S is the 
sensitivity of the investigation, and N is the number of cases of disease 
present. Taking the cost per case detected to be the decision criterion, then 
for two tests, A and B, A will be cost-effective relative to B if 
CAMSA 4 CB/NSB 
or, by rearranging, if. 
CA/Cil 
'4 SA/SB 
for an identical case-mix. The yield depends on the prevalence of disease in 
the group with a positive screening result and the sensitivity of the test. The 
cost calculation is slightly more complicated and includes the following 
elements: 
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i) the cost of the preferred diagnostic procedure multiplied by the number to 
be investigated; 
ii) the number referred for the alternative investigation, either because the 
initial investigation_ is incomplete, equivocal, or (in the case of a referral 
from radiology to endoscopy) requiring biopsy/excision of a lesion 
detected 
- 
this is referred to below as the 'cross-referral' rate; 
iii) the proportion who experience a complication serious enough to require 
active in-patient care (as opposed to observation which is already 
included in the costs calculated in Chapter Four) multiplied by the cost of 
such care; 
iv) the cost of a false negative result in terms of the additional treatment cost 
multiplied by the number of cases missed. 
Initially, the model is applied to the investigation of symptomatic patients 
since most of the available data apply to this group; diagnostic investigation 
of positive screening results is considered subsequently. 
Investigating symptomatic patients 
Prevalence 
Investigation of people with lower gastrointestinal symptoms reveals cancer 
in 8% of cases (Irvine et al. (1988), Lindsay et al. (1988)), although in the 
absence of a definitive diagnostic test it is difficult to say how many cases are 
missed; these comments also apply to sensitivity estimates. 
Sensitivity 
Estimates of the sensitivity of colonoscopy and BEXR to cancer vary. 
Combining the results of several studies (Aldridge and Sim (1986); Durdey et 
al. (1987); Irvine et al. (1988), Lindsay et al. (1988)) implies that. the yield of 
cancers on colonoscopy is 40% higher than the yield on BEXR in similar 
populations. As the sensitivity of colonoscopy is commonly thought to be in 
the region of 95% this implies that the sensitivity of BEXR is 68%. 
Cross-referrals 
One study reports cross-referral rates of 27% from BEXR to colonoscopy and 
8% in the reverse direction (Lindsay et al. (1988)). 
Procedure costs 
Assumptions on the frequency and cost of treating complications are as in 
Chapter Four. The cost of colonoscopy is E105.10 but complications are now 
endogenous to the model, hence a net figure of E103.30 is used; for BEXR 
the cost of E78-87 is adjusted to E78.07 on a similar basis. 
Treatment costs of missed cases 
The cost of a missed case is based on the difference between an elective 
and an emergency admission. This assumes that all cases diagnosed at 
investigation are of the former type while all cases missed are In the latter 
category. Patients admitted as emergencies stay in hospital for four days 
longer on average (see literature review in Chapter Ten), valued at El 16.90 
per day (as in Chapter Four) implying a total of E468 per case missed. 
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Results 
In a population of 100 people, 8 of whom have cancer, the total cost of the 
regime which prefers colonoscopy is El 1,322 while the cost of the regime 
which prefers BEXR is El 1,874, a difference of E552 or E5 per person 
investigated. In addition colonoscopy would detect 7.6 cases of disease 
while BEXR would detect 5.44 cases. There is some evidence that the 
radiological misses are most likely to be small stage A cancers in the sigmoid 
colon (Aldridge and Sim (1986); Farrands et al. (1983); Kalra and Hamlyn 
(1988)). As the cure rate for these cases is particularly high the health 'costs, 
of a missed diagnosis may be severe. 
Analysis of robustness 
Clearly, the model is constructed from many different sources with variations 
in sample sizes and study design making bias possible Under what 
circumstances would the conclusion be reversed? While it is easy to say 
what values of the variables give the BEXR strategy a lower cost, this still 
does not take account of the higher sensitivity of colonoscopy. A rise in the 
relative cost of colonoscopy by 7% or a fall in the cost of BEXR by the same 
amount would produce this effect, as would a cross-referral rate from 
colonoscopy exceeding 15% or of less than 22% in the opposite direction. 
Large changes in other variables would be necessary, although it is 
interesting to note that BEXR has a cost advantage if the prevalence of 
cancer in the group investigated falls by half. 
One extension of this model is to compare colonoscopy against a regime 
using both BEXR and flexible sigmoidoscopy (referred to below as the 
combined strategy). The same studies used above suggest that there is very 
little difference between the sensitivity of these two strategies (Aldridge and 
Sim (1986); Irvine et al. (1988); Durdey et al. (1987); Farrands et al. (1983); 
Kalra and Hamlyn (1988)). The cross-referral rate is also similar. On the 
basis of the investigation costs calculated in Chapter Four, colonoscopy has 
a slight advantage as the initial investigation (El 03 versus E125). Cross- 
referrals from colonoscopy will not incur the full cost of the combined strategy 
since only BEXR will be required in most cases. The referral rate from the 
combined strategy will still be high if lesions are detected beyond 60cm. 
Finally, the need for two investigations is likely to delay the diagnosis slightly, 
increasing the anxiety to the patient and the risk of the cancer obstructing 
and resulting in an emergency admission. Counting against colonoscopy, 
however, is the comparatively high risk of fatal complications. If a factor to 
reflect the risk of mortality is included in the costs in Chapter Four, valuing a 
life at E500,000 in accordance with Department of Transport assumptions 
(Department of Transport (1987)) then radiology is preferred under almost all 
circumstances. 
This model has been constructed with the detection of cancer in mind, 
although it has included the cost of cross-referrals to treat adenomas by 
polypectomy. Most of the studies above have also found colonoscopy to be 
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more sensitive to adenomas, hence the assumption of no benefit to excision 
is likely to count against colonoscopy, making this scenario the 'worst case' 
for that investigation. In general, BEXR tends to over-diagnose very small 
lesions as it is unable to distinguish faeces from polyps in some cases: this 
reduces its specificity. 
Ultimately, the choice of investigation must depend upon the local availability 
of resources and the skill of the practitioner: colonoscopy is a technically 
difficult procedure, and in untrained hands the rate of incomplete 
investigations and even of complications could be high. This model has 
identified the best way of detecting symptomatic cancer but this may not be 
the aim of the doctor taking a decision in an out-patient clinic. More 
significant may be to find a source of the patient's symptoms, and in this 
respect BEXR may redeem itself by its higher sensitivity for other bowel 
diseases. 
INVESTIGATION OF POSITIVE SCREENING RESULTS 
Two issues are considered under this heading. Firstly, the need to minimise 
the number of false positive investigations is discussed and the option of 
retesting positive results prior to diagnostic investigation considered. 
Secondly, the choice of diagnostic test following a positive screening test is 
evaluated using data for the relevant population to replace that for a 
symptomatic group wherever possible. 
The role of retesting positive results 
On the basis of Chapter Four, 57,800 complete a test out of a population of 
100,000 and 3.4% have an initial positive test, implying 1,965 would require 
colonoscopy. Even allowing for the fact that this would be spread over two 
years, the workload would swamp the facilities currently available; a report 
from the British Society of Gastroenterology suggested that at least 200 
investigations per 100,000 population would be required but 500 should be 
allowed for (Working Party (1991)). The screening programme alone would 
double this figure, with extra investigations in the group not accepting 
screening, those outside the age range and those being followed-up after 
adenoma excision to be added on. At present, therefore, any such policy 
would not be feasible. One way to cope with this is to reduce the false 
positive rate prior to diagnostic investigation; the problem is to achieve this 
without any loss in sensitivity. 
As outlined in Chapter Two, the MRC trial Protocol retests all Positive results 
using a six-day FOB test to be completed while observing dietary restrictions: 
retest positives are investigated (Thomas et al. (1989)). Retest negatives 
receive a third test after three months and once again Positives are 
investigated while negatives are assumed to have had a false initial positive 
and are not contacted ! gain until the next round of screening. Participation is 
high for the first retest but falls to 79% for the second retest. Investigation is 
105 
by colonoscopy which, for the purposes of this section alone, is assumed to 
be definitive and fully accurate at the first attempt 
Data from the IVIRC trial show that, of 647 people who carried out the retest, 
251 (39%) were positive and hence were investigated without further delay; 
35 cancers were found in this group (prevalence 14%). Of the 396 retesting 
negative, 79 refused the three-month retest (20%); there have been no 
symptomatic cases of disease in this group to date after a minimum follow-up 
of 18 months. Of the remaining 317 people, 31 (10%) were positive at the 
second retest; investigation found four cases of cancer in this group. Follow- 
up of the 286 negatives at this retest has found one case of advanced 
disease after a median follow-up of 24 months. 
How many cases of disease were present initially? Retesting finds 39 cases 
(35 retest positive, 4 second retest positive) and misses one case. It is 
possible that other cases of disease which retested negative were still 
asymptomatic at 24 months. Also 79 people refused the second retest: if the 
decision to participate with this retest was independent of whether or not the 
person had asymptomatic disease then there were also 1.2 cases of disease 
in this group which had not presented within the period of follow-up allowed. 
Thus the total yield of initial colonoscopy would have been 41.2 cases. In 
addition 5% of those offered retesting do not respond i. e. the above figures 
excludes 32 people who were initially positive but refused the retest. Based 
on the disease prevalence among acceptors, this implies that two cases of 
disease in this group had also not presented within the follow-up period. 
How accurate are the imputed prevalence rates for refusers? Since 
participation is negatively correlated with age, one would expect a higher 
prevalence rate in this group than in those who accepted. However, if the 
cases have not presented in the follow-up period then they behave quite 
benignly. Nevertheless, in line with the remainder of this analysis, the 
intermediate outcome measure of screening is taken to be the number of 
cases of malignant disease detected, and this assumption is continued here. 
The cost of the MRC trial protocol is 679 initial six-day retests plus 396 
further six-day retests at three months, plus colonoscopy for 251 positives at 
the first retest and 31 positives at the second retest. As calculated in Chapter 
Five, six-day testing costs E3.03 including postage and development while 
the cost of colonoscopy is E105-10 (from Chapter Four). In addition, the cost 
of case presenting in the interval following a negative screen has been shown 
to exceed that of a screening detected case by E612, after allowing for 
discounting to a present value (Tuck et al. (1989)): this is the cost'penalty, of 
a missed case, the health'costs'of which are still unknown. 
Retesting detects 39 cases but one is missed and a further 3.2 are among 
those refusing one of the retests. The total Cost of retesting is E35,465 (of 
which colonoscopy represents 84%) and the average cost is Egog. 
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Colonoscopy of all those testing positive initially (no retesting at all) would 
have cost E71,363, assuming 100% participation. The yield would have 
been 43.2 cases at an average cost of E1,732 each. 
The difference in average costs seems quite small, but the extra 4.2 cases 
are detected at an extra cost of E35,898, or E8,547 each. A more realistic 
assumption on the participation rate for colonoscopy is the MRC trial figure of 
92%: this would reduce the cost of the'no retesting; strategy to E65,654 with 
a yield of 39.7 cases (assuming participation to be independent of disease 
prevalence). The extra cost per extra case is now E43,127. 
A third possibility is to stop offering a second retest three months later. 
compared to the full retesting protocol this would save E4,458 but miss four 
cases. 
Discussion 
A protocol of colonoscopic investigation following a single positive test is 
expensive; 94% of colonoscopies performed will be negative for cancer. 
Over 90% of the yield can be obtained at 50% of the cost, even if full 
participation is assumed for colonoscopy. Under more realistic assumptions, 
98% of the yield is obtained for 54% of the cost, in line with other clinical 
research findings (Elliot et al. (1984)). 
The Haemoccult test may lack sensitivity in the asymptomatic population but 
it is accurate as a means of identifying a high-risk group who require 
investigation from among initial positives. Those who have two negative 
retest results are returned to the general population; they are a low-risk group 
rather than a'no-risW group but the cost of detecting additional cases of 
disease appears high. By reducing the false positive rate one of the 
objections to mass screening by FOB testing is removed (Simon (1985)). 
Of particular interest in this respect are the Swedish trial data on the effects 
of retesting following a positive test result using the rehydration technique for 
developing completed tests. Chapter Five showed that, while the sensitivity 
rate was high, almost 6% of the population required diagnostic investigation, 
counting heavily against the regime overall. This suggests a role for 
retesting. 
Only limited data are available (Kewenter et al. (1990)). Of 579 initial 
positives, 544 completed a retest (94%) and 186 were positive (34%). As 
part of the research trial, all 544 people were offered investigation, although 
27 refused (5%). Cancer was found in 14 people in the positive retest group 
(7.7%) and three in the negative retest group (0.9%). Using the same 
method as that described above 0.5 cases are present among those 
completing a retest but refusing investigation and one case among those 
refusing the retest. Investigation of all positives would have cost E57,81 0 
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based on the observed participation rate in investigations of 95%; the yield 
would have been 17.6 cases out of the total 18.5 cases present in the whole 
group. The average cost would have been E3,285. Retesting costs E1.65 
per person (including postage and development) giving a total cost of 
E20,504 with a yield of 14 cases at an average of E1,465. The extra cost of 
detecting the 3.6 extra cases is E37,306 or El 0,363 each. 
Retesting in the Swedish trial could substantially reduce the number of 
people requiring investigation (to 32% of those testing positive initially), but 
this is at a loss of sensitivity: if the test is 85% sensitive on the basis of the 
initial test alone then the retesting protocol reduces this to 70% and much of 
its advantage over unhydrated testing is lost. 
In summary, retesting initial positive results can reduce the health service 
costs of screening as well as the number of people investigated 
unnecessarily; this is crucial in making screening a practical possibility given 
currently available diagnostic facilities. The trade-off is the small number of 
cases initially positive but retesting negative: the acceptability of this protocol 
depends on the policy maker's willingness-to-pay to detect one more case. 
Choice of diagnostic test 
The results above are based on the study of patients presenting with 
symptoms of lower gastrointestinal disease. Differences between this case 
and that of the asymptomatic screened population include the greater 
proportion of neoplasia in the sigmoid colon and the added significance of 
adenoma detection and excision. 
In terms of cancer detection, several reports from the randomised FOB 
screening trials have been critical of BEXR in comparison with colonoscopy. 
The proportion of cancers screening positive but missed on BEXR alone has 
been reported as 11 % (Kewenter et al. (1987)), 25% (Winawer et al. (1985)) 
and 36% (Mandel et al. (1988)). An uncontrolled study of asymptornatic 
screening has reported that nine out of the 12 cancers detected were 
negative on BEXR, including all of the stage A cases, with sites in the 
sigmoid and transverse colon and in the caecum (Elliott et al. (1984)); this 
confirms the evidence presented above for symptomatic cases. The 
accuracy with regard to adenomas is harder to calculate because of the lack 
of prevalence data. As noted above, the health'cost' of missing a stage A 
cancer are potentially large, but a further complication in the screening case 
is that if such lesions are asymptomatic then they are also most likely to be 
, lifetime latent'cases. 
Swedish trial reports acknowledge the weakness Of 13EXR alone but believe 
that in combination with flexible sigmoidoscopy an accuracy at least 
comparable to that of colonoscopy can be achieved (Jensen et al. (1990)). 
All the other trials use colonoscopy wherever the patient is fit enough, with 
recourse to BEXR only in cases where a full examination proves impossible. 
108 
To address this issue a similar approach to that outlined for symptomatic 
people is used. 
Prevalence 
The results of three-day testing in the MRC trial show that the prevalence of 
cancer in the group undergoing investigation is 15.3 per 100 (Thomas et al. (1990)). Of these 13% were in the rectum, 69% were in the sigmoid colon, 
8% were in the transverse colon (including flexures) and 9% were in the 
caecum. The Danish trial shows a slightly more even spread, albeit with 
smaller numbers; the combined series gives figures of 20%, 60%, 11 % and 
10% respectively. To estimate what proportion of these cases would be 
identified by each strategy site-dependent sensitivity data are required 
together with an estimate of the probability the segment would be 
satisfactorily visualised. 
Cfoss-referral rates following investigation 
To assess the number of patients requiring a second (or subsequent) 
investigation when colonoscopy was the investigation of choice, the MRC trial 
records of 163 patients investigated following a positive test result were 
examined. 12% were unsuitable for the first choice investigation, 
colonoscopy, and were investigated by BEXR; half this group also underwent 
flexible sigmoidoscopy. The remaining 88% of patients underwent 
colonoscopy; 30% subsequently required a BEXR to complete the 
investigation and a further 6% needed a second colonoscopy. In all, only 
56% of the sample were investigated by a single colonoscopy alone, with 9% 
of the sample requiring three investigations. Of those initially deemed 
unsuitable for colonoscopy, over one-third (7/19) were eventually 
investigated by that method. 
In total, the 163 patients were offered 165 colonoscopies (1 refusal), 65 
BEXRs (3 refusals) and 10 flexible sigmoidoscopies. On the basis of the 
costs in Chapter Four, the total cost was E22,604 (76% on colonoscopy), or 
El 39 per person. 
The combined investigation (BEXR plus flexible sigmoidoscopy) has a cross- 
referral rate of at least 19%, based on data from the Swedish screening trial 
(Jensen et al. (1990)). This is a low estimate owing to the rehydration 
screening method having such low specificity. In a study of symptomatic 
patients the view on the combined investigation was unsatisfactory in 18% 
(Irvine et al. (1988)) to which must be added the need for polypectomy of any 
findings beyond 60cm. 
In the early stages of the MRC trial, the combined investigation was preferred 
owing to the unavailability of colonoscopy, producing a cross-referral rate of 
21 %. Unfortunately the screening protocol at the time offered tests to people 
aged less than 50, used the Fecatwin/Feca-EIA test which has a high false 
positive rate, and did not use the retesting technique described above. The 
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results are also biased estimates of the figures obtained following three-day 
testing without rehydration but with retesting. 
Completeness of investigations and sensitivity 
In the MRC trial, 30% of colonoscopies are incomplete and require a BEXR; 
rates as low as 8% have been reported, however (Rex et al. (1990)). It is 
assumed that this means that 30% of colonoscopies fail to reach the caecum 
and 15% do not visualise the transverse colon or the flexures. The scope will 
always pass through the rectum since rigid sigmoidoscopy will previously 
have proven possible; however I% of investigations do not get beyond the 
rectosigmoid junction (e. g. due to strictures or to obstructing carcinoma). 
Site-dependent sensitivity for colonoscopy is taken to be 98% for the rectum 
and sigmoid: the former can be missed by the endoscopist when the scope is 
initially inserted and in addition there is some evidence from the Swedish trial 
that endoscopy can miss cancers in the rectosigmoid junction. When they 
can be visualised sensitivity in other sites is 99%: studies which have 
undertaken repeat examinations either immediately or at a six week interval 
have failed to demonstrate further cancer (Hixson et al. (1990)). 
The combination investigation is assumed inadequate in 20% of cases, 
based on results for symptomatic patients (Irvine et al. (1988), Lindsay et al. 
(1988)). As an initial assumption the completeness of investigations of the 
sigmoid is taken to be 97%, based on reports of a 'blind spot! between the 
sigmoid and descending colon. The radiological investigation may also have 
some problems visualising the caecum (one case was missed in Rex et al. 
(1990), with several missed cases on follow-up of negative BEXR in the MRC 
trial). Arbitrary assumptions are made that the sensitivity is low (95%) but 
that sigmoidoscopy makes up for many radiological failings in the rectum and 
sigmoid colon: nevertheless, the Swedish trial has shown that misses occur 
and a rate of 98% is assumed for both sites. 
The initial version of the model uses the following assumptions, although 
these can be varied: 
Table One 
Colonoscopy 
Complete (%) Sensitivity 
Rectum 100 98 
Sigmoid 99 98 
Transverse 85 99 
Caecum 70 99 
Combined Investigation 
Complete (%) Sensitivity 
99 98 
97 98 
99 99 
95 95 
Costs for the three investigations are as in Chapter Four but exclude the cost 
of complications, as above The figures used are El 03.30 for colonoscopy, 
E78.07 for BEXR and E46.81 for flexible sigmoidoscopy (implying a cost for 
the combined investigation of E124.88). 
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Results 
The results for 100 people with positive results on unhydrated three-day 
Haemoccult testing with retesting (prevalence of 15.3 cancers) are as follows: 
Table Two 
Total cost (E) Cases 
Colonoscopy preferred 13,782 14.83 
Combination preferred 15,055 14.69 
The two strategies are very evenly balanced with the difference only 
amounting to El 3 per person investigated and 0.14 cases (9% and 1% of the 
lower total respectively). Nevertheless, colonoscopy is both cheaper and 
more accurate under the assumptions used. 
Sensitivity analysis and discussion 
This result is robust in the face of changes in many assumptions because 
sizeable minorities of the people investigated under each protocol are cross- 
referred, thus muting the effects of (say) a change in test cost. A 10% 
reduction in the cost of the combined investigation still leaves the 
'colonoscopy preferred' option cheaper. A shift in the site distribution towards 
the right-hand side of the colon would favour the combined investigation 
given the low colonoscopy completion rate but this would have to be large to 
reverse the conclusion. Given the number of assumptions on the sensitivity 
and completeness of investigations it is difficult to present the results of a 
systematic variation; however, a scenario can be constructed in which the 
combined investigation would be more accurate than colonoscopy. Suppose 
that the combined investigation achieved a sensitivity of 99% for rectal 
cancers and 98% for sigmoid and caecal cancers, with the sigmoid fully 
visualised in 99% of cases then it would detect only 0.01 extra cases at an 
additional cost of E1,204. The extra cost per extra case detected Is 
E114,331. Note that this scenario exceeds the claims of 'combination' 
advocates: the Swedish trial reports sensitivity in the sigmold area of only 
90% (Jensen et al. (1990)). 
Studies of patient preferences have shown little significant difference 
between each type of investigation, although a weak trend is favour of 
colonoscopy can be detected (van Ness et al. (1987), Aldridge and Sim 
(1986), Lindsay et al. (1988)). The unpleasant side-effects of out-patient 
flexible sigmoidoscopy, such as incontinence while travelling home, has also 
been demonstrated (Thomas et al. (1990)). 
The choice of a diagnostic investigation in a screening programme brings to 
the fore the question of what the programme is trying to detect. The 
calculations above have assumed that the objective is to detect asYmptomatic 
cancer, but many claim advantages to detecting and excising adenomas 
(Atkin et al. (1993)). Adenomas are included above as a cost factor, 
increasing the number of patients with radiological findings beyond 60cm. 
ill 
requiring colonoscopy as well as causing a proportion of the repeat 
colonoscopies for excision in expert hands. There is evidence, however, that 
any benefit would also accrue to colonoscopy; even the Swedish study claims 
no decisive advantage for either form of investigation (Jensen et al. (1986)). 
CONCLUSION 
One researcher has written, 'We may have stepped unwittingly into a 
diagnostic quagmire when we embarked down the road of colon cancer 
screening for the general population. " (Lieberman (1990)). Certainly, the 
choice of diagnostic test is finely balanced, but the evidence suggests that 
colonoscopy should be preferred in centres where the caecum is reached on 
at least 70% of examinations. 
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Chapter Ton 
THE IMPACT OF SCREENING ON TREATMENT COSTS 
Introduction 
By changing the staging distributions of cancers at detection, screening can 
affect the costs of treating the disease. Treatment may be simpler, for 
example by allowing the endoscopic removal of small cancers (polypectomy). 
Patients should generally be fitter than symptomatic presenters, implying 
better post-operative survival, and a shorter hospital stay. This chapter 
analyses data from the MRC trial to consider the size of this effect. 
Preceding this is a discussion of the methodology of costing hospital care. 
The need for better cost data 
- 
case proven? 
Routinely available cost data suffer from a number of faults, particularly that it 
rests so heavily on average costs and thus does not relate directly to the 
costs incurred in treating any individual patient. Attempts to improve on 
these figures have centred on increasing the relevance of costs to each 
individual case. These gains in accuracy for the individual are expensive in 
terms of research time, however, hence all such refinements must be 
considered against the criterion of whether the increased accuracy affects the 
results of the evaluation. As one textbook puts it: "it is important to question 
the purpose of refinements since they are likely to involve considerable time 
and effort. One should not necessarily aim to produce the best possible 
information every time. " (Drummond (1980)). A number of studies reflect this 
concern (e. g. Brooks (1981); Piachaud and Weddell (1972)). 
An example of a study where detailed work made no difference to the ranking 
of the options and hence to the results of the evaluation is that of Culyer and 
Maynard (1981). They compared treatment options for duodenal ulcers and 
showed that a 'refined' approach to costing gave a cost per operation one- 
third lower than that derived from multiplying the national average length-of- 
stay for the procedure by the national average cost per day for hospitals of 
that size. However, re-working their results shows that the use of the national 
average figure would not have affected their conclusion. 
In general technical efficiency questions (identifying the cheapest way of 
providing a given service) generally require less refined costings since the 
options often have common elements which cancel each other out. For 
example, Culyer et al. (1983) found no significant difference between groups 
using different types of wound dressing in terms of length-of-stay, and hence 
were able to ignore it. 
The chance of a refinement affecting an evaluation is related to the 
significance of the costs involved in the overall total cost; thus, a small error 
in a major item is potentially more important than a major error in a small 
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item. The major items in acute hospital budgets are nursing and medical staff 
time and service overheads. It is easy to get bogged down in counting the 
number of pathology tests or aspirins but unless these items are particularly 
important to the treatment process the impact on the total cost will be 
minimal. 
One commentator has summarised the position as follows "it would be 
incautious to conclude that a major increase on expenditure on costing is 
necessary. Costing is itself a costly activity, and since it is likely to be subject 
to diminishing returns in improving decisions, it will not be worthwhile seeking 
to abolish our ignorance entirely. It is approximate information that should be 
sought rather than perfection. " (Hurst (1978)). 
Many of the issues arising can be illustrated by a detailed consideration of 
the handling of nursing costs which constitute over one third of acute sector 
spending (Department of Health (1992)). 
NURSING COSTS: Altemative allocation methods 
The accountant's approach to allocating nursing costs is to determine the 
total nursing bill for each specialty and then to divide by some measure of 
workload such as the occupied bed-day. Thus, within specialties, patient 
costs per day are assumed to be homogeneous. (Some evaluations using 
these figures have also attempted to verify that the relevant patients are 
indeed typical (e. g. Gravel le et al. (1982))). 
To reflect the care received by individuals some evaluations have used 
measures of nursing dependency as a proxy for the allocation of nursing 
time. In an evaluation of treatment for patients with bleeding peptic ulcers 
(Rees (1987)), ward sisters estimated the care required by a patient in the 
four categories of a standard dependency measure, the Telford Scale. 
Scores for each category were obtained by the ratio of the care in that 
category to the care given to a patient in the least dependent category. 
Summing these scores across the patients on the ward gave an estimate of 
the total workload and hence a cost per workload unit was derived from the 
daily total nursing cost. The costs used were as follows: 
Table One 
Category Workload score Daily cost (E) 
Ambulant (pre-op., convalescing) 1 8.80 
Semi-ambulant (recovering) 2.5 22.01 
Partially helpless (a few days post-op. ) 4.5 39.61 
Totally helpless (immediately post-op. ) 8 70.42 
Nursing records were used to determine the patient's dependency category 
day-by-day, and hence the cost of nursing them in the course of their stay. 
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An even more thorough analysis using a similar method was conducted as 
part of the heart transplant study; the researchers carried out extensive 
samplings of the time grades of staff spent with various patients (Buxton et a[. 
(1985)). However, this is unlikely to be a practical possibility for any but the 
best funded study: others have chosen the simpler method developed by 
Rees (e. g. Ridley et al. (1991)). 
An application to the care of patients treated for colorectal cancer 
To explore the increased accuracy of the dependency-based method, data 
were gathered for a sample of 65 patients undergoing a resection for 
colorectal cancer over a six-month period at University Hospital, Nottingham 
(UHN). In two cases, patients were readmitted within one calendar month of 
discharge and the two care episodes are treated as one continuous episode 
for each patient. As UHN is a research centre, patients are often admitted 
several days earlier than necessary in order to participate in medical trials: 
only the three days preceding the operation are considered. 
The staffing structure of the relevant surgical ward was costed using total 
salaries plus national insurance and pension contributions, as in Table Two: 
Table Two 
Grade Number Unit cost (E) Total cost (E) 
Sister 1 13,489 13,489 
Staff Nurse 4 10,278 41,112 
State Enrolled Nurse 2 8,896 17,972 
Auxiliary Nurse 2 6,676 13,352 
Student Nurse 
(Third year) 2 6,634 13,26 
(First year) 4 5,742 22,968 
TOTAL 121,161 
Average occupancy of the 28 beds was estimated to be 91.7%, implying 
9,375 patient bed-days per annum. The average nursing cost per day per 
occupied bed was El 3.03. 
The division of time between shared care and care for individual patients was 
determined by the ward sisters. The proportion of total time spent on 'shared' 
care as opposed to that spent with individual patients was estimated to be: 
Sister 60% 
Staff nurse 40% 
State Enrolled nurse 25% 
Auxiliary nurse 50% 
Student nurse 40% 
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The employment cost for each grade was then divided according to these 
proportions, to yield total costs of shared care (E50,202) and patient-specific 
care (E71,959). 
Dependency data are routinely collected at UHN using a system developed in 
North Lincolnshire District Health Authority and based on a scale similar to 
that described in the peptic ulcer study. Ward sisters estimated the nursing 
time required for each dependency category, as in Rees's study. These data 
were then treated as units of work, one unit being the daily care received by a 
category 1 patient. Table Three displays workload ratios, the observed 
average dependency mix for the wards and the derived total number of daily 
workload units. 
Table Three 
Category Workload ratio Patients Total work per day 
1 1 5 5 
2 2.5 13 32.5 
3 4.5 5 22.5 
4 7.5 3 22.5 
Total 26 82.5 
Thus the average daily workload was 82.5 units, or 30,116 per annum, giving 
a patient-specific cost per workload unit of E2.39. 
Results 
The mean length of stay of the sample was 15.1 days within a range of 10 to 
38. Figure One shows the pattern of changes in dependency category for the 
sample by day of treatment up to the tenth day post-operatively. For any 
given day of treatment the top point of the line represents the highest 
dependency category recorded in the sample, while the bottom point 
represents the lowest category (0 implies the patient was discharged). The 
mean dependency category is denoted by the mark within the range. Most 
patients were in categories I or 2 prior to operation and in state 4 on the day 
of the operation, with a gradual reduction in dependency to state I or 2 
before discharge, although some patients are very dependent for several 
days after the operation. 
The 'average' patient requires less care in the earlier and later stages of the 
episode than implied by the average method, although this is compensated 
by above-average needs immediately after the operation. This is illustrated 
by the cost per day under each method in Figure Two. 
Total nursing costs across the length of stay were calculated for each patient 
using each method. The mean total cost for each method were identical at 
g: l 95.90. For individual patients total costs calculated by each method were 
highly correlated (Spearman rank correlation coefficient, r=0.93, p<0.01), 
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owing to the strong association between length of stay and patient-specific 
workload units (r = 0.82, p<0.01). 
Figure Three shows the difference between the cost of each method for 
individual patients. In 12 cases out of 65 the two costing methods produce 
the same result within 2.5%. In more than one third of cases (23/65), the two 
estimates differ by more than 7.5%, although the number of over-estimates 
above 2.5% (29/65) is approximately equal to the number of under-estimates 
below 2.5% (24/65). These differences are associated with the number of 
patient-specific workload units (r = 0.32, p<0.01) but not with 
dependency-based costs, average costs or with length of stay. 
Discussion 
The dependencY-based approach offers a superior measure of the 
day-to-day variance in resource consumption. The fundamental problem is 
how accurate does a cost figure have to be? Three-quarters of the estimates 
derived above are equivalent (within plus or minus 12.5%), implying that the 
refinement is unlikely to affect the evaluation results. A re-working of Rees's 
data show that a simple average cost would also have been adequate in that 
case. 
Given the increasing availability and routine use of dependency measures, 
data are easily available and have been used in other studies (Brooks 
(1981)). However, a number of assumptions are required which would ideally 
be tested in a sensitivity analysis. More importantly, the scales used 
measure dependency alone, which is a subjective concept, influenced by the 
experience of the nurse making the judgement (Proctor (1993)). There is 
some evidence that dependency does not correlate with time spent with a 
patient (and thus resource consumed) (Bagust (1990)); empirical evidence of 
this is provided by the heart transplant study which found large differences 
within dependency categories (Buxton et al. (1985)). This was acknowledged 
in the peptic ulcer study: 'The ward staff costs covering the salaries of 
medical and nursing personnel are in fact medium term marginal costs, and 
the element of variability in response to changes in the level of patient care is 
more apparent than real. " (Rees (1987)). In other words, the dependency 
approach is a model which is not based on observed behaviour. The 
dependency-mix of the ward influences the average cost per workload unit: if 
the ward were full of people in the least dependent state the cost per 
workload unit would rise and care would appear to be more expensive, 
whereas in practice nursing staff would be reallocated to busier wards. The 
model has nothing to say about the quality of care: if total staff time is fixed in 
the 
-short term, a rise 
in workload means quality may suffer. 
Another problem is the allocation of 'Shared care', which is equivalent to a 
ward-specific overhead cost. The allocation is inevitably arbitrary; for 
example, the peptic ulcer study (implicitly) and the heart transplant study 
(explicitly) allocate shared care in direct proportion to differences in individual 
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Implications for this study 
Variations in the costs of treating individual patients are important, 
particularly if they can be predicted in advance, e. g. by linking them to some 
observable characteristic when the patient is admitted. However, the 
implication of the results is that these are unlikely to be significant for care 
following a bowel resection and that the cost included in the specialty total in 
hospital accounts is adequate. 
ALLOCATING OTHER COSTS 
This means that the allocation of two major items in the cost of treating 
colorectal cancer will either be by specialty average figures (nursing) or on an 
arbitrary basis (overheads). This implies there is little point in using detailed 
refinement methods for other categories. 
1. 
- 
Medical staff 
Problems in allocating medical staff time to individual patients include the 
element of shared care and other duties. Prospective data collection is 
unpopular but there are no other sources available. Various proxy measures 
have been proposed but the situation is very complex: the stage of the 
patient's treatment, type of admission and operation, diagnosis and 
prognosis, and the number and nature of complications are all relevant. A 
scoring system using some of these factors was attempted in the peptic ulcer 
study but the approach was not validated (Rees (1987)). For this study, 
medical staff time is thus allocated on the basis of the specialty average per 
day. 
2. Operating theatre 
In the past evaluations such as the heart transplant study calculated a staff 
cost per hour and a standard cost per operation for equipment. This was 
used to value the duration of operations which recorded in patient notes and 
theatre records. A detailed study of theatre costs estimated an average cost 
per hour of E216.50 (NHS Management Executive (1989)). While these 
figures exclude gases, operation-specific items of equipment and other 
support services such as X-ray, they have been used in the present study. 
3. Blood transfusion 
The peptic ulcer study based cost on the charge made by the NHS blood 
transfusion service to the private sector (Rees (1987)): this is intended to 
reflect the long-run marginal cost of provision per unit of blood. The figures 
used were E20 per unit plus E3 per unit for grouping and cross-matching, and 
these have been updated. 
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4. 
, 
Drugs 
Drug dosage is recorded in case notes and can be valued according to the 
standard figures compiled in the British National Formulary. The recording of 
drug consumption for individual patients can be extremely laborious, 
however. A small pilot study confirmed that the costs of largely generic 
versions of drugs made little difference to the total costs of treatment. Further 
research could give more attention to a few expensive drugs or to define a 
standard regime to derive an average cost per patient based on a small 
sample. In the present study, however, drugs and fluids are ignored. 
5. Pathology and radiology 
Radiology and pathology tests are production processes in themselves, 
bringing together staff, equipment and raw materials: costing individual tests 
represents a major study in itself (Stilwell (1981)). Using published figures is 
dangerous if work practice, staff levels and available equipment vary but in 
colorectal cancer care the costs are not large enough to matter. The existing 
costing system groups procedures under a small number of headings which 
are (broadly) homogeneous in terms of resource use. In a similar manner to 
the dependency approach for nursing, each group is assigned a score which 
can be used to derive a total number of workload units for the department. 
The cost per point can be calculated and hence the average cost for each of 
the groups of procedures. This does not reflect the cost of any particular 
procedure, still less the resources consumed by an individual patient. In the 
present study the figures for UHN are used. 
6. Overhead costs 
General service departments either support the work on the wards (laundry 
and catering) or relate to the running of the hospital itself (administration and 
maintenance). Studies have attempted to devise more appropriate ways to 
allocate overhead costs to departments, wards and ultimately to patients, but, 
"The main point to note at the outset is that there is no unambiguously right 
way to apportion such costs. " (Drummond, Stoddart and Torrance (1987)). 
Examples of enthusiasm outrunning common-sense abound. For example, 
the report on the cost of operating theatres mentioned earl ierca Iculated the 
proportion of windows in each of the hospitals in its sample which were in the 
theatre block and apportioned the total window cleaning budget accordingly. 
Another methodological review considers allocating patient catering costs on 
the basis of a sample of menus offered to patients for meals retained for more 
detailed costing, as well as allocating more catering costs to male wards than 
to geriatric wards as the former are given larger portions (Hillman and Nix 
(1984)). Thus an accounting cost allocated equally over all the work of the 
hospital seems the only satisfactory method. In this study the method 
described in the Appendix to Chapter Four was used. 
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PREVIOUS STUDIES OF THE COST OF TREATING COLORECTAL 
CANCER 
Despite growing interest in the costs of all forms of health care activity, the 
literature on the costs of treating colorectal cancer is sparse. This is more 
surprising in view of analysis of American Medicare data which reveals that 
colorectal cancer is one of the most expensive cancers to treat (Baker et al. (1989)). 
Some of the findings were as follows: 
Treatment costs in the five years from diagnosis were E3,531 for colon 
cancer and E4,462 for rectal cancer (1990 figures) (Wessex Cancer 
Intelligence Unit (1990)). In the case of rectal cancer 55% of costs were 
due to hospital stay, 15% were costs of theatre time and 9% were the 
costs of colostomy supplies after discharge; all other categories 
represented less than 5% of the total. 
Mean length-of-stay is about 15 days for a resection. There is common 
agreement that post-operative complications are an important factor 
(Arabi et al. (1980); Payne et al. (1987); Tartter (1988)). Other factors 
considered include: need for pre-operative assessment, performing a two- 
stage operation, and need for blood transfusion. None of the studies 
found stage at diagnosis to have a significant effect. 
Only the Danish screening trial has reported the impact of screening on 
length-of-stay: the data imply a median reduction of four days (Kronborg 
et al. (1989)). Breast cancer screening forms an interesting comparison, 
however. Mathematical models predict that following a rise of about 15% 
in workload following the initial screening, the overall number of 
operations then resumes its previous level and trend (de Koning et al. (1990); de Koning et al. (1992); Holmberg et al. (1986)). Net treatment 
cost savings represent one-third of the costs of the screening programme. 
THE IMPACT OF SCREENING ON TREATMENT COSTS IN THE MRC 
TRIAL 
To examine the impact of screening on treatment costs in the IVIRC trial, data 
were gathered for all cases with a minimum of three years of follow-up since 
their diagnosis. This interval was chosen to maximise the sample size but 
also to allow time for disease to recur and follow-up expenses to be Incurred. 
IVIRC trial records identified 371 such cases and provided basic information 
on date of birth, date of entry to trial, date of death and cause of death (as 
recorded on the death certificate). 
The main data source was the patients' hospital case notes. Clinical data 
collected included the cancer stage, site, differentiation, size and fixity, as 
well as symptom duration, type of admission, type of operation, number of 
post-operative complications and clinical assessment of prognosis at the time 
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of treatment. Resource-use data related to diagnostic investigations, length 
of stay in hospital, length of operation, radiology, pathology and ECG 
requests, and units of blood ordered. 
Many patients were treated at University Hospital, Nottingham, a teaching 
and research centre, and hence procedures related to research were 
excluded wherever possible. For example, a comparative trial of 
pre-operative methods of imaging rectal cancer was in progress during part of 
the study period: all resources used as a result have been excluded. This 
creates particular problems with regard to post-discharge follow-up, and 
treatment of recurrent and of terminal disease. There appears to be 
considerable variation in practice even within a centre: some patients receive 
chemotherapy, others radiotherapy, while surgeons in Nottingham have 
started to use cryotherapy as an aid to the resection of liver metastases. 
(While the current focus is on the costs of treatment, this variation may also 
be reflected in the success of that treatment, of course). Practice outside of 
Nottingham is likely to show similar variations. These items were excluded 
from the analysis awaiting clearer statements on what represents 'good 
practice' in these areas. The costs used relate only to in-patient care for 
surgery or for other forms of patient care such as symptom control and non- 
surgical treatment such as endoscopic investigation. 
Costing method 
As noted above, the perspective of the costing is the use of hospital 
resources since these will have a direct bearing on opportunity cost of a 
screening programme to purchasers. This excludes costs incurred In the 
community (either by the NHS or other agencies); an example of a category 
excluded is the on-going cost of supplying colostomy equipment, although an 
estimate can be made from the literature (see Wessex Cancer Intelligence 
Unit (1990)) noted above). 
Costs for hotel services, out-patient clinics, pathology, ECG and X-ray 
requests were derived from the Hospital Cost Returns (FR1 1) for University 
Hospital, Nottingham. Note that the hotel services excluded theatres, 
diagnostic and support services and overheads. General service overhead 
costs are derived using the method outlined in Chapter Four. X-ray costs use 
the radiology points system with chest, abdominal and pelvic X-rays counting 
as one point and ultrasound and upper gastrointestinal investigations as two 
points. The costs of other diagnostic investigations are as in Chapter Four. 
The duration of an operation was recorded from the anaesthatist's record and 
valued according to the average cost per hour calculated in the Bevan 
Report. (One type of rectal examination, the examination under anaesthetic 
(EUA), is common but rarely has a duration recorded: it was assumed that the 
duration was thirty minutes on average). The figure for a pathology request 
is the average of the costs of haematology, microbiology and clinical 
chemistry requests. The cost per ITU day is calculated from the Wessex 
figures assuming a similar ratio between ward and ITU costs; other recent 
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estimates include E399 per day (Ridley et al. (11991)) and E500 per day as an 
average across England (Shiel et al. (1989)). 
Description Unit cost (E) 
Out-patient clinic 18.02 
Hotel stay (per night) 76.10 
Overheads (per night) 40.56 
ECG 5.22 
X-ray (per point) 5.11 
.,, 
Theatre (per minute) 4.47 
Histopathology (per request) 36.42 
Pathology 3.77 
Flexible sigmoidoscopy 47.81 
Gastroscopy 47.81 
BEXR 78.87 
Colonoscopy 105.10 
ITU (per night) 332.90 
Drugs and fluids were excluded. 
As noted in Chapter Three, the follow-up period of three years for the sample 
is insufficient to justify discounting of future effects, although this would be 
important once long-term follow-up data are available. 
Results 
Of the 371 patients, eleven (3%) were excluded (nine treated privately, two 
hospital notes could not be found). This sub-set is sufficiently small that the 
results are not felt to be seriously affected. 
patient characteristics 
The age and sex distribution for each group were: 
Table Four 
Con trot group Number Mean age 
90 67.6 Male 
Female 62 66.9 
152 67.3 All 
Study group Number Mean age 
Male 119 67.4 
Female 89 66.7 
All 208 67.1 
In the sample as a whole men outnumber women by 1.45: 1. The male 
preponderance is not as large in the group offered screening. The study 
group can be sub-divided into three further groups: screening detected cases 
(, positives'), cases presenting symptomatically within two years of a negative 
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screening test (Intervals') and people who did not return a completed test ('refusers'). Of the 208 cases in the study group 77 were screening detected 
(38%), 26 were intervals (12%) and 105 were refusers (51 %). The sex 
distribution is similar to the study group as a whole. Refusers are the oldest 
group (average age 68.4); positives and intervals have similar mean ages 
(65.8 and 65.6 respectively) but the variation in interval cases is higher 
(standard deviation of 9.06 versus 7.04 for positives). 
Tumour characteristics 
Synchronous cancers were found in four control cases (3%) and in two study 
group cases (1 %); the convention of classifying these patients according to 
the more advanced stage is followed here. Table Five shows the staging 
distribution by trial group: 
Table Five 
Stage Control Study Positive Interval Refuser 
A 15 60 39 7 14 
B 42 58 18 4 36 
c 49 41 15 7 19 
D 43 49 5 8 36 
Missing 3 0 
Screening detects cases at an earlier stage but the refuser group nulli I fies, 
much of the advantage over the control group. The 56 excess cases in the 
study group represent a combination of the early detection of future cases 
and over-diagnosis of 'lifetime latent' cancers; given the very similar numbers 
of stage C and D cases in each group, over-diagnosis may be an important 
problem. 
The distribution of cases within the large bowel* is as follows: 
Table Six 
Site Control Study 
Rectum 74 86 
Left colon 33 66 
Mid colon 13 19 
Right colon 27 30 
Missing 5 7 
Positive Interval Refuser 
28 10 48 
33 5 28 
8 2 9 
7 a 15 
1 1 5 
Cases in the sigmoid colon were twice as common in the study group: this is 
almost entirely due to screening detected cases, and mirrors the results for 
adenomas presented in Chapter Seven. Cases can also be compared In 
terms of the size and differentiation of the tumour. 
* site distributions are defined as follows: rectum Includes rectosigmold junction; left colon 
inciudes the sigmoid and descending colon; mid colon Includes the transverse colon and both 
the splenic and hepatic flexures; right colon Includes the ascending colon and the caecum. 
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Table Seven 
Control Study Positive Interval Refuser 
Mean size (cm. ) 3.6 3.4 29 3 3.8 
Differentiation 
Good 12 26 18 3 5 
Moderate 86 126 45 18 63 
Poor 24 19 7 2 10 
Missing 30 37 7 3 27 
Thus screening conforms to all expectations: in comparison with those 
presenting with symptoms, asymptomatic cases are smaller, are detected at 
an earlier stage, and are better differentiated. 
As noted in Chapter Three, many American evaluations assume that all 
symptomatic cases are homogenous. This assumption can now be 
considered further. Interval cases have proportionately more very early and 
very late stage cases than controls, although in size and differentiation they 
are similar to screening positives. One way of explaining this would be that 
some interval cancers are aggressive and grow quickly before presenting at a 
late stage, even though they are no larger than early stage cases. Others 
grow at a slower rate but are detected earlier either because the person has 
been alerted to the significance of bowel symptoms or because those who 
complete a screening test (even if it is negative) are more aware of their 
health and have a lower'triggee threshold for consulting their GP. It is also 
possible that GPS involved in the screening programme have different referral 
patterns to those who are not; this could also influence the (comparatively) 
high proportion of stage A cases in the control group. 
The same pattern of extremes is found among screening refusers in 
comparison with controls. The incidence rate is higher among refusers than 
controls, probably because the former is an older group on average. The site 
distribution shows a higher proportion of refuser cases in the left side colon 
than would be expected from the control distribution. Differentiation and size 
are similar, but refuser cases are slightly older. How can this be interpreted? 
It has been suggested previously that people who do not accept a screening 
invitation are not homogeneous: some have a very poor opinion of their own 
health and their ability to influence it while others do not perceive personal 
vulnerability to colorectal cancer. It may be the former group who represent 
the large number of advanced stage cases and the latter who represent the 
early stage cases. However, if this is correct then why are the same trends 
not present in the control group? Assuming that the two groups are truly 
identical, one explanation would be that the counterparts of control group 
cases in the study group are the symptomatic presenters (refusers plus 
intervals) and the cases of advanced disease in the positive group. The 
staging distributions would then be virtually identical. This implies that the 
benefits of screening (of whatever magnitude) have not yet had time to reveal 
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themselves. At this early stage screening detected cases would all still have 
been 'silent', prevalent cases. 
Resource use 
Before calculating the costs of treating cases from each group some details 
of the resources used is provided. As this information is untainted by local 
cost factors, it is more 'general isable' to other locations. 
Unlike the surgical series discussed in Chapter One, the present sample is 
drawn from a whole population rather than just those admitted to a surgical 
ward. In the trial as a whole, 3% of cases were not admitted to hospital: 
some were post mortem findings while others were treated by polypectomy on 
a day-case basis. Of those admitted 22% of controls were emergencies 
compared to 18% of the study group. Only 4% of screen-detected cases 
were emergencies compared to 23% of intervals and 26% of refusers. 
As noted in Chapter One, surgery remains the principle treatment for 
colorectal cancer. Table Eight summarises the proportion of patients 
undergoing each type of operation as their initial treatment: 
Table Eight 
Operation Control Study Positive Interval Refuser 
None 21 12 0 1 11 
Resection 112 154 56 22 76 
(colostomy) (28) (36) (7) (5) (24) 
Endoscopy 10 20 15 1 4 
Other 9 19 3 2 14 
(colostomy) (6) (10) (1) (0) (9) 
(Note that the 'other' category includes laparotomy only, colostomy only and 
complicated palliative procedures). The main features of this table are the 
high proportion of screen positive cases amenable to polypectomy (in line 
with the finding that they are smaller tumours) and the high proportion of 
refusers who do not undergo a full resection owing to the presence of very 
advanced disease. 
Variations in treatment are reflected in the average length of time spent in 
theatre (in minutes): 
Table Nine 
Control Study Positive Interval Refuser 
Initial operation 106 117 115 120 118 
Ail operations 118 136 133 135 139 
While screening-detected cases are smaller and more amenable to 
polypectomy, it appears that theY take more theatre time. One explanation is 
that the perceived chances of cure are much greater in these cases, hence 
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they merit fuller attention. Another possibility is that the majority of 
screening-detected cases were treated in University Hospital, hence the 
operation may have been prolonged for teaching purposes. 
A similar table shows the average length-of-stay in days surrounding the 
main initial form of treatment and over the whole course of treatment: 
Table Ten 
Control Study Positive Interval Refuser 
Initial stay 20 20 15 18 24 
Total stay 26 28 20 30 32 
Screening detected cases have a generally shorter length of stay than any 
other group, reflecting the proportion treated by endoscopy alone. This 
advantage does not extend to the study group as a whole because of the 
comparatively long stays in the refuser group. 
Costs 
Table Eleven presents the average cost per case in the study and control 
groups: 
Table Eleven 
Category Control (E) Study (E) 
Investigation 103 121 
Pre-operative 248 192 
Main treatment 2,698 2,717 
Readmit 150 271 
Other follow-up care 805 1,010 
TOTAL 4,005 4,311 
These data are presented graphically in Figure Four. As the standard 
deviation for each sub-category is larger than the mean none of these 
differences achieves statistical significance. While the analysis has 
concentrated on the average costs of treatment, there are 37% more cases In 
the study group than in the control group implying a higher total cost. The 
total cost of treating the control group was E608,760 compared to E896,688 
for the study group. The total cost is 47% higher in the study group. It is 
interesting to note that a similar excess has been observed in the Danish trial 
(see Chapter Two). 
The results for the study group can also be analysed according to response 
to the offer of screening: 
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Table Twelve 
Category 
Investigation 
Pre-operative 
Main treatment 
Readmit 
Other follow-up care 
TOTAL 
Positive (E) 
162 
115 
2,241 
218 
734 
3,471 
Interval (r) 
86 
72 
2,376 
447 
1,440 
4,421 
Refuser (E) 
100 
277 
3,150 
266 
1,106 
4,899 
Once again, standard deviations are so large that differences are not 
statistically different. The components of treatment costs in each sub-group 
is illustrated in Figure Five. The results reflect variations in resource use 
described earlier. Screening detected cases are more expensive to diagnose 
as there are no signs or symptoms to give a clue to the primary site. Pre- 
operative costs are higher in the groups that present symptomatically owing 
to the higher proportion of patients who require stabilisation following 
emergency admissions. Treatment costs are notably higher in the group who 
refuse screening, stemming from the longer time spent in hospital. Follow-up 
costs are highest in the interval and refuser groups; this is consistent with the 
hypothesis that screening detected cases are from the less aggressive end of 
the spectrum while intervals and refusers are more prone to recurrent 
disease. 
Discussion 
The results have several strengths: 
j) the sample is large, giving a good chance of showing any significant 
differences in the data; 
ii) the data collection methods adopted in the research trial mean that a 
very high proportion of cases occurring in the trial population have been 
identified; 
almost all of the available hospital case notes were tracked down; 
iv) the minimum follow-up period is three years from the operation, implying 
that many of the costs of recurrent and terminal disease are included. 
In absolute terms, screening detected cancers are the cheapest to treat. 
Cases presenting symptomatically in the group offered a screening test, 
either following a negative test or having refused a test, are the most 
expensive groups. However, the standard deviations are so large that none 
of the differences between groups are statistically significant. 
Why is there no significant difference between the groups in terms of 
treatment costs? To identify the factors which determine treatment Costs a 
regression analysis was performed on the combined data sample. A total Of 
85 observations were excluded because the relevant data were not complete: 
these cases tended to be those who do not undergo surgery, resulting in 
uncertainty over the site, size and stage of the primary tumour. 
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The initial equation attempted to explain the variation in the total cost per 
patient and included all potentially relevant variables. The coefficient on the 
following variables did not achieve statistical significance: 
0 screening group (control/study group) 
0 Dukes' stage 
0 primary site within bowel 
number of primary tumours 
type of initial admission (elective/emergency) 
wound infection (none/minor/major) 
wound dehiscence (none/minor/major) 
The remaining variables were used to re-estimate the equation, with the 
following results, all the coefficients being significant at the 5% level: 
Total cost = 
- 
E541 (Constant) 
+ E41 Age (years) (t-statistic = 2.17) 
+ E818 Sex (O=male, I 
--female) (t = 2.95) 
" E1,199 Initial operation involved colostomy (0 = no, I= yes) (t = 3.73) 
" E1,079 Number of complications (excluding wound) (t = 4.96) 
" E797 Died during hospital stay (0 = no, 1= yes) (t = 2.14) 
" E982 Readmitted following initial treatment (t = 3.65) 
" E1,322 Number of subsequent admissions (t = 11.56) 
The equation explains 51 % of the variation in total cost per patient, according 
to the R-squared measure. 
How should the coefficients be interpreted? 
Age and sex appear to be standing as proxies for the general physical 
condition of the patient and possibly for the number of concurrent 
conditions. It may also be harder to discharge elderly patients if they live 
alone in unsuitable accommodation. There appears to be no correlation 
between age and stage of disease at diagnosis. 
An operation requiring a colostomy can be an indication of a palliative 
procedure, implying a poor general condition, but even curative resection 
involving a colostomy may have prolonged post-operative stay as the 
patient comes to terms with and learns to manage their stoma. A 
colostomy can also be used as a temporary measure to cover an 
anastamosis, implying a subsequent readmission for closure. 
A patient with several complications (e. g. cardiovascular, respiratory) will 
be in a poor condition and unsuitable for discharge until they are resolved. 
The number of non-wound complications is a subjective element since it Is 
not based on an objective clinical standard. Instead, it is coded according 
to the discharge letter to the patient's GP and simply counts the number of 
complications mentioned. 
The size and sign of the coefficient on the variable coded for death in 
hospital implies that terminal care is often prolonged rather than a short 
sudden post-operative death from complications. This variable may also 
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be correlated with the number of subsequent admissions. Clearly, this 
may be correlated with both the age of the patient and the number of 
complications. 
The readmission rate following the initial operation can be either to 
complete a two-stage operation or as an emergency; in either case the 
costs will be higher. - 
Subsequent hospital admissions may be either for routine surveillance 
(e. g. of an excised rectal tumour) but may be to treat recurrence or for 
terminal care. 
Do these variables help to explain the higher costs in the group refusing an 
offer of screening (and, to a lesser extent, among interval cases)? 
it has already been shown that those refusing screening are the oldest 
age group on average, being three years older than the other sub-sets of 
the study group and one year older than controls. 
The proportion of women in each group is similar, although the difference 
between screening detected cases (40% women) and interval cases (46% 
women) is more marked. 
There is a difference between groups with regard to the proportion 
requiring a colostomy during their initial treatment. Refusers and the 
control group have a higher proportion of operations requiring a stoma 
than do cases which accept screening (29% and 28% for refusers and 
controls, compared to 19% and 13% for intervals and screening detected 
cases). 
" 
The average number of complications for the control group was 0.23. 
Figures for screening detected and interval cases in the study group were 
much lower (0.17 and 0.15 respectively), but the average number per 
refuser case was much higher at 0.31. 
" 
The figures for deaths in hospital (during any admission) are similar for 
refusers and controls (30% and 25% respectively) but the interval case 
fatality rate is also high at 23% while the rate for screening detected 
cases is low (9%). 
" 
The readmission rate is consistently higher in the study group than in the 
control group. The proportion of controls being readmitted was 16% while 
the figures for the screening detected, interval and refuser groups were 
21%, 23% and 22% respectively. 
" 
The number of subsequent admissions was also higher in the study 
group, although the average number among screening positive cases (at 
0.58) was comparable with that of the control group (at 0.61). The Interval 
and refuser groups both had an average of 0.85 subsequent admissions. 
In summary, cases in the group refusing a screening test are more expensive 
because the people are older when they are diagnosed, are more likely to 
require a colostomy (as a palliative procedure), suffer complications to other 
body systems, require subsequent hospital care and are more likely to have 
prolonged admissions for terminal care. 
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EFFECTS ON GP WORKLOAD ý 
The above analysis has concentrated on the impact of screening on use of 
hospital resources by changing treatment patterns; another potentially 
significant impact is on the workload of GPs. Unfortunately, it is a 
characteristic of the primary health care sector that there is little routinely 
available data on activity levels to use to make such calculations. However, 
the national census of GP workload conducted every decade indicates that 
approximately a quarter of a million GP consultations each year relate to 
cancer of the digestive tract (Royal College of General Practitioners (1986)); 
this implies a total cost of just over El million using a standardised value of 
GP time (Hughes (1991)). 
It has been established that a postal invitation to complete an FOB test has 
no significant impact on GPs'workload (Pye et al. (1988)). Enquiries related 
to the appropriate diet, where to return the test to, and why the individual was 
singled out for testing. The receptionist had been briefed before hand and 
was able to deal with all of these problems. There are similar findings for 
breast cancer screening (Ashby et al. (1990)) and education in breast self- 
examination (Nicholls et al. (1982)). Note, however, that this does not 
include the longer term effects of prompt cards being placed in the notes of 
screening refusers, as described in Chapter Six. 
To assess the impact of screening on those with neoplasia, a study of the 
records of two GP practices was undertaken. Patients were identified from 
MRC trial records and, with the permission of the GPs, their notes were 
studied. Six cases of cancer in the control group generated a total of 42 
consultations, whereas nine cases in the test group resulted in 22 
consultations (only two of these were among the three screening detected 
cases). Three patients found to have adenomas in the control group 
generated four consultations, while 15 test group patients made ten 
consultations. Given the number of cases studied any conclusions drawn 
must be heavily qualified; however, there appears to be a shift from 
consultations for patients with advanced cancer in the control group to more 
reassurance for patients with screening detected adenomas in the screened 
group. Overall there is a fall in the number of consultations, but this Is not 
large in the context of the weekly workload of the two practices. 
In summary, the findings for primary care mirror those for the acute sector. 
screening does not result in large-scale savings in terms of GPs' time. 
CONCLUSION 
it is possible to estimate the resource use of a sample of patients undergoing 
surgery from their case notes, although care should be taken to avoid over- 
elaboration in measuring and valuing resource use. 
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It is too early to assess the full impact of screening on treatment costs in the 
MRC trial. At this stage, however, screen ing-detected cases are cheaper to 
treat than cases detected by any other means but there are two problems. 
Firstly, there is an excess of cases in the group offered screening, partly 
reflecting the earlier detection of cases, but also attributable to over- 
diagnosis on screening. Secondly, cases presenting symptomatically in the 
study group are very expensive to treat, especially those who refuse 
screening. This is not attributable to any one factor, but to a generally 
unfavourable set of variables for these groups. The net effect is that no 
treatment cost saving can be expected from screening, at lest in the early 
years of the operation of a programme. 
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Chapter Eleven 
COMPARING SERVICES FOR COLORECTAL CANCER 
Introduction 
The technical efficiency of colorectal cancer screening, in terms of the cost 
per cancer detected of various protocols, has been thoroughly explored in the 
chapters above. Without trial data to convert this into health gain, the 
allocative efficiency of screening cannot be assessed. As an interim step this 
chapter draws together the evidence on various treatments and interventions 
for colorectal cancer alone. Given that cancer treatment is likely to remain a 
high priority treatment it seems reasonable to suppose that the policy issue 
faced by health service purchasers is how to treat a particular form of cancer 
rather than whether to treat. No previous research has tried to draw together 
the evidence in this way. 
Service options 
The main areas in which services for colorectal cancer could be extended 
are: 
" primary prevention, by reducing exposure to factors which increase the 
risk of developing the disease; 
" screening various groups at increased risk of having asymptomatic or 
pre-malignant disease; 
" 
treating symptomatic disease, particularly treatments which 
complement potentially curative surgery. 
From these categories a list of options to compare can be drawn up. These 
include: 
" 
faecal occult blood (FOB) testing of the general population aged 50- 
74; 
" 
flexible sigmoidoscopy screening of the general population on a one- 
off basis between the ages of 55 and 60; 
" systematic follow-up of adenoma patients by endoscopy; 
" radiotherapy following potentially curative surgical resection of rectal 
cancer; 
" chemotherapy following potentially curative resection of stage C 
cancer of the colon; and 
" surgical resection of hepatic liver metastases for advanced disease (subject to tightly defined criteria). 
Primary prevention is not considered because of the uncertainty regarding 
the causes of colorectal cancer, specifically the interaction between 
environmental and genetic components. While estimates of the effects exist, 
the cost involved (and the feasibility of such a dietary change) and the timing 
of the benefits are very uncertain. 
The other main area excluded from the analysis is the follow-up of patients 
who have had a supposedly curative resection with aggressive treatment of 
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recurrence (as opposed to palliation). Despite the lack of evidence of proof 
of benefit from randomised trials this practice is widely established, albeit with 
considerable inter-surgeon variation in protocol. The problem is in two 
stages: is it worth screening asymptomatic people for recurrence, and is it 
worth treating recurrence once it has been identified? The second issue is 
harder to tackle than the first since it requires a precise estimate of the 
numbers who will benefit plus the extent of the benefit; surgical series tend to 
confine their comments to the operative mortality rate. An additional problem 
for evaluation in this area is that much of the benefit of follow-up may come 
from the reassurance provided merely by'going through the motions' of 
monitoring progress. Other than noting the need for better evidence in this 
area, follow-up of curative resections is thus not considered further. 
The evidence on the health service costs and health benefits of each of the 
options is now considered in turn in order to produce comparable data. 
1. FOB testing of asymptomatic 50-74 year olds 
Survival data from the MRC trail will not be available for several years; results 
cannot be presented or discussed in advance of the first official report. The 
only randomised trial evidence available to date relates to screening with the 
Haemoccult test using rehydration prior to development. On this basis 
colorectal cancer mortality is reduced by 30% with annual screening and by 
10% for two-yearly screening (Mandel et al. (1993)). An American case- 
control study also claimed a mortality reduction of 31 % for those completing 
an FOB test although the 'protective' effect lasted for less than three years (Selby et al. (1993)). However, doubt has subsequently been cast on the 
validity of these figures (Simon (1993)). In this country, one group of experts 
concluded that the mortality reduction form screening was likely to be less 
than 20% (Chamberlain and Miller (1988)); even this seems optimistic in the 
light of the Minnesota findings of a 10% reduction even with a more sensitive 
test. 
Where will this benefit from screening be observed? Allowing for lead-time 
effects, there should be little reduction in mortality before the age of 55, given 
that screening commences at 50. Similarly, it is assumed that there will be no 
mortality reduction after the age of 80, given that screening stops at age 75. 
The figures quoted in Table One of Chapter Two can be used to estimate the 
life-years gained. If the mortality reduction is 20% then 2,092 lives and 
25,686 life-years would be saved. Reductions of 10% and 5% are also 
considered. While they are small the health losses attributable to 
investigations and surgery should also be calculated for completeness. 
The UK population in the target age range is 12 million people (OPCS 
(1993)), half of whom are screened each year. The 'steady-state' cost of 
screening 100,000 people given in Chapter Four was El 84,324, the figure for 
the third round. However, those in the youngest age groups will be screened 
for the first time at a higher cost (E381,105 in Chapter Four). The cost of a 
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screening round over two years would, therefore, be E23,060,640, or 
El 1,530,320 per annum. Average costs are shown in Table One: 
Table One 
Mortality reduction 
20% 
10% 
5% 
E per life saved 
5,512 
11,023 
22,047 
E per LY saved 
449 
898 
1,796 
Note that cases detected and costs incurred are not the only effects of 
screening: as noted in Chapter Four, people will test falsely positive, while 
others will suffer complications following investigation. 
Chapter Ten showed no difference in treatment cost per case as a result of 
screening, but 37% more cases were detected in the group offered screening. 
Some of these are expected to represent the early detection of asymptornatic 
cases, but a proportion will be due to detection of 'lifetime-latent' cases. 
Making the arbitrary assumption that 50% of the excess cases are lifetime 
latents, and costing these cases as if they were screening detected cases 
(the cheapest to treat) implies an extra cost of E8,253,361. This would add 
72% to the above results. 
While, Chapter Seven demonstrated the potential cost savings from adenoma 
excision, a mortality reduction from colorectal cancer of 10% or less implies 
that lower estimates of the numbers of cancer prevented by adenoma 
excision is appropriate. This would imply that the cost savings would be 
lower than the figure given in the final section of that chapter. 
2. FOB testing of first degree relatives of patients diagnosed as having 
cancer 
There have been no randomised trials to establish the efficacy of screening 
relatives of colorectal cancer patients for the disease. The rationale for 
screening is based on the observed higher incidence and mortality in this 
group (Dunlop (1992)); the effect is particularly marked for first-degree 
relatives (children, siblings, parents). Some research indicates that the risk is 
highest for relatives of a newly diagnosed cases in younger people (aged 45 
or under). 
The following estimates are based on the data of Houlston et al. (1990). In 
England and Wales, 664 cases of colorectal cancer occurred in patients aged 
less than 45, generating 2,445 first degree relatives (60% parents, 40% 
siblings). Regular colonoscopy screening could prevent 244 cases. These 
people would be colonoscoped every five years, except for the 11 % in whom 
adenomas are detected, requiring three-yearly follow-up. 
Thus, 1,007 siblings with an average life-expectancy of 40 years (assuming 
them to be aged 40 on average) and 1,438 parents with a life-expectancy of 
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15 years (assume average age 65) would require surveillance. Of the 269 
found to have adenomas, an even distribution between these two groups is 
assumed. Multiplying out gives a total of 13,241 colonoscopies in all at 
El 05.10 each (from Chapter Four). 
Of the 244 cases detected only 65% represent lives saved, since a proportion 
of these people would have undergone a curative resection even if 
presenting symptomatically; only 159 lives will be saved. The cost per life 
saved is thus E8,752. The calculation of the number of life-years saved is 
more problematic. The clinical data give the total number of cases that might 
be detected but give no idea of when these will occur. There is also no 
information on the distribution of cases between the younger and older age 
groups, yet this will have an important bearing on life-expectancy. 
.r 
While there are costs to identifying, contacting and counselling the relatives, 
these are unlikely to be great relative to the costs of investigation. Potentially 
more serious is the problem of getting relatives to undergo surveillance. The 
figures above assume full participation, yet one study found that only 30% of 
those identified accepted an offer of screening (Armitage et al. (1986)). 
While this restricts the impact of the screening programme on the disease it 
also reduces the cost, hence for the current purpose the average cost per life 
saved is hardly affected. The calculations also assume no net effects on 
treatment costs. 
3. Flexible sigmoidoscopy for age group of general population 
There are no'gold standard'data from randomised trials to support such a 
programme, but some researchers have enthusiastically advocated 
implementation in this country (Atkin et al. (1993)). The basis for their 
calculations is an American case-control study of rigid sigmoidoscopy 
screening which calculated that mortality was reduced by 60% within the 
range of the sigmoidoscope used. If this was the case, then the longer 
flexible instrument could reduce total mortality by 30% (Selby et al. (1992)). 
Supporting evidence has been provided by a similar American study 
(Newcomb et al. (1992)). 
The flaws in the calculations of Atkin et al. (1993) have been pointed out in 
Chapter Five, where the option was shown to be inferior to some FOB 
screening protocols. While it was more expensive than unhydrated three-day 
testing (option 1 above), however, it was also more accurate, hence it is 
included here. ' 
Transferring the data from Chapter Five to a national population means 
600,000 people aged 57 would be screened each year. The costs of 
invitation plus investigation, including colonoscopy, give a total Cost Of 
El 5,148,458. The number of cases of disease detected would be 804, but 
35% of these would be cured in any event; 523 people thus benefit from 
screening. The cost per life saved is E28,965. 
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4. Follow-up of patients with a previous adenoma excision 
The potential significance of the costs of adenoma follow-up are 
demonstrated by the finding of one evaluation that 25% of the total costs of a 
screening programme were due to adenoma follow-up alone (Wagner et al. 
(1991)). However, there is no randomised trial evidence on the health gain of 
adenoma follow-up by any protocol. 
One study calculated that 226 colonoscopic investigations would be 
necessary to save one life (Ransohoff et al. (1991)). This was based on 5- 
yearly colonoscopy follow-up of a 50-year old who has had an adenoma 
excised; this protocol averts 75% of the colorectal cancer deaths which would 
have resulted from recurrence. If colonoscopy costs El 05 the cost per life 
saved is E23,753. The results in the original study were sensitive to the 
assumption of 75% effectiveness and the cumulative risk of colorectal 
mortality after polypectomy of 2.5%. If the true risk is half of this figure then 
the cost per life saved is doubled. The study concluded that in low risk cases 
3-yearly follow-up (as widely recommended in America) is "excessively 
costly". 
5. Radiotherapy for rectal cancer 
While a randomised trial of pre- and post-operative radiotherapy as a 
complement to curative surgical resection for rectal cancer is in progress, no 
details are yet available. 
However, a course of out-patient radiotherapy of 20 fractions for stage B and 
stage C rectal cancer will result in an extra 10% of patients being cured (Dr. 
Fearon, consultant oncologist, Western General Hospital, Edinburgh, 
personal communication). About 10% of patients suffer some adverse 
reaction to therapy and require a short in-patient admission for monitoring: an 
average of five days in hospital is assumed. 
On the basis of figures in Chapter One, there 10,581 cases of rectal cancer 
are diagnosed each year, with 66% being stages B or C. A radiotherapy 
fraction costs E70 (Fearon, as above) and an in-patient day costs El 16.66 
(hotel costs plus other overheads) as in Chapter Ten. The total cost for 
6,983 patients isE10,183,343. Given the survival data at five years quoted in 
Chapter One 2,870 would be cured by resection alone; an extra 698 lives are 
saved as a result. The average cost per life saved is E14,589. 
6. Chemotherapy for stage C colon cancer 
An American randomised trial implies that chemotherapy for stage C colon 
cancer reduces colorectal cancer mortality rate in that group by 10% (Moertel 
et al. (1990)) 
- 
13ased on the figures in Chapter One, 4,428 stage C colon cancers present 
each year. A six-month course of chemotherapy on an out-patient basis 
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costs E1,600 (Fearon, as above), but trial data are based on a twelve-month 
course of treatment hence the cost is doubled. Side-effects of chemotherapy 
are generally more serious: the American trial found 30% of patients 
experienced significant side-effects and it is assumed that all of these require 
admission. The same cost and length-of-stay assumptions are used as for 
radiotherapy above. 
The total cost of treatment is E14,944,455. Of these people, 22% would be 
cured without chemotherapy on the basis of data in Chapter One. An extra 
10% are cured as a result of chemotherapy, so 443 lives are saved at an 
average cost of E33,735 each. 
7.,, Aggressive surgical and chemotherapeutic treatment of hepatic 
_-, 
-- 
metastases 
There is no evidence of benefit for this intervention from randomised 
controlled trials. However, expert opinion suggests that 5% of cases with 
metastases could be cured as a result of resection if guidelines for case 
selection were carefully adhered to. 
From Chapter One 6,714 people with advanced disease present each year. 
The mortality rate following initial admission is 31 % (Umpleby et al. 0 984)); 
these people are not considered further. The 4,632 survivors are assumed to 
undergo a CT scan to establish the extent of their disease: this costs El 93 
(Hutton (1988) updated). Only 5% will be eligible i. e. 232 people. Based on 
observations in University Hospital, Nottingham, in the course of the 
screening study, the operation lasts four hours with in-patient stay of 15 days. 
Using the cost figures above, with theatre time valued at E4.47 per minute (as 
in Chapter Ten), the total cost is E1,548,888. If 20% of those undergoing the 
operation are cured as a result (Fearon, as above) then 46 lives are saved; 
the cost per life saved is E33,671. Once again, the losses to operative 
mortality will be small but should be calculated for completeness. 
summaty 
The above results can be drawn together in Table Two: 
Table Two 
Intervention 
Screening first degree relatives 
FOB screening (10% mortality reduction) 
Radiotherapy for rectal cancer 
FOB screening (5% mortality reduction) 
Flexible sigmoidoscopy screening 
Adenoma follow-up 
Resection of liver metastases 
Chemotherapy for colon cancer 
Cost per life saved (E) 
8,752 
11,023 
14,589 
22,047 
23,965 
23,753 
33,671 
33,735 
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Discussion 
These results have a number of weaknesses. Many assumptions are based 
on poor quality data, particularly those relating early detection to health gain. 
The effectiveness measure used is the number of lives saved as a result of 
treatment, which is unsatisfactory since it gives no indication of the length of 
life thus gained: many people would not regard saving the life of a 40-year 
old as having the same value as saving the life of an 80-year old, for 
example. Aside from these extreme cases the age group affected is relatively 
homogeneous, hence a comparison on this basis has some value. To the 
extent that this is important it would tend to reinforce the ranking since a 
younger age group will tend to benefit from screening, especially if the 
screening of first degree relatives focuses upon siblings in preference to 
parents. However, the measure also excluded aspects which affect health 
status such as post-operative complications and the psychological impact of 
screening. 
Potential users of the results must make a judgement about the quality of the 
data. Given the lack of reliable epidemiological evidence, are the 
assumptions used good enough to base purchasing decisions upon? How 
conclusive does evidence have to be before it can be considered proof? 
F013 screening provides a good example: if a 10% reduction in mortality can 
be achieved as a result then it represents good value for money, yet a more 
pessimistic (but possibly more realistic) 5% reduction casts serious doubt on 
this use of resources. 
one important element excluded from the calculations by virtue of the 
effectiveness measure used is the health status of patients with, during, and 
without treatment. One thorough Dutch study of the breast cancer screening 
literature concluded that quality-adjustment of life-year gains made little 
difference to the results i. e. rankings based upon life-year gains alone were 
unaffected (de Haes et al. (1991)). Can this finding be generalised to 
colorectal cancer? This is considered under a number of headings. 
The main concern regarding quality of life in colorectal cancer treatment 
relates to adjustment to a colostomy. A study of the post-operative life of 
such patients found them to be 'normal' on a variety of indicators although 
they are more prone to depression and anxiety (MacDonald and Anderson (1985)). When asked to value their quality of life, a sample of people with 
a colostomy gave values of 80 to 90% of normal (Boyd et al. (1990)). 
The ability to return to work is another indicator of post-operative health. 
In the MRC study found that of 18 people in paid employment previous to 
their operation, II had decided to return and 7 had decided to retire; 
many of this latter group were close to retirement age already. Similar 
findings are reported for patients requiring an ileostomy for inflammatory 
bowel disease; while more reported lethargy, the operation is more radical 
than many used to treat cancer (Wyke et al. (1988)). 
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The quality of life of people with terminal colorectal cancer has not been 
widely studied: the only available data showed that patients with a life 
expectancy of a few months rated their own health at 56% of normal 
(McGowan et al. (1989)). 
In summary the evidence for colorectal cancer appears to broadly confirm the 
Dutch finding of the limited quality of life implications of screening. Only 
during terminal disease are the effects of the disease likely to be so 
unpleasant as to be important. As the resource use patterns in Chapter Ten 
indicate, the terminal stages of the disease are mercifully brief for many 
patients. This implies that lives saved are a reasonable basis for comparing 
the benefits of alternative interventions. 
CONCLUSION 
Given the poor quality of the data used, many of the conclusions must be 
heavily qualified. While this may hamper choices between two interventions 
with small differences in cost-effectiveness ratios, the differences between 
screening relatives of young cancer patients and performing surgical 
resections on liver metastases is striking and cannot be explained by 
erroneous assumptions alone. If care is taken over interpretation, the results 
can be a guide to economic efficiency for purchasers in this field. 
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CONCLUSION 
The conclusions of this evaluation can be divided into those relating to policy 
ind those relating to methodology. 
Policy conclusions 
Týe questions posed at the start of this evaluation were as follows: 
i) what are the costs and benefits to NHS purchasers of screening for 
colorectal cancer in an asymptomatic population aged 50-74 by an 
offer of Haemoccult 11 testing every two years? 
ii) is this the most efficient way to screen for colorectal cancer? 
iii) is this the most efficient way to reduce the health loss of colorectal 
cancer? 
iv) can such a policy be justified in comparison with other uses of health 
service resources? 
The first question has been considered in detail, first by a simple model (Chapter Four) and then by detailed analysis of aspects which may affect 
these results. The findings of the relevant chapters are considered below. 
Chapter Four established the cost per case detected by three-day 
Haemoccult screening using the MRC trial protocol as being E3,347 at the 
initial round of screening andE2,989 in the 'steady-state' round. Given the 
likely order-of-magnitude of health gains resulting from screening this implies 
that FOB screening is worth considering in more detail: it cannot be ruled out 
as an efficient use of resources on the basis of this data alone. However, the 
results are sensitive to the cancer detection rate of the test and to the 
participation rate, and these were noted as areas requiring further 
investigation. 
participation is one of the key variables in determining the clinical 
effectiveness and the economic efficiency of a programme. Chapter Six 
showed that, given the costs and the number of extra responders, the MRC 
trial protocol is justified on economic grounds, although this remains subject 
to the relationship between numbers screened and health benefits. Some 
methods suggested for distributing FOB tests such as a GP-based system 
are expensive by comparison; the same is true of pursuing persistent non- 
participants in postal-based FOB screening. 
Given the importance of the detection rate, the significance of the adenoma 
to cancer sequence was then assessed. Unfortunately, this is probably the 
area in which existing knowledge is weakest: this was fully revealed by a 
comparison of methods of calculating the preventive effects of adenoma 
excision. On the basis of literature estimates, between 5 and 86% of 
adenomas excised on screening may have become cancers within the 
lifetime of the patients. Previous evaluations have shown this to be a crucial 
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variable in determining the efficiency of screening; this finding is likely to 
exacerbate the problem. If the reduction in mortality from colorectal cancer 
screening is less than 10%, as seems likely on the basis of the American 
data, then it is possible that none of the model presented is correct: all are 
too optimistic about the eventual impact of adenoma excision. The 
predictions of large savings from excision can only be squared with the 
modest mortality reduction if either the cancers prevented from excision 
would have been easily cured in any event or the Minnesota trial has 
insufficient follow-up to capture any effect. 
The detection rate and participation rates can also be influenced by the age 
group chosen for screening. Chapter Eight considered the effects of varying 
the screening protocol for various age ranges, including extensions to 
younger and older age groups. The rationale for screening the younger age 
group would be to excise adenomas but, given the uncertainty noted above, 
this is difficult to evaluate. Nevertheless, trial data indicate the yield is very 
low in this group. Screening older people gives a high yield but there are 
doubts about their ability to undergo surgery if a resection is required; 
nevertheless, there is some evidence that post-operative mortality in this age 
group is falling over time. In terms of the 50-74 year age group, two-yearly 
screening appears justified for the older group but not for the younger part of 
the population since detection rates fall to zero. This suggests a one-off 
screen for younger people at some point in their fifties with two-yearly 
screening commencing at about 65 years of age. Unfortunately, the data are 
not available to evaluate such a protocol 
The calculations so far have accepted the MRC trial protocol for the follow-up 
of positive screening results, but Chapter Nine explores the efficiency of 
these aspects. The retesting of initial FOB positives observing dietary 
restrictions is shown to have minimal effect on yield while reducing the costs 
of diagnostic investigations quite considerably. Trial data indicate that the 
barium enema X-ray alone is insufficiently sensitive to small cancers in the 
sigmoid colon to investigate a positive FOB test. The addition of 60cm. 
flexible sigmoidoscopy makes an attractive combined test which Is 
comparable to colonoscopy as the test of choice in most respects. However, 
colonoscopy is shown to fractionally more cost-effective so long as the 
investigation is complete first time in at least 70% of cases. This is feasible 
in the hands of a well-trained operator, but is unlikely to be the case for 
unsupervised junior doctors. 
The final factor to consider is the impact of screening on the costs of treating 
colorectal cancer. It is possible that the trial is at too early a stage to 
consider this question fully, since screening has the initial effect of clearing 
out all prevalent cases; this would imply offsetting cost savings occurring at 
some point in the future. Considering only cases with at least three years of 
follow-up shows that the total cost of treating the group offered screening is 
47% higher than the cost for the control group. This is mainly explained by 
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the excess of cases in this group: there is no significant difference between 
average costs in each group. In general, there is much more variation within 
the study and control groups in terms of treatment costs than there is 
between them. An attempt to explain variation in cost per case (for any 
screening group) indicated a range of factors as having some explanatory 
power. These include the age and gender of the patient, whether the initial 
operation involved a colostomy, the number of complications in post- 
operative recovery (including whether the patient died before being 
discharged), plus the need for a second (and subsequent) admissions. 
These offer at least a partial explanation of the higher costs of study group 
cases and particularly of those who refuse an offer of screening and are 
subsequently diagnosed as having cancer. 
The second question related to the best test to use in colorectal cancer 
screening. To address this the model constructed in Chapter Four was used. 
Chapter Five compared Haemoccult screening with a variety of other 
screening tests for colorectal cancer; a set of options which dominated the 
others in the sense of having higher yield and lower costs was identified. 
This included FOB screening on the IVIRC protocol, but also FOB testing with 
rehydration of samples, the Hemeselect immunological test and colonoscopy. 
While colonoscopy can probably be ruled out as infeasible given the 
availability of resources in this country, the decision rule of cost per case 
does not allow purchasers to choose between the remaining options. To do 
so, further information on the health benefits of detecting a case and the 
willingness of purchasers'to pay for extra health benefits is required. 
The third study question was considered in Chapter Eleven, with an 
evaluation of various ways of reducing the health cost of colorectal cancer. 
The available evidence for a range of interventions was assessed and found 
to be of generally poor quality. 'Order-of-magnitude' estimates of the cost per 
life saved were made for each option identified. Caution must be used In 
interpreting and using the results given the quality of the data used, but some 
broad conclusions can be drawn. For example, screening the relatives of 
people aged less than 45 who are diagnosed as having colorectal cancer 
should be implemented before surgical resection of liver metastases in 
advanced disease is considered. Better data are urgently required in order to 
place more certainty on results. 
The same comment applies to addressing the final question, with the added 
requirement that some common measure of outcome be developed for 
comparing widely differing programmes in terms of their costs and benefits. 
A drawback in both instances is the lack of data from the IVIRC trial. Much of 
the research carried out for this work was funded by the MRC, who request 
that trial results with respect to survival are not analysed in advance of the 
publication of the first set of survival figures. This has enforced the present 
evaluation to a (possibly excessive) reliance on interim measures of the 
output of screening such as cases detected. 
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What advice can currently be offered to purchasers? In the light of the 
evidence from the Minnesota trial the MRC trial is unlikely to show a large 
mortality difference, especially in its first mortality report due in the mid- 
1990s. This implies that health gains from the detection of cancer at an 
asymptomatic stage are likely to be modest. The potential gains from 
adenoma excision are potentially larger but are also less certain; 
considerable patience will be required from all concerned in order to assess 
this effect, if any, since about 15 years of follow-up will be required. The net 
cost of screening is also uncertain at this stage of the MRC trial. The survival 
gains necessary to justify the costs of screening and diagnosis are not 
implausible. The crucial issue on this side of the'cost-benefit equation' is the 
net effect on treatment costs. Screening increases the total cost in the early 
years, as would be expected, but adenoma excision could potentially 
outweigh this effect in the long-term, even with discounting to a net present 
value. 
In summary, the policy conclusion is rather disappointing: it is simply too 
early to say. On a more optimistic note, the crucial pieces of missing data 
can eventually be observed from the MRC trial: will we have the patience to 
wait that long? 
Methodological conclusions 
Apart from the conclusions relating to the policy questions posed, there are a 
number of implications of this study for the evaluation of mass screening. 
One problem rarely addressed in the literature relates to the timing of the 
evaluation. A central requirement of information for purchasers is that 
information is available promptly to make a decision. In this case the results 
of the evaluation must be available soon after evidence on efficacy if 
efficiency is to be considered. Even a limited evaluation such as this can 
take a considerable amount of time, however, hence the need to commence 
the work before efficacy data are available. There is a risk, however, that the 
economics research will be in vain if the treatment has no benefit over the 
alternative. In addition there are great difficulties in coping with the 
uncertainty regarding the magnitude of health gains as a result of screening. 
More generally, the role of clinical trials lasting 15 to 20 years is at issue. 
Such trials provide 'gold standard' data of the type needed to evaluate many 
of the competing claims for scarce resources; however, the data arising often 
relate only to one test and to one protocol. Evidence from other sources 
comes to light while the trial is in progress, placing pressure upon purchasers 
to act before the results become available. Recent case-control study results 
and the support achieved by advocates of endoscopic screening are 
examples of this. A related problem is that by the time the efficacy (or 
otherwisO) of the screening test is established new and better tests will be 
available. Clinical trials of preventative interventions may need rethinking, 
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possibly using the mathematical models of the disease process described in 
Chapter Three. Trials would then be designed specifically to address gaps in 
the current medical knowledge. Such models are often so sophisticated in 
terms of their statistical structure as to be inaccessible to the non-specialist, 
fostering suspicion of their results. This complexity is necessary, however, to 
address the screening problem. 
Other methodological developments will be of interest to economists carrying 
out evaluations. The level of detail required in the costing of hospital 
procedures is an example. Chapter Ten demonstrated that individual patient- 
based costing of nursing time is unlikely to add greatly to the accuracy of 
average nursing costs on a surgical ward. This is of particular interest as 
hospitals develop individual patient-billing systems as part of the move 
towards disaggregated contracts in the internal market. Much effort may well 
be expanded on this, as on other aspects of costing, in the unthinking pursuit 
of yet greater precision. 
I One particular area of screening evaluation advanced here is the 
development of methods for determining the economic optimum participation 
rate. it is interesting to note that in this, as in other aspects of the evaluation, 
the MRC trial protocol for screening the study group does very well in 
comparison with the alternatives: the choice of screening test, the retesting 
protocol for positive FOB results and the choice of diagnostic work-up all 
appear technically efficient. The only variation uncovered by the economic 
evaluation would be in terms of varying the frequency of screening for 
different age groups. The trial protocol was devised to minimise research 
funding requirements: one interpretation, therefore, would be that medical 
staff are capable of devising efficient practice protocols when explicitly faced 
with the constraint of limited resources. It would interesting to gather 
experience from other trials to find whether this is generally true. 
The model has identified many of the 'plethora' of margins referred to 
elsewhere (Shackley and Cairns (1993)), but this is often at the expense of 
sacrificing some of the (spurious) certainty which other evaluations convey. 
This certainty often results from the use of simplistic decision criteria such as 
preferring the option with the lowest cost per case detected. The correct 
comparison is in terms of the additional cost per additional unit of output or 
outcome, whether this is over and above doing nothing or in comparison with 
an alternative intervention. This principle has been applied in the evaluation 
of colorectal cancer screening wherever possible. 
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